Curriculum Vitae



Eleftherios P. Diamandis

Revised December 14, 2009

Department of Pathology
and Laboratory Medicine
Mount Sinai Hospital
Suite m6-201
60 Murray Street
Toronto, Ontario, Canada
M5T 3L9

Department of Clinical Biochemistry
University Health Network
200 Elizabeth Street
Toronto, Ontario, Canada
M5G 2C4

Department of Laboratory Medicine
and Pathobiology
Faculty of Medicine
University of Toronto
100 College Street
Toronto, Ontario, Canada
M5G 1L5

Contact Information

Mail Address: Box 32
60 Murray Street
Mount Sinai Hospital
Toronto, ON, Canada M5T 3L9

Telephone: 416 586-8443; Fax: 416 619-5521; Mobile: 416-505-2844

E-Mail: ediamandis@mtsinai.on.ca

Web Site: http:/www.acdcLab.org/

Table of Contents

Date and Place of Birth 3
Elementary Education 3
Citizenship Status 3
Degrees 3
Present Positions 3
Cross-Appointments 3
Previous Positions 3
Distinctions and Awards 4
Certifications 5
Society Memberships 5
Experience in Education 5
University of Athens, Greece 5
University of Toronto, Canada 5
Other University Activities 5
Organization of Scientific Meetings 6
Organization of Workshops 7
Journal Referee 8
Referee for Granting Agencies 9
Member of Scientific Advisory / Editorial Boards 9
Other Professional Activities 10
Direction of PhD and MSc Theses 10
The Research Laboratory of Dr. Eleftherios P. Diamandis [December 2009] 12
Research Coordinator: 12
Mass Spectrometry Specialists: 12
Post-Doctoral Fellows: 12
PhD Candidates: 12
MSc Candidates: 12
Past Research Associates and Post-Doctoral Fellows/Graduate Students {MSc} 12
Post-Doctoral Fellows 12
Medical Residents 13
Research Assistants 13
Undergraduate/Co-Op Students 13
Summer Students & Volunteers 14
Committee Member of Graduate Students 15
Experience in Management 16
Invited Lectures — National and International Events 16
Invited Lectures — Local and Commercial Events 21
Invited Lectures — Clinical Rounds 23
Roundtables 23
Interviews: Media Publications & Press Releases 24
List of Publications: Books 24
Book Chapters 25
Reviews 26
Original Research Papers 31
Editorials/Commentaries 57
Letters to the Editor 58
Science Fiction 60
Patents 60
GenBank Submissions 62
Abstracts 64

Date and Place of Birth

October 8, 1952 in Limassol, Cyprus

Elementary Education

Elementary and High School in Limassol, Cyprus. Graduation, June 1970.

Citizenship Status

Citizen of Canada.

Citizen of Cyprus

Degrees

1972-76	B.Sc.	Chemistry, University of Athens, Greece
1976-79	Ph.D.	Analytical Chemistry, University of Athens, Greece
1982-84	Clinical Biochemistry Diploma	University of Toronto, Canada
1978-82, 1984-86	M.D.	University of Athens, Greece

Present Positions

Head, Section of Clinical Biochemistry, Department of Pathology and Laboratory Medicine
Mount Sinai Hospital, Toronto, Ontario, Canada [1995 to present]

Professor and Head, Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology
Faculty of Medicine, University of Toronto, Ontario, Canada [1997 to present]

Biochemist-in-Chief, Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada [2005 to present]

Cross-Appointments

Department of Surgery, Faculty of Medicine, University of Toronto – 2006 to present

Previous Positions

Dates	Position Held
1970-1972	Served in the Cyprus Army.
Aug 1976 - Jan 1978	Post-graduate student, Hellenic National Research Foundation.
Jan 1978 - Oct 1979	Research Assistant, Laboratory of Analytical Chemistry, University of Athens.
Nov 1979 - Aug 1982	Instructor, Laboratory of Analytical Chemistry, University of Athens.
Jul - Sep 1981	Post-Doctoral Research Associate, University of Illinois, Urbana-Champaign, USA
Sep 1982 - Aug 1983	Trainee in Clinical Biochemistry, The Hospital for Sick Children, Toronto.
Sep 1983 - Mar 1984	Trainee in Clinical Biochemistry, Mount Sinai Hospital, Toronto.
Apr 1984 - Jul 1984	Trainee in Clinical Biochemistry, Sunnybrook Medical Centre, Toronto.
Aug 1985	Trainee in Pediatrics. Kaplan Hospital, Rehovot, Israel.
1982-1986	Lecturer, University of Athens.
1986-1988	Director of Research and Development, CyberFluor Inc.
1986-1990	Assistant Professor, Department of Clinical Biochemistry, University of Toronto.
1988-1993	Chairman, Scientific Advisory Board, CyberFluor Inc.
1988-1994	Deputy Biochemist-in-Chief, Toronto Western Division, The Toronto Hospital.

Dates	Position Held
Mar - Dec 1994	Director of Laboratories, Doctor's Hospital.
1990-1996	Associate Professor, Department of Clinical Biochemistry, University of Toronto.
1993-1997	Deputy Chair, Department of Clinical Biochemistry, University of Toronto.

Distinctions and Awards

1. Chisholm Memorial Fellowship for the period 1983-84 from the Faculty of Medicine, University of Toronto.
2. American Association for Clinical Chemistry Award for Outstanding Scientific Achievements by a Young Investigator (1985).
3. The MedChem Laboratories Award for the best poster presentation, at the annual Canadian Society of Clinical Chemists meeting. Co-author of nine winning posters in Vancouver (1985), Winnipeg (1988), Montreal (1991), Toronto (1992), Banff (1993), Quebec City (1994), Chicago (1996), Ottawa (1998), Chicago (2001).
4. Annual Van Slyke Society Research Grant Award of the American Association for Clinical Chemistry (1989).
5. Annual Research Excellence Award of the Canadian Society of Clinical Chemists (1995).
6. Excellence in Teaching Award, Department of Clinical Biochemistry, University of Toronto (1997).
7. Kubasik Lecturer, Upstate New York Section of the American Association for Clinical Chemistry (October 1998).
8. Distinguished Scientist Award, Clinical Ligand Assay Society (CLAS) (1999).
9. American Association for Clinical Chemistry Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research (1999).
10. Van Slyke Award, the New York Metro Section of the American Association for Clinical Chemistry (1999).
11. 1999 Burlina Prize. Co-author of best abstract presented at the International Society for Enzymology meeting in Venice, Italy, June 4-6, 1999.
12. Distinguished Scientist Award, National Academy of Clinical Biochemistry (NACB) (2000).
13. Honorary President, Society of Scientists / Clinical Chemists of Cyprus (April 2000).
14. Recognition of Scientific Contributions by the Municipality of Agios Athanasios, Limassol, Cyprus (September 15, 2000).
15. Miriam Reiner Award from the Capital Section of the American Association for Clinical Chemistry (December 2001).
16. Abbott Award from the International Society for Oncodevelopmental Biology and Medicine (ISOBM) (September 2002).
17. Annual Education Excellence Award of the Canadian Society of Clinical Chemists (2003).
18. Elected "Corresponding Member" of the Academy of Athens (2005).
19. Frey-Werle Commemorative Gold Medal from the Frey-Werle Foundation (2007).
20. The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics from the American Association for Clinical Chemistry (AACC) (2007).
21. Outstanding Contributions to Clinical Biochemistry Award from the Ontario Society of Clinical Chemists (OSCC) (2008).
22. Elected "Member" of the Royal Society of Canada (2008).
23. The IFCC/Abbott Award for Significant Contributions to Molecular Diagnostics (2009).

Certifications

1985	Certified Clinical Chemist by the Canadian Society of Clinical Chemists
1985	Certified Clinical Chemist by the American Board of Clinical Chemistry
1995	Fellow of the Royal College of Physicians, Canada
2006	Licensed Medical Biochemist, College of Physicians and Surgeons of Ontario, Canada [Registration # 85455]

Society Memberships

1976-	Greek Chemists' Association
1982-	American Association for Clinical Chemistry
1982-	Canadian Society of Clinical Chemists
1986-	Fellow, Academy of Clinical Biochemistry of USA
1986-	Founding Member, Canadian Academy of Clinical Biochemistry
1989-	Clinical Ligand Assay Society
1989-	International Society of Clinical Enzymology
1994-	American Association for Cancer Research
1995-	American Association for the Advancement of Science
1995-2002	The Endocrine Society, USA
1995-1998	The Canadian Association of Pathologists
1997-	Ontario Medical Association
1998-2002	The Society for Biomolecular Screening
2001-	Affiliate Member, American Urological Association
2005-2008	American Society for Biochemistry and Molecular Biology [ASBMB]

Experience in Education

University of Athens, Greece

1977-1982	Taught Qualitative and Quantitative Analytical Chemistry, Chemical Instrumentation and Instrumental Analysis to 2nd Year Pharmacy Students and 3rd Year Chemistry Students.
1984-1986	Organized and taught a new full course entitled 'Clinical Chemistry' to 4th Year Chemistry Students.

University of Toronto, Canada

1987-1997	Taught in Courses 1509 and 1603 (Graduate Students & Postdoctoral Fellows). Taught Clinicopathological Conferences to 3rd Year Medical Students.
1987-2000	Teacher, Course LMP 1505
1990-1991	Coordinator and Teacher of a Graduate course entitled "Advanced Analytical Biochemistry" (CLB 1506).
1991-2002	Coordinator and Teacher of a Graduate course entitled "Molecular Biology Techniques" (CLB 1510F now LMP 1510F).
1992-1994	Departmental Representative in the "Pathobiology of Disease" course, which started September 1993.
1995-1999	Teacher of course entitled "Cellular and Molecular Mechanisms of Human Disease" (CLB404).
1998-2004	Co-Coordinator and Teacher of University of Toronto Graduate course LMP 1019S entitled "Research Techniques in Molecular Biology and Pathology".
2000-2004	Co-Coordinator and Teacher of University of Toronto Graduate course LMP 1506S entitled "Techniques in Functional Genomics and Proteomics".

Other University Activities

1997-	Director of the Royal College Medical Biochemistry Residency Program, University of Toronto
1995-	Committee Member, Royal College General Pathology Residency Program, University of Toronto

Organization of Scientific Meetings

Date	Position	Description	Location
June 3 - 6, 1987	Co-organizer	"Update in Analytical Biochemistry" course, Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
May 30 – Jun 1, 1989	Secretary	8th International Congress of Clinical Enzymology	Toronto, Canada
Sept 13 - 15, 1990	Co-organizer	"Advances in Interpretative Biochemistry" course, Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
May 24 - 28, 1992	Co-organizer	Annual Meeting, Canadian Society of Clinical Chemists	Toronto, Canada
May 13- 14, 1994	Organizer	Annual Meeting, Upstate New York Section, American Association for Clinical Chemistry	Corning, NY
Aug 1 - 6, 1994	International Advisory Board	2nd International Conference on f-elements	Helsinki, Finland
Sept 10 - 12, 1994	Scientific Committee	International Symposium: "Enzymology Days"	Athens, Greece
Oct 5 - 6, 1994	Organizer	Annual Meeting, Upstate New York Section, American Association for Clinical Chemistry	Rochester, NY
Nov 17 - 18, 1994	Chairman	First Specialty Conference, Canadian Academy of Clinical Biochemistry: "Molecular Biology in Clinical Medicine - Techniques, Applications and Future Prospects"	Toronto, Canada
Dec 3 - 4, 1994	Scientific Committee	International Symposium on the Health Effects of Moderate Alcohol Consumption	Toronto, Canada
May 24 - 27, 1995	Organizing Committee	Clinical Ligand Assay Society 21st National and 1st International Meeting	Toronto, Canada
Oct 29- Nov 2, 1997	Secretary	Clin Chem '97	Philadelphia
April 23 - 24, 1998	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	Raleigh, NC
May 7 - 9, 1998	Treasurer	"Enzymes, Receptors and Drugs in Atherosclerosis and Obesity" (combined meeting of the International Society for Enzymology and the Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology)	Toronto, Canada
May 8 - 9, 1998	Organizing Committee	"Standards of Laboratory Practice Guidelines in the Use of Tumour Markers for the Diagnosis and Monitoring of Cancer"	New York, NY
Oct 13, 1998	Organizer	"Prostate Cancer — New Developments" mini-symposium	Toronto, Canada
Oct 23, 1998	Organizer	Kubasik Symposium: "Prostate Specific Antigen — New Developments"	Rochester, NY
April 23 - 24, 1999	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	San Jose, CA
June 4 - 6, 1999	Co-organizer	International Society for Enzymology meeting: "Novel Aspects of Enzymes in Human Disease"	Venice, Italy
June 22, 1999	Organizer	"Recent Advances on Obesity and Atherosclerosis" mini-symposium	Toronto, Canada
Nov 19, 1999	Chair	1-day symposium: "Advanced Biotechnology & Clinical Diagnosis"	Toronto, Canada
May 5 - 6, 2000	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	Boston, MA
May 21 - 24, 2000	Organizing Committee	Basic and Clinical Enzymology 2000	Naples, Italy
May 4 - 5, 2001	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	Seattle, WA
April 25 - 26, 2002	Organizing Committee	Oak Ridge Conference, American Association for Clinical Chemistry	La Jolla, CA
Sept 1 – 3 , 2005	Chair	1st International Symposium on Kallikreins	Lausanne, Switzerland
May 30-Jun 2, 2006	International Advisory Board	Kinin 2006	Berlin, Germany
May 16-19, 2007	Co-Chair Organizing Committee	CLAS Annual Meeting	Puerto Rico
June 9-14, 2007	Member Organizing Committee	CSCC/CAMB/CAP Annual Meeting	Toronto
Oct 16-18, 2007	International Advisory Board	2nd International Symposium on Kallikreins	Santorini, Greece

Date	Position	Description	Location
Oct. 20-24, 2007	Organizing Committee	International Proteolysis Society	Patras, Greece
Aug 30-Sept 2, 2009	Scientific Advisory Board	3rd International Symposium on Kallikreins and Kallikrein-related Peptidases	Munich, Germany

Organization of Workshops

Date	Days	Description	Sponsor	Location
May 25, 1992	1	Introduction to Molecular Biology Techniques	Canadian Society of Clinical Chemists	Toronto, Canada
May 29-31, 1992	3	Molecular Biology Techniques	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
June 25-27, 1993	3	Molecular Biology Techniques	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
Nov 14-16, 1994	3	Molecular Biology Techniques	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
April 23, 1995	1	Molecular Biology Workshop	Canadian Society of Clinical Chemists	Whistler, B.C.
Nov 2, 1995		PSA Workshop	Department of Clinical Biochemistry, University of Toronto	Toronto, Canada
Aug 2, 1998	1	Breast, Ovarian and Prostate Cancer: New Developments in Diagnosis and Management	American Association for Clinical Chemistry	Chicago, IL
July 25, 1999	1	Breast, Ovarian and Prostate Cancer: New Developments in Diagnosis and Management	American Association for Clinical Chemistry	New Orleans
July 23, 2000	1	Breast, Ovarian and Prostate Cancer: New Developments in Diagnosis and Management	American Association for Clinical Chemistry	San Francisco
July 24, 2000	1/2	Development of New Diagnostics from the Human Genome Project	American Association for Clinical Chemistry	San Francisco
Nov 30, 2000	1/2	Impact of the Human Genome Project on Clinical Diagnostics	AACC Michigan Section	Windsor, ON, Canada
July 29, 2001	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Chicago, IL
Aug 1, 2001	1/2	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Chicago, IL
May 19, 2002	1/2	Genomic and Proteomic Technologies and Their Relevance to Clinical Diagnostics	Canadian Laboratory Medicine Congress	Calgary, ALTA
July 28, 2002	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Orlando, FL
July 31, 2002	½	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Orlando, FL
July 20, 2003	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Philadelphia, PA
July 23, 2003	½	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Philadelphia, PA
July 24, 2004	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Los Angeles, CA
July 26, 2004	½	Genomics, Proteomics and New Opportunities for Clinical Diagnostics	AACC Annual Meeting	Los Angeles, CA
July 24, 2005	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Orlando, FL
July 27, 2005	1	NACB Guidelines for Use of Tumor Markers at the Clinic [EduTrak]	AACC Annual Meeting	Orlando, FL
July 23, 2006	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Chicago, IL
July 25, 2006	½	The New Tools of Proteomics: Mass Spectrometry and Protein Microarrays	AACC Annual Meeting	Chicago, IL
July 17,2007	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	San Diego, CA
July 18, 2007	½	The New Tools of Proteomics: Mass Spectrometry and Protein Microarrays	AACC Annual Meeting	San Diego, CA

Date	Days	Description	Sponsor	Location
July 28, 2008	1	Tumour Markers: How We Use Them in the Clinic and New Developments	AACC Annual Meeting	Washington, DC
July 29, 2008	½	The New Tools of Proteomics: Mass Spectrometry and Protein Microarrays	AACC Annual Meeting	Washington, DC
July 20, 2009	½	Enzymes as Biomarkers of Human Diseases	AACC Annual Meeting	Chicago, IL

Journal Referee

1. Analyst
2. Analytica Chimica Acta
3. Analytical Biochemistry
4. Analytical Chemistry
5. Annals of Clinical Biochemistry
6. Biochimica Biophysica Acta
7. Biochemical and Biophysical Research Communications
8. Biochemistry
9. Biological Chemistry
10. Brain
11. Breast Cancer Research
12. British Journal of Cancer
13. Cancer Detection and Prevention
14. Cancer Epidemiology Biomarkers and Prevention
15. Cancer Investigation
16. Cancer Research
17. Cell Growth & Differentiation
18. Clinica Chimica Acta
19. Clinical Biochemistry
20. Clinical Cancer Research
21. Clinical Chemistry
22. Clinical Laboratory News
23. DNA and Cell Biology
24. EMBO Journal
25. European Journal of Oral Sciences
26. European Urology
27. Genomics
28. Glia
29. International Journal of Cancer
30. Journal of Biological Chemistry
31. Journal of Neurochemistry
32. Journal of Urology
33. Journal of Cellular Physiology
34. Journal of Clinical Oncology
35. Journal of Immunoassay
36. Journal of Pharmaceutical Sciences
37. Journal of Proteomic Research
38. Journal of the National Cancer Institute
39. Microchimica Acta
40. Molecular and Cellular Endocrinology
41. Molecular and Cellular Proteomics
42. Nature Biotechnology
43. Nature Medicine
44. Neuroscience Letters
45. Oncogene
46. Peritoneal Dialysis International
47. PLoS Medicine

48. Proteomics
49. Science
50. Sensors and Actuators
51. Talanta
52. Trends in Pharmacological Sciences
53. Tumour Biology
54. Urology
55. Zoological Science

Referee for Granting Agencies

1. National Science Foundation, USA
2. National Sciences and Engineering Research Council (NSERC)
3. Medical Research Council of Canada
4. International Science Foundation
5. Health Services Utilization and Research Commission (HSURC), Province of Saskatchewan
6. Grant Miller Cancer Awards, University of Toronto
7. Dean's Fund Awards, University of Toronto
8. National Medical Research Council of Singapore
9. National Institutes of Health, USA (NIH)

Member of Scientific Advisory / Editorial Boards

1. Member, Board of Editors, Clinical Laboratory News (1992-1996).
2. Member, Scientific Advisory Board, Clinical Biochemistry (1995-).
3. Member, Board of Editors, Clinical Chemistry (1995-2004) and Associate Editor (2008-)
4. Member, Editorial Board, Critical Reviews in Clinical Laboratory Sciences (1998-2002).
5. Associate Editor, Critical Reviews in Clinical Laboratory Sciences (2003-2008).
6. Member, Editorial Board, Clinica Chimica Acta (1999-2006).
7. Specialist Advisor, Human Gene Nomenclature Committee, Human Genome Organization (2000-).
8. Member, Editorial Advisory Panel, Expert Review of Molecular Diagnostics (2000-).
9. Member, Editorial Advisory Board, Tumour Biology (2001-)
10. Member, Editorial Advisory Board, International Journal of Biological Markers (2002-).
11. Special Issue Editor of Clinical Chemistry; Theme: Cancer Diagnostics. Discovery and Clinical Applications (Aug. 2002 issue).
12. Member, Editorial Board, IN VIVO (2003-).
13. Member, Editorial Board, Anticancer Research (2003-).
14. Member, Editorial Board, Clinical Proteomics (2004-) and Associate Editor (2005-).
15. Regional Editor, Journal of Medical Sciences (2004-).
16. Special Issue Co-Editor, Clinical Biochemistry; Theme: Recent Advances in Cancer Biomarkers (July 2004 issue).
17. Member, Editorial Board, British Journal of Cancer (2005-).
18. Member, Editorial Board, Cancer Letters (2005-2008).
19. Associate Editor, Cancer Research (2005-2008).
20. Member, Editorial Board, Journal of Clinical and Molecular Pathology [Italy] (2005-).
21. Member, Editorial Advisory Board, Current Cancer Therapy Reviews (2005-).
22. Member, Editorial Advisory Board, Molecular Oncology (2007-).
23. Member, Editorial Board, Expert Opinion on Medical Diagnostics (2007-2009).
24. Member, Editorial Board, The Open Clinical Chemistry Journal (2007-).
25. Member, Editorial Advisory Board, Biomarkers in Medicine (2007-).
26. Member of the Board, Minerva Endocrinologica (2007-).
27. Member, Editorial Advisory Board, International Journal of Cancer (2008-).
28. Member, Editorial Board, Journal of Cancer Epidemiology (2008-).
29. Section Editor for Medical Biochemistry, Canadian Journal of Pathology (2009-).
30. Member, Editorial Board, BMC Medicine (2009-).
31. Member, Reviewing Board, Journal of Pediatric Biochemistry (2009-).

Other Professional Activities

1. Chairman-elect [1994] and Chairman [1995] of the Upstate New York Section of the American Association for Clinical Chemistry.
2. Member, Awards Committee, CLAS Society, [1996 and 1997].
3. Member, Awards Committee, National Academy of Clinical Biochemistry (NACB), USA, [1996].
4. Member, Awards Committee, American Association for Clinical Chemistry (AACC), USA, [2001- 2004].
5. Chair, Laboratory Medicine Practice Guidelines on Tumour Markers. National Academy of Clinical Biochemistry (NACB), USA, [2002-2008].
6. Secretary [2000-2003], Vice-President [2004-2007] and President [2008-2011] of the International Society for Enzymology (ISE).
7. Member of the Board, International Society of Biomarkers in Medicine (ISOBM) [2008-].

Direction of PhD and MSc Theses

	Date	Degree	Name of Student	Title of Thesis	University of
1	June 1980 – June 1986	PhD	A. Mitsana-Papazoglou	Development of new ion-selective electrodes for drug analysis in biological fluids and formulations	Athens
2	Sept 1981 –Nov 1986	PhD	T.K. Christopoulos	Studies on the binding of ligands to macromolecules with ion-selective electrodes	Athens
3	Sept 1991 – Sept 1992	MSc	S. Hassapoglidou	Quantification of the p53 Tumour suppressor gene product in cell lines and serum of cancer patients — Development of new methodology and clinical studies	Toronto
4	Sept 1992 -Feb 1996	PhD	H. Yu	Clinical applications of prostatic and non-prostatic prostate specific antigen	Toronto
5	Sept 1993 –Dec 1996	MSc	M. Levesque	Immunoreactive p53 protein as a prognostic indicator in ovarian carcinoma	Toronto
6	Sept 1992 -Jan 1997	PhD	N. Zarghami	Mechanistic and clinical aspects of prostate-specific antigen expression in non-prostatic tissues	Toronto
7	Sept 1992-June 1997	PhD	K. Angelopoulou	Immune response against the p53 Tumour suppressor gene product: clinical studies and molecular mechanisms	Toronto
8	Sept 1995 – Sept 1997	MSc	R. Rosenberg (Co-Supervisor)	The effects of plant derived components on sex hormone receptors: Implications for hormone-dependent cancer treatment	Toronto
9	Sept 1996 – May 1998	MSc	M. Black	Molecular forms of prostate specific antigen in female sera	Toronto
10	Dec 1996 –Aug 1999	PhD	M. Levesque	Clinical utility of the p53 Tumour suppressor protein in various malignancies	Toronto
11	Sept 1997 – Nov 1999	MSc	C.V. Obiezu	Hormonal regulation of prostate specific antigen and human glandular kallikrein in males and females *in-vivo*: effects of androgens and antiandrogens on plasma and urinary PSA and hK2 levels	Toronto
12	Sept 1999 –Feb 2001	MSc	G. Foussias	Identification, characterization and mapping of novel members of the siglec family.	Toronto
13	Sept 1997 – April 2001	PhD	R. Rosenberg Zand	Flavonoids and hormone-dependent cancers.	Toronto
14	Sept 1999 – May 2001	MSc	A. Chang	Identification and characterization of a novel kallikrein gene, KLK-L4/KLK13	Toronto

	Date	Degree	Name of Student	Title of Thesis	University of
15	Sept 1998 -Feb 2002	PhD	G.J. Soleas	Analytical and biochemical aspects of wine constituents that affect human health	Toronto
16	Sept 1999 –July 2002	PhD	G.M. Yousef	The human kallikrein gene family: New gene discovery, locus characterization and clinical applications	Toronto
17	Sept 1997 –July 2002	PhD	L-Y. Luo	Human kallikrein 10: Genomic and proteomic aspects and its clinical applications	Toronto
18	Sept 2000 – Aug 2002	MSc	M. Zarghooni	The role of human kallikrein 5 in the pathogenesis of Alzheimer's disease	Toronto
19	Sept 2000 – Aug 2002	MSc	N. Memari	Clonig and protein expression of human kallikrein 12	Toronto
20	July 1998 – Nov 2002	PhD	A. Magklara	Co-expression of human kallikreins 2 and 3 in prostate and breast cancer: clinical utility and mechanism of steroid hormonal regulation	Toronto
21	Sept 2000 – May 2003	MSc	C. Borgono	Human kallikrein 14: Proteomic aspects and preliminary applications	Toronto
22	May 2002 – Sept 2003	MSc	M. Sidiropoulos	Tumour-specific loss of humankallikrein 10, KLK10/NES1 by CpG Island hypermethylation in breast	Toronto
23	Sept 2001 – July 2003	MSc	C. Kapadia	Human kallikrein 13:Development of a sensitive and specific immunofluorometric assay and identification of its binding proteins	Toronto
24	Jan 2000 – Sept 2004	PhD	C.V. Obiezu	Human kallikrein 4: Protein expression, enzymatic activity and association to cancer	Toronto
25	Sept 2002 – Sept 2004	MSc	L. Kurlender	Survey of alternative kallikrein transcripts and identification of a human kallikrein 5 splice variant which is differentially expressed in ovarian and prostate cancer	Toronto
26	Sept 2002 – Aug 2004	MSc	K. Oikonomopoulou	A pilot study to evaluate KLK6 as a biomarker for the detection of circularing tumour cells in ovarian cancer patients	Toronto
27	Sept 2004 – July 2005	MSc	I.P. Michael	Human kallikrein 5 (hK5): Biochemical characterization and its role in cancer	Toronto
28	Sept 2003 – Aug 2005	MSc	M. Elliott	Molecular evolution of new and old mammalian kallikrein gene families	Toronto
29	Sept 2004 – May 2006	MSc	S.J.C. Shan	Up-regulation of human tissue kallikrein 6 in ovarian cancer	Toronto
30	May 2003 – Dec 2006	PhD	C.A. Borgono	Functional characterization of human kallikrein 14	Toronto
31	Sept 2004 – Jun 2008	PhD	V. Kulasingam	Identification and validation of candidate breast cancer biomarkers: A mass spetrometric approach	Toronto
32	Sept 2004 – Jul 2008	PhD	J.L.V. Shaw	Distribution of human tissue kallikrein-related peptidases in tissues and biological fluids: Localization, hormonal regulation and physiological functions in the female reproductive system	Toronto
33	Sept 2004 – Aug 2008	PhD	K. Oikonomopoulou	Kallikrein-related peptidases signalling via proteinase-activated receptors	Toronto
34	Sept 2003 – Sept 2008	PhD	G. Sardana	Proteomic analysis of prostate cancer cell line conditioned media for the discovery of candidate biomarkers for prostate cancer	Toronto
35	Sept 2000 – Sept 2008	PhD	N. Memari	Roles of human kallikrein-related peptidases 9 and 12 in cancer	Toronto
36	Sept 2005 – Dec 2008	PhD	N. Emami	Identification and functional characterization of a novel activation cascade of the KLK family in seminal plasma	Toronto

	Date	Degree	Name of Student	Title of Thesis	University of
37	May 2007 - Jun 2009	MSc	C. Kuk	Mining the ovarian cancer ascites proteome for the identification of candidate cancer biomarkers	Toronto
38	Sept 2004 - Dec 2009	PhD	C.G. Gunawardana	Discovery of novel ovarian cancer biomarkers via proteomics and mass spectrometry	Toronto

The Research Laboratory of Dr. Eleftherios P. Diamandis [December 2009]

Research Coordinator:

1. Antoninus Soosaipillai — September 2008 –

Mass Spectrometry Specialists:

1. Chris Smith — January 2006 –
2. Ihor Batruch — March 2007 -

Post-Doctoral Fellows:

1. Andrei Drabovich — August 2008 –
2. Vathany Kulasingam — September 2008 -
3. Jian Zou — April 2009 -

PhD Candidates:

1. Iannis (John) Prassas — January 2005 –
2. Jane Chan-Kyung Cho — January 2006 -
3. Azza Eissa — May 2007 –
4. Uros Kuzmanov — March 2007 –
5. Jane Bayani — January 2008 -

MSc Candidates:

1. Maria Pavlou — May 2007 –
2. Shalini Makawita — September 2008 –
3. Georgios Karagiannis — January 2009 -
4. Punit Saraon — September 2009 –
5. Daniela Cretu — September 2009 –

Clinical Research Associate

1. Ana Konvalinka — April 2008 –

Past Research Associates and Post-Doctoral Fellows/Graduate Students {MSc}

Post-Doctoral Fellows

1. T.K. Christopoulos — January 1989 to September 1992
2. E.S. Lianidou — June 1989 to February 1990; September 1996; February 1997; June to July 1997
3. S. Kakabakos — September 1990 to July 1991
4. A. Chan — June 1991 to July 1992
5. R. Evangelista — January to May 1992
6. D. Tsuyuki — March to July 1996
7. G. Borchert — March to December 1996
8. M. Hui — May to October 1997
9. S. Majumdar — July 1996 to March 1998
10. K. Angelopoulou — June 1997 to December 1998
11. B. Bharaj — February 1997 to August 1999; May 2000 to October 2001
12. C. Shimizu — June 2000
13. A. Scorilas — October 1998 to August 2000

14.	C. Stephan	April 2001 to September 2001
15.	T. Nakamura	April 2001 to April 2003
16.	A. Mellati	July 2002 to December 2002
17.	A. Magklara	November 2002 to March 2003
18.	X. Duan	November 2002 –September 2003
19.	M. Moridani	September 2003 – December 2003
20.	L-Y. Luo	July 2002 – August 2004
21.	M. Ghosh	December 2002 – December 2004
22.	T. Kishi	April 2001 – December 2005
23.	N. Komatsu	April 2003 – March 2007
24.	M. Paliouras	May 2005 – December 2007
25.	C. Planque	July 2006 – June 2008
26.	Y. Courty	September 2007 – June 2008
27.	N. Memari	September 2008 – December 2008
28.	K. Oikonomopoulou	September 2008 –October 31, 2009
29.	H. Yoon	November 2008 – November 2009

Medical Residents

1.	P. Papanastasiou	November 1992 to March 1993
2.	K. Karambolova	May to October 1990
3.	M. Abd Ellatif Said	September 2001 to December 2001
4.	D-E. van der Merwe	October 2004 to October 2005

Research Assistants

1.	R. Kitching	January 1989 to January 1990
2.	H. Edgecomb	June 1994 to March 1995
3.	M. Solomou	November 1994 to June 1995
4.	C. Jia	March to October 1995
5.	D. Melegos	May 1994 to July 1998
6.	M. Black	January 1999 to May 1999
7.	W. Arnett	September 1998 to April 1999
8.	E. Vassilikos	September 1998 to May 1999
9.	G. Wasney	March 2002 to August 2003
10.	C. Linda Grass	September 1988 to August 2006
11.	D. Chin Du	September 2002 to July 2006
12.	I. Karakucuk-Koker	January 2004 to August 2006
13.	R. Thanabalan	May 2007 – June 2008
14.	A. Soosaipillai	September 2005 – August 2008
15.	T. Earle	September 2005 to August 2008
16.	M.Yazdanpanah	January 2006 – December 2008

Undergraduate/Co-Op Students

1.	W. Arnett	September 1996 to September 1997
2.	E. Vassilikos	September 1996 to September 1997
3.	Y. Antebi	September 1994 to May 1995
4.	J. Tsang	September 1998 to June 1999
5.	A. Kwamie	September 2000 to June 2001
6.	G. Sidiropoulos	September 2000 to June 2001
7.	Y. Tomic	September 2001 to June 2002
8.	M. Sidiropoulos	September 2001 to June 2002
9.	M-E. Polymeris	September 2002 to May 2003
10.	C. Davidian	September 2002 to May 2003
11.	J. Cho	September 2004 to May 2005
12.	A. Liu	September 2005 – May 2006
13.	C. Goard	September 2006 – May 2007

14.	A. Li	September 2007 – May 2008
15.	N. Zilbershtein	September 2007 – May 2008
16.	F. Jiang	September 2007 – May 2008

Summer Students & Volunteers

1.	C.C. Bean	June - July 1990, June - July 1991, February - July 1992
2.	G. Oreopoulos	March - July 1992
3.	D. Sahlas	May - July 1993
4.	M. Kalyvas	May - July 1994, May - July 1995, May - July 1996
5.	J. Karanikolas	May - July 1994
6.	A. Kang	May - September 1994
7.	S. Zammit	May - July 1995, May - July 1996
8.	A. Karumanchiri	May - July 1996
9.	D. Tambasco	May - July 1996
10.	F. Paiwand	May - August 1996
11.	G. Foussias	May - August 1997, May - July 1998
12.	H. Pappas	May - August 1997, May - July 1998
13.	B. Arnett	May - August 1997, May - July 1998
14.	I. Herrera	May - Aug in 1998, 1999, 2000, 2001 and 2002
15.	S. Michalitsianos	May - August 1998
16.	N. Matthews	May - August 1998
17.	M. Angelini	May - August 1998
18.	R. Ghatalia	May - August 1999
19.	J. Poulopoulos	May - Aug 1999, May - Aug 2000
20.	S. Croitoru (Taylor)	July - Aug 1999, May - Aug 2000
21.	H. Kim	September 1999 - March 2000
22.	A. Porter	February - September 2000
23.	M. Sidiropoulos	May - August 2000
24.	M. Diamandis	May - August 2000
25.	P. Giannakopoulos	May - August, 2000
26.	L. Rendl	May - August, 2000
27.	A. Kwamie	May - August, 2000
28.	P. Shames	May - August, 2000
29.	G. Sidiropoulos	May - August, 2000; May-August 2001
30.	P. Diamandis	May - August, 2000; May-June 2003
31.	M. Ordon	September 2000 - May 2001
32.	C. Chow	March 2001 - July 2001; May-August 2002
33.	M.E. Polymeris	May-August 2001; May-August 2002
34.	L. Iskander	May-August 2001
35.	K. Lawrie	May-August 2002
36.	C. Popalis	May-August 2002
37.	A. Kopolovic	May-August 2002
38.	K. Kwan	May -August 2002
39.	A. Emadi	May - August 2002; May-August 2003
40.	M. Elliott	May - August 2002; May-August 2003
41.	S. Hutchinson	January 2002 - August 2002
42.	J. C-K. Cho	May-August 2003; May-August 2004
43.	S.J. Cui	May-August 2003
44.	C. Kuk	May-August 2004; May-August 2005; May-August 2006
45.	C. Yeung	May-August 2004; May-August 2005
46.	N. Fountas	May-August 2004
47.	A. Masotti	May-August 2004; May-August 2005
48.	S. Khan	May-August 2004; May-August 2005
49.	B. Bowles	May-August 2004
50.	A. Liu	May-August 2005

51.	J. Fleisher	May-August 2005; May-August 2006
52.	A. Grass	May-August 2005; May-August 2006
53.	A. Martin	May-August 2005; May-August 2006; July-August 2007
54.	Y. Soleas	July-August 2006; May- August 2008; May-August 2009
55.	A. Campbell	May-August 2005; May-August 2006
56.	M. Wafer	May-August 2006
57.	R. Thanabalan	May-August 2007
58.	F. Jian	May-August 2007
59.	N. Zilbershtein	May-August 2007
60.	A. Li	May –August 2007
61.	J. Jayakar	May-August 2007
62.	P. Costa	May-August 2007
63.	C. Kuk	May-August 2007
64.	S. Bromberg	July-August 2007
65.	B. Judd	July-August 2007; May-August 2009
66.	B. Knezevic	July-August 2007
67.	A. Papanastasiou	July-August 2007
68.	S. Dawson	May- August 2008; May-August 2009
69.	B. Dineley	May- August 2008
70.	S. Makawita	May- August 2008
71.	V. Amodeo	May-August 2009
72.	D. Kagedan	May-August 2009
73.	I. Lecker	May-August 2009
74.	I. Soleas	May-August 2009
75.	K. Moshiri	May-August 2009
76.	J. Presvelos	May-August 2009
77.	A. Sperou	May-August 2009

Committee Member of Graduate Students

1.	Judith Stone, Ph.D.	February 1991 (S. Soldin)
2.	Joanne McLaurin, Ph.D.	November 1991 (M. Moscarello)
3.	Arlene Ali, Ph.D.	December 1991 (A. Baines)
4.	Robert Steward, Ph.D.	May 1993 (B. Bapat)
5.	Susan Hahn, Ph.D.	September 1994 (D. Goldberg)
6.	Alice Chatzilias, M.Sc.	May 9, 1995 (C. Whiteside)
7.	George Soleas, M.Sc.	January 1997 (D. Goldberg)
8.	Claudio Soravia, M.Sc.	September 1997 (B. Bapat)
9.	Polly Ghaunia, PhD.	October 1999 (K. Pritzker)
10.	Janita Lovgren, Ph.D.	December 1999, Malmo, Sweden (H. Lilja)
11.	John Choe, Ph.D.	September 2000 (T. Cruz)
12.	Melissa Cooper, M.Sc.	February 2001 (R. Kandel)
13.	Peter C. Papageorgiou, M.Sc.	April 2001 (D. Osmond)
14.	Changiz Taghibiglou, Ph.D.	October 2001 (K. Adeli)
15.	George Charames, M.Sc; Ph.D.	September 2002 (B. Bapat)
16.	Ma Jung, Ph.D.	June 2002 (C.C. Liew)
17.	Louise Pontrelli, M.Sc.	July 2002 (K. Adeli)
18.	Christopher Ton, Ph.D.	July 2002 (C.C. Liew)
19.	Vessela Vassileva, M.Sc.	September 2002 (B. Bapat)
20.	Aristotle Liontas, M.Sc.	September 2003 (H. Yeger)
21.	Crystal Au, M.Sc.	August 2003 (K. Adeli)
22.	Jean-Paul Morand, M.Sc.	June 2004 (K. Adeli)
23.	Sheron Perera, Ph.D.	September 2005 (B. Bapat)
24.	Eva Christensen, M.Sc.	September 2005 (R. Bristow)
25.	Noha Mousa, Ph.D	November 2006 (R. Casper)
26.	Claudia J. Arana M.Sc.	July 2008 (R. Kandel)

27. Drew Taylor, Ph.D. January 2009 (R. Kandel)

Experience in Management

Direction of approximately 8 Ph.D's and 4 technologists during my employment at CyberFluor Inc.
Direction of the Department of Clinical Biochemistry at the Toronto Western Hospital. I am currently directing the Section of Clinical Biochemistry, Mount Sinai Hospital, the Department of Clinical Biochemistry, University Health Network and the Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology, University of Toronto.

Invited Lectures — National and International Events

1. Fluorescence immunoassay: Current status and future prospects. Ontario Society of Clinical Chemists. Annual Scientific Meeting, Toronto, November 29, 1988.
2. Fluorescence immunoassay: Current status and future prospects. National Clinical Ligand Assay Meeting, Los Angeles, May 4, 1989.
3. Critical comparison of enzyme immunoassay with other alternative immunoassay techniques. 8th International Congress of Clinical Enzymology, Toronto, June 1, 1989.
4. New developments in time-resolved fluorescence immunoassay. St. Joseph's Institute of Laboratory Medicine Symposium, London, Ontario, April 26, 1990.
5. Multiple labelling and time-resolvable fluorophores. Oak Ridge Conference, St. Louis, April 11, 1991.
6. Principles and recent advances of time-resolved fluorescence immunoassays. 74th Canadian Society of Chemistry Symposium Hamilton, Ontario, June 5, 1991.
7. Time-resolved fluorometry with lanthanide chelates as labels – Principles, applications and new developments. IUPAC International Congress on Analytical Sciences, Chiba, Japan, August 29, 1991.
8. Oncogenes and Tumour suppressor genes – Biochemical Tumour markers of the future. Clinical Research Society of Toronto. Toronto, April 11, 1992.
9. Nucleic-acid probes. MDS Clinical Biochemistry Symposium, Toronto, June 19, 1992.
10. New developments in time-resolved fluorometric immunoassays. Clin Chem 92, Tarrytown, NY, October 16, 1992.
11. Time-resolved fluorometric immunoassay using lanthanide chelates as labels. 20th International Rare Earth Conference, Monterey, CA, September 12, 1993.
12. The p53 Tumour suppressor gene product and its application to clinical medicine. International Symposium on Clinical Enzymology. Sidney, Australia, November 10-12, 1993.
13. PSA in the cytosol of breast cancers. 2nd Stanford Conference on International Standardization of PSA Assays. Stanford, September 2, 1994.
14. PSA as a prognostic indicator in breast cancer. International Symposium on Clinical Enzymology, Athens, Greece, September 11, 1994.
15. Tumour markers in breast cancer. 5th IFCC Bergmeyer Conference, Tutzing, Germany, December 12-14, 1994.
16. Tumour suppressor genes and oncogenes in cancer: Are the present techniques meeting the challenge? Biochemiche Analytic 95. Leipzig, Germany, April 27, 1995.
17. Prostate specific antigen as a prognostic indicator in breast cancer. Cambridge Healthtech Institute "Prognostic factors in cancer". Arlington, VA, June 7-8, 1995.
18. Prostate-Specific Antigen: New developments and applications in non-prostatic Tumours. Clin Chem 95. Teaneck, NJ, October 11-14, 1995.
19. Prostate-Specific Antigen – a favourable prognostic indicator for women with breast cancer. Second International Congress of the Hellenic Society for Breast Cancer Research, Kos Island, Greece, October 25-28, 1995.

20. Prostaglandin D synthase in amniotic fluid and maternal serum: Possible association with fetal abnormalities. International Colloquium on β-trace. Osaka, Japan, November 17, 1995.
21. Ultrasensitive time-resolved fluorescence immunoassays. 2nd Symposium on analysis of peptides. Swedish Academy of Pharmaceutical Sciences. Stockholm, Sweden, January 29-31, 1996.
22. New clinical applications of PSA. Seminar, Department of Pathology and Laboratory Medicine. Hartford Hospital, Hartford, CT, USA, February 13, 1996.
23. New diagnostic applications of PSA. International Conference, PSA/Prostatic Disease. Llanberis, Wales, UK, May 21-22, 1996.
24. Prostaglandin D Synthase. Development of analytical methodology and preliminary clinical studies. 10th International Conference on Prostaglandins and the Related Compounds. Vienna, Austria, September 22-27, 1996.
25. Prostate-specific antigen: New Developments. Annual Endocrinological Society of India Conference (ESICON-96), Cochin, India, December 1, 1996. Also gave lectures in New Delhi (Nov. 26, 1996), Lucknow (Nov. 28, 1996), Madras (Dec. 5, 1996) and Mumbai (Dec. 7 & 9, 1996).
26. Prostate-specific antigen, a Tumour marker for prostatic and breast carcinoma. Royal Victoria Hospital, Division of Medical Genetics, Department of Medicine, McGill University, Montreal, March 13, 1997.
27. Prostate-specific antigen as a Tumour marker for breast and prostatic carcinoma. Visiting Professor, Washington University, School of Medicine, May 21-22, 1997.
28. PSA as a prognostic and monitoring marker of breast and prostate cancer. 5th Balkan Clinical Laboratory Federation Meeting, Ioannina, Greece, October 10, 1997.
29. Health effects of wine. A myth or a reality? 5th Balkan Clinical Laboratory Federation Meeting, Ioannina, Greece, October 10, 1997.
30. Prostate specific antigen: New knowledge. Fox Chase Cancer Center, Philadelphia, PN, October 31, 1997.
31. PSA: Free vs total, microassays and other variants. Urology Update 1997, Toronto, Nov. 8, 1997.
32. Monitoring of prostate cancer with ultrasensitive assays. Conference on new diagnostic tools for prostate cancer. Athens, Greece, December 12, 1997.
33. Clinical applications of the p53 Tumour suppressor gene. CSCC Annual Meeting, Ottawa, June 17, 1998.
34. Prostate specific antigen: New developments. AACC Upstate New York Section, Rochester, NY, October 23, 1998.
35. Prostate cancer and prostate specific antigen: A review. The Society of Scientific Clinical Laboratory Directors of Cyprus. Limassol, Cyprus, November 1, 1998.
36. Recent developments in Tumour markers - clinical applications for disease diagnosis, prognosis and monitoring. 2nd Panhellenic Clinical Chemistry Conference. Glyfada, Athens, November 6, 1998.
37. p53 Autoantibodies. Tumour Markers at the Millennium. Santa Barbara, CA, Feb 26-Mar 2, 1999.
38. The human kallikrein gene family – association with breast and prostate cancer. Annual meeting of the Clinical Ligand Assay Society, Philadelphia, PA, May 7, 1999.
39. Overview of enzymes used in molecular biology. International Society for Enzymology Meeting, Venice, Italy, June 6, 1999.
40. Tumour markers in prostate cancer. IFCC-WorldLab Meeting, Florence, Italy, June 8, 1999.
41. Tumour markers for breast and prostate cancer. Annual meeting of the Society of Clinical Chemists of Quebec, Saint Adele, PQ, Oct. 21, 1999.
42. PSA changes in benign prostatic hyperplasia. Urology Update, Toronto, Nov. 6, 1999.
43. The impact of genomics in clinical diagnostics. NRC/IRAP Biotechnology Forum, Toronto, Nov. 29-30, 1999.
44. The new kallikrein gene family – implications in carcinogenesis. Department of Clinical Chemistry, Lund University, Malmo, Sweden, Dec. 15, 1999.

45. The new human kallikrein gene family: connection to breast and prostate cancer. Feist-Weiller Cancer Centre, Louisiana State University Medical Center, Shreveport, LA, March 18, 2000.
46. Kallikeins and cancer: Visiting Professor, University of Pennsylvania, PA, April 24, 2000.
47. Discovery of new human kallikreins and genomic organization of the human kallikrein gene locus. Enzymology 2000, Naples, Italy, May 21-24, 2000.
48. Birth, growth, death and resurrection of the Clinical Chemist. Athena Society Meeting, Spetses, Greece, Sept. 19-21, 2000.
49. Application of human kallikrein genes in prostate and other cancers. 6th World Hellenic Biomedical Congress, Athens, Greece, Oct. 11-14, 2000.
50. PSA and novel biomarkers in prostate cancer. Prostate cancer symposium on novel stragegies in prostate cancer treatment and diagnosis. Royal Melbourne Hospital, Australia, Nov. 3, 2000.
51. Kallikreins as cancer biomarkers. Plenary lecture at the 38th Annual Scientific Conference of the Australian Association of Clinical Biochemists. Canberra, Australia, Nov. 8-10, 2000.
52. Current trends in biochemical testing for prostate cancer. Pacific Laboratory Medicine Services (PALMS) Pathology Forum. Royal North Shore Hospital, Sydney, Australia, Nov. 9, 2000.
53. Time-resolved fluorescence and its applications to immunoassays and molecular diagnostics as well as microarrays. Symposium entitled "Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics". University of Turku, Finland, Feb. 6, 2001.
54. Prostate cancer biomarkers. Symposium entitled "Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics". University of Turku, Finland, Feb. 6, 2001.
55. The human kallikrein gene family. Symposium entitled "Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics". University of Turku, Finland, Feb. 7, 2001.
56. Future of clinical diagnostics and the human genome project. "Time-Resolved Fluorescence Technologies and Prostate Cancer Diagnostics". University of Turku, Finland, Feb. 8, 2001.
57. Sequencing with microarray technology, genomic approaches to developing new diagnostics. 47th Congress of the Egyptian Society of Clinical Chemistry. Cairo, Egypt, Feb. 10, 2001.
58. Development of new Tumour markers for prostate and varioous cancers. 47th Congress of the Egyptian Society of Clinical Chemistry. Cairo, Egypt, Feb. 11, 2001.
59. Time-resolved fluorometry for protein microarrays. Workshop on Protein Microarray Technologies. Boston, MA, Feb. 20, 2001.
60. Two new ovarian cancer biomarkers. Conference entitled: "Tumour Markers: A New Era". Santa Barbara, CA. March 4, 2001.
61. Towards identification of new prostatic biomarker. Conference entitled "Tumour Markers: A New Era". Santa Barbara, CA. March 5, 2001.
62. New human kallikrein genes: possible novel disease biomarkers.
Dept. of Pathology, The University of Texas, Southwestern Medical Center, Dallas, TX, March 19, 2001.
63. Clinical application of human kallikrein genes. Eli Lilly, Indianapolis, IN, March 16, 2001.
64. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. University of Montreal, Montreal, PQ, April 6, 2001.
65. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Roswell Park Cancer Institute, Buffalo, NY, April 11, 2001.
66. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. University of Michigan, Ann Arbor, April 13, 2001.
67. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. 1st Iranian Congress of Cancer Research (Keynote Speaker), Urmia, Iran, May 15, 2001.

68. Three novel ovarian cancer biomarkers. XXIX ISOBM Meeting, Barcelona, Spain, October 1, 2001.
69. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Mauriziano Hospital, Torino, Italy, October 4, 2001.
70. Expression of tissue kallikreins in the pituitary gland. 8th International Pituitary Pathology Meeting, Delphi, Greece, October 6, 2001.
71. Duties and responsibilities of laboratory scientists. International Conference on Laboratory Medicine, Padova, Italy, October 23, 2001.
72. Human kallikreins and cancer: New opportunities for diagnostics and therapeutics. 2nd General Meeting of the International Proteolysis Society, Munich, Germany, November 3, 2001.
73. Human kallikreins: Gene discovery and clinical applications. Capital Section of the American Association for Clinical Chemistry.Washington DC, December 5, 2001.
74. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Pathology Rounds, Department of Pathology, Johns Hopkins University, Baltimore MD, December 6, 2001.
75. Human kallikreins: Gene discovery and clinical applications.CLAS Annual Meeting. Houston TX, May 23, 2002.
76. Human kallikreins and PSA for prostate cancer diagnosis. American Association for Clinical Chemistry Annual Meeting. Orlando, FL, July 31, 2002.
77. Clinical applications of human kallikreins.Molecular Medicine: XXVIII Nordic Congress in Clinical Chemistry. Reykjavik, Iceland, August 11, 2002.
78. The kallikrein family in the testis and testicular neoplasia. 5th Workshop on Carcinoma In-Situ and Testicular Cancer. Copenhagen, Denmark, August 30, 2002.
79. Clinical Applications of human kallikreins. International Society for Fibrinolysis and Proteolysis. Munich, Germany, September 9, 2002.
80. Discovery of the human kallikrein locus. ISOBM Annual Meeting. Boston, MA, September 11, 2002.
81. Human kallikreins: Gene discovery and clinical applications. Hamamatsu University School of Medicine. Hamamatsu, Japan, October 17, 2002.
82. Human kallikreins as cancer biomarkers. International Society for Enzymology Meeting. Hamamatsu, Japan, October 18, 2002.
83. Tumour markers in ovarian cancer. IX International Symposium on Biology and Clinical Usefulness of Tumour Markers. Barcelona, Spain, February 13, 2003.
84. New Tumour markers in ovarian cancer. IX International Symposium on Biology and Clinical Usefulness of Tumour Markers. Barcelona, Spain, February 15, 2003.
85. Kallikreins as Tumour markers. Tumour Markers: Discovery to Practice. Santa Barbara, CA, March 3, 2003.
86. Kallikreins: New ovarian cancer biomarkers. 9th Bi-Annual Int'l Forum on Ovarian Cancer, Helene Harris Memorial Trust. Stratford-Upon-Avon, March 27, 2003.
87. Strategies for discoviering new cancer biomarkers. Annual Clinical Ligand Assay Society, Baltimore, MD. May 8, 2003.
88. Kallikreins as cancer biomarkers. IFCC Euromedlab Conference, Barcelona, Spain, June 5, 2003.
89. Kallikreins as diagnostic markers. Early Detection Research Network Meeting, Pittsburg, PA, June 25, 2003.
90. Cancer biomarkers: From discovery to clinical practice – kallikreins as an example. Gordon Conference: New Frontiers in Cancer Detection and Diagnosis, Proctor Academy, Andover, NH, August 17-22, 2003.
91. Practice guidelines for tumour markers. The XXXI Meeting of the International Society for Oncodevelopment Biology and Medicine [ISOBM], Edinburgh, UK, August 30-September 4, 2003.
92. Kallikreins: A new family of serine proteinases [Keynote Lecture]. Proteinase Inhibitors (an IBC Conference), Zurich, Switzerland, September 3-4, 2003.

93. Human kallikreins: Gene locus characterization and clinical applications. 57th Harden Conference, Oxford, UK, September 10-12, 2003.
94. The status of clinical chemistry in Canada. 3rd Athena Society Meeting, Samos, Greece, September 22-26, 2003.
95. Kallikreins as ovarian and prostate cancer biomarkers. The Prostate Cancer Charity Lecture: 5th World Congress on Urological Research, London, UK, September 24-27, 2003.
96. Human kallikreins: A novel family of cancer biomarkers. Lab Rad 2003 International Conference, Cairo, Eqypt, December 12-15, 2003.
97. Human kallikreins: Promising new biomarkers. IBC's 2nd Annual Scientific and Technological Advances in Cancer Research, Reston, VA, February 11-13, 2004.
98. Point/Counterpoint Debate: Serum proteomics pattern diagnostics. Panelists: E. Petricoin III, L. Liotta, S.J. Skates, E.P. Diamandis. IBC's 2nd Annual Scientific and Technological Advances in Cancer Research, Reston, VA, February 11-13, 2004.
99. Limitations of mass spectrometry-derived serum proteomic patterns for cancer diagnostics. Analytica, Munich, Germany, May 11-14, 2004.
100. Human tissue kallikreins: Novel prognostic and diagnostic biomarkers for ovarian carcinoma. Canadian Conference on Ovarian Cancer Research, Ottawa, ON, May 16-18, 2004.
101. Early diagnosis of ovarian carcinoma by SELDI-TOF mass spectrometry: Opportunities and potential limitations. Canadian Conference on Ovarian Cancer Research, Ottawa, ON, May 16-18, 2004.
102. Human tissue kallikreins: Novel prognostic and diagnostic cancer biomarkers. The XXXII meeting of ISOBM, Helsinki, Finland, June 19-23, 2004.
103. Kallikreins as cancer biomarkers: Recent developments. 5th Central European Conference on Human Tumour Markers. Prague, Czech Republic, October 103, 2004.
104. A 30-year journey in science and medicine. Academy of Athens, Athens, Greece, April 5, 2005.
105. Strategies for discovering new cancer biomarkers: Opportunities and pitfalls. Biomarkers in HIV and Cancer Research, Mathematical Society Institute, Ohio State University, Columbus, OH, April 18-22, 2005
106. Mass spectrometry as a diagnostic tool: Advantages and disadvantages. 22nd International Papillomavirus Conference, Vancouver, BC, April 30 & May 6, 2005.
107. Technology primer for Oncologists: Cancer Proteomics. Meet the Professor Session. 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.
108. Tumor Markers: Present and future. Professional Practice in Clinical Chemistry: A review and update. Alexandria, VA, May 15-19, 2005.
109. Human Tissue Kallikreins as Biomarkers for Breast, Ovarian and other malignancies, Era of Hope Meeting, Philadelphia, PA, June 8-11, 2005.
110. Human Tissue Kallikreins: Discovery and Clinical Applications. Visiting Professor, Medical University of S. Carolina, August 8, 2005.
111. Tumor Markers – Present and Future. Visiting Professor, Medical University of S. Carolina, August 8, 2005.
112. Kallikrein World. 1st International Symposium on Kallikreins, Lausanne, Switzerland, September 1-3, 2005.
113. Human Tissue Kallikreins as Potential Markers of Prostate Cancer. EDRN Steering Committee Meeting, Seattle, WA, September 20, 2005.
114. Proteomic and Genomic Technologies for Biomarker Discovery, Annual ISOBM Meeting, Rhodes Island, Greece, September 25, 2005.
115. Human Tissue kallikreins – Update, Annual ISOBM Meeting, Rhodes Island, Greece, September 25, 2005.
116. Mass Spectrometry and Protein Microarrays: Two Powerful Tools for Proteomic Research and Applications. Proteomics Conference, AACC, Washington, DC, October 24-25, 2005.

117. Strategies for Discovering New Cancer Biomarkers. Canadian Chinese Association Annual Conference, Toronto, ON, November 26, 2005.
118. Proteomic and Genomic Approaches for Discovering Cancer Biomarkers: Current Status and Future Prospects. National Institutes of Health [NIH], Bethesda, MD, March 3, 2006.
119. Serum Kallikreins as Biomarkers for Cancer. Tumor Markers for Personalized Medicine: The New Frontier. Mauna Lani Resort, Island of Hawaii, March 2-3, 2006.
120. Serum Kallikreins as Biomarkers for Cancer Plus Proteomic Approaches Biomarkers In Prostate Cancer Workshop. Canadian Prostate Cancer Research Initiative. Niagara-on-the-Lake, ON, May 13, 2006.
121. Technology Primer for Oncologists: Cancer Proteomics. Meet the Professor Session. 41st Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA, June 2-6, 2006.
122. Junk-Omics®. Athena Society Meeting, Mykonos, Greece, September 5-8, 2006.
123. Quality Assurance in the "Omics Era". Athena Society Meeting, Mykonos, Greece, September 5-8, 2006.
124. Human Tissue Kallikreins: Physiology, Pathobiology and Clinical Applications. XXV Congress of the Sociedad Española de Bioquímica Clínica y Patología Molecular, Bilbao, Spain, October 9-11, 2006.
125. Kallikrein enzymes as biomarkers for cancer. International Conference on Laboratory Medicine, Padova, Italy, October 24-25, 2006.
126. Strategies for new biomarker identification.Innovation and reform in clinical trials.Toronto, Canada, November 1-2, 2006.
127. Human Tissue Kallikreins: Physiology, Pathobiology and Clinical Applications. Cyprus Neurological Center, Nicosia, Cyprus, March 28, 2007.
128. Is Early Detection of Cancer with Serum Biomarkers or Proteomic Profiling Feasible? (Invited presentation). Annual American Association for Cancer Research Meeting, Los Angeles, CA, April 14, 2007.
129. Tumor markers: Professional Practice in Clinical Chemistry: A Review and Update.Washington D.C., April 22, 2007.
130. Desquamation: What's new? Barrier Function of Mammalian Skin. Gordon Research Conference, Newport, RI, August 5-10, 2007.
131. Novel biomarkers for prognosis and therapy response in ovarian cancer. EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer". Brussels, Belgium, November 15-17, 2007.
132. An integrated approach for biomarker discovery with tandem mass spectrometry. Thermo Fisher Workshop. Annual AACC Meeting, Washington, DC, July 30, 2008.
133. Strategies for discovering novel cancer biomarkers by using mass spectrometry. Ontario Society of Clinical Chemists (OSCC) Annual Scientific Meeting, Toronto, ON, November 6, 2008.
134. Strategies for discovering novel cancer biomarkers by using mass spectrometry. Convergent Medical Technologies (CMT), Crowne Plaza Hotel, Toronto, ON, November 6, 2008.
135. An integrated approach for biomarker discovery with tandem mass spectrometry. German Cancer Aid Symposium on "Novel Tools for Risk Assessment and Early Detection of Premalignant Lesions and Cancer". Hotel Bristol Bonn, Germany, May 6-7, 2009.
136. 5th Annual Athena Society Meeting, Porto Heli, Greece, September 6-10, 2009.

Invited Lectures — Local and Commercial Events

1. Ion-selective electrodes in routine clinical chemistry and beyond. Update in Analytical Biochemistry. Toronto, June 3, 1987.
2. Time-resolved fluorescence immunoassay. Update in Analytical Biochemistry, Toronto, June 4, 1987.

3. Time-resolved fluorescence in immunological assays. Department of Chemistry & Biochemistry, University of Windsor, February 16, 1990.
4. Principles and applications of the polymerase chain reaction. Advances in Interpretative Biochemistry. Toronto, September 13, 1990.
5. Applications of time-resolved fluorometry. Mitsubishi Research Centre, Yokohama, Japan, August 28, 1991.
6. Avidin-biotin techniques - Linkages of antibodies to solid phases. Advances in Immunodiagnostic Techniques. Theory and Applications. Toronto, September 12, 1991.
7. Oncogenes and Tumour suppressor genes. New biochemical tests and the future of clinical chemistry. Toronto Society of Clinical Chemists, Toronto, April 14, 1992.
8. Serological diagnosis of cancer. Department of Chemistry and Biochemistry, University of Windsor, October 30, 1993.
9. PSA as a breast cancer marker. Medgenix Diagnostics, Brussells, Belgium, September 2, 1994.
10. PSA and female breast tissue. Toronto Society for Clinical Chemistry, Toronto, April 5, 1995.
11. PSA, New Insights. Andy Bruce Symposium, Toronto, May 27, 1995.
12. PSA in non-prostatic tissue. Keynote Lecturer, Interuniversity Pathology Research Day, June 2, 1995.
13. PSA: A new growth factor? DSL Third International Scientific Meeting. Feldafing, Germany, September 30 – October 4, 1995.
14. Prognostic factors in breast cancer. Ontario Society of Medical Technologists' Annual Meeting, Niagara Falls, September 22, 1995.
15. Time-resolved fluorometry. Bracco Research. Princeton, NJ, May 30, 1996.
16. Prostate-specific antigen – New Developments. Clinical Ligand Assay Society, Texas Section. Houston, TX, November 2, 1996.
17. The Role of Ultrasensitive PSA Assays in Prostate Cancer Monitoring. The Biology and Treatment of Prostate Cancer, Toronto, November 11, 1996.
18. Clinical applications of ultrasensitive PSA assays. Industry workshop at the annual CSCC meeting, Ottawa, June 16, 1998.
19. PSA: Application beyond the prostate. Industry luncheon lecture at the Annual AACC meeting, August, 3, 1998.
20. The normal epithelial cell-specific gene 1 (NES1) resides on chromosome 19q13 and appears to be a new member of the human kallikrein gene family. 4th Annual DSL Scientific Meeting, Gleneden Beach, OR, September 9-12, 1998.
21. Ultrasensitive PSA assays – clinical applications. Cross Cancer Centre, Edmonton, Alberta, November 13, 1998.
22. Ultrasensitive PSA and non-prostatic PSA. Commercial presentation at "Tumour Markers at the Millennium", Santa Barbara, CA, February 26 - March 2, 1999.
23. Tumour markers for breast and prostate cancer. MDS Fall Scientific Symposium, Toronto, Oct. 29, 1999.
24. Do I have prostate cancer? A biochemical approach. Industry Workshop, Australian Association of Clinical Biochemists Annual Meeting, Canberra, Australia, Nov. 8, 2000.
25. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Millennium Pharmaceuticals, Boston, MA, April 20, 2001.
26. Human kallikreins: Gene discovery, phylogenetic analysis and clinical applications. Corixa Corp., Seattle, WA, May 4, 2001.
27. Human kallikreins: Biotechnology. Symposium entitled "Frontiers in Laboratory Medicine", Toronto, Nov 8, 2001.
28. Human kallikreins and clinical applications. Clinical Biochemistry Rounds, Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, January 9, 2002.

29. Evaluation and treatment of PSA recurrence recognizing the hormonal axis in the management of the prostate cancer patient.One day conference organized by Charite Hospital and DPC Academy,Berlin,Germany, June 12, 2002.
30. Human tissue kallikreins: Novel prognostic and diagnostic biomarkers for ovarian carcinoma. The Weismann Institute Conference, Toronto, May 31, 2004.
31. Mass spectrometry – derived serum proteomic pattern for cancer diagnosis. Novartis Institute for Biomedical Research, Cambridge, MA, USA, March 23, 2005.
32. Kallikreomics and Proteomics.Amgen, Thousand Oaks, CA, USA, August 3, 2006.
33. Human Tissue Kallikreins: Physiology, Pathobiology and Clinical Applications. Samuel Lunenfeld Research Institute Luncheon Presentation. Toronto, ON, April 27, 2007.
34. Strategies for discovering novel cancer biomarkers by using mass spectrometry. Panacea Pharmaceuticals, Gaithersburg, MD, USA, November 5, 2008.
35. Ovarian cancer biomarker discovery using proteomics and mass spectrometry, Ovarian Cancer Research Retreat, Princess Margaret Hospital, Toronto, ON, November 21, 2008.
36. New biomarker discovery using proteomics and mass spectrometry, Ortho Clinical Diagnostics, Rochester, NY, USA, May 21, 2009.

Invited Lectures — Clinical Rounds

1. Renal Rounds, Toronto Western Division, The Toronto Hospital, June 1987.
2. Grand Rounds, Toronto Western Division, The Toronto Hospital, May 1991.
3. Renal Rounds, Toronto General Division, The Toronto Hospital, June 1993.
4. Medical Oncology Rounds, Princess Margaret Hospital, September 20, 1993.
5. Grand Rounds, Toronto Western Division, The Toronto Hospital, February 9, 1994.
6. Immunology Rounds, Toronto Western Division, The Toronto Hospital, February 15, 1994.
7. Renal Rounds, Toronto General Division, The Toronto Hospital, February 18, 1994.
8. Oncology Rounds, The Toronto Hospital Oncology Research Center, November 3, 1994
9. Grand Rounds, Toronto General Division, The Toronto Hospital, February 9, 1995.
10. Endocrine Rounds, Hospital for Sick Children, December 13, 1995.
11. Urology Residents Rounds, Hospital for Sick Children, December 15, 1995.
12. Urology Rounds, Princess Margaret Hospital, July 4, 1997.
13. Measurement of Hormones in Serum with State-of-the-Art Techniques. Advantages and Pitfalls. Postgraduate Endocrine Series, March 27, 1998.
14. The Kallikrein Gene Family. Preventive Oncology Rounds, Ontario Cancer Institute, February 10, 1999.
15. Kallikreins and Breast Cancer. Pathology Rounds, Women's College Hospital, March 30, 1999.
16. Human Kallikreins and Ovarian Cancer. Princess Margaret Hospital, January 21, 2002.
17. Cancer Diagnostics – The Old and the New. Department of Genetics, North York General Hospital, Toronto, December 2, 2002.
18. Kallikreins as Biomarkers for Ovarian Cancer. Ovarian Cancer Clinical Rounds, Princess Margaret Hospital, Toronto, November 22, 2004.
19. Human tissue kallikreins: Novel prognostic and diagnostic biomarkers for cancer. Pediatric Clinical Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY, June 23, 2005.

Roundtables

1. Breakfast and Luncheon Roundtable, Annual AACC Meeting, New York, July 1993.
2. Breakfast Roundtable, Annual CSCC Meeting, Quebec City, May 30, 1994.
3. Breakfast and Luncheon Roundtable, Annual AACC Meeting, New Orleans, July 1994.
4. Breakfast Roundtable, Annual CSCC Meeting. Halifax, Nova Scotia, July 7, 1997.
5. Breakfast and Luncheon Roundtable, Annual AACC Meeting. Atlanta, Georgia, July 22, 1997.
6. Breakfast and Luncheon Roundtable, Annual AACC Meeting. Chicago, Illinois, August 4, 1998.
7. Breakfast Roundtable, Annual CLAS Meeting, Houston, Texas, May 25, 2002.

Interviews: Media Publications & Press Releases

1. Globe and Mail, March 25, 1994.
2. University of Toronto Bulletin, March 28, 1994.
3. The Toronto Star, April 2, 1994.
4. The Toronto Sun, April 3, 1994.
5. The Medical Post, April 5, 1994.
6. AACR Press Release, March 16, 1995.
7. The Toronto Star, March 20, 1995.
8. Clinical Lab Letter, April 15, 1995.
9. Genetic and Engineering News, April 15, 1995.
10. Tomorrow's Medicine Magazine, July 22, 1995.
11. Reader's Digest, December 1995; pg. 101.
12. Physician's Weekly, May 26, 1997.
13. Clinica, October 27, 1997; pg. 18.
14. Globe and Mail, October 30, 1997.
15. Physician's Weekly, July 19, 1999.
16. The Toronto Star, October 6, 1999.
17. The Chronicle of Urology and Sexual Medicine, February 2000.
18. Reuter's Health, June 30, 2003.
19. Analytical Chemistry, November 1, 2003; pgs. 472A-476A.
20. Nature Medicine, 2003;9:980.
21. The New York Times, February 3, 2003.
22. Canadian Living Magazine, September 2004.
23. Nature, January 15, 2004;427:268.
24. National Review of Medicine, February 15, 2004;1:3.
25. Oncology Exchange, February 15, 2004;2: #4.
26. The New York Times, February 3, 2003.
27. The Wall Street Journal, March 12, 2004.
28. National Review of Medicine, March 15, 2004;2: #5.
29. Clinical Laboratory Strategies, March 2004;9:5.
30. The Scientist, April 12, 2004;18:4.
31. Journal of the National Cancer Institute, 2004;96:500-501 [Apr. 7/04 issue].
32. Journal of the National Cancer Institute, 2004;96:816-818 [June 2/04 issue].
33. Technology Review, 2004;66-68 [July/August issue].
34. New York Times, February 3, 2004 [Section F].
35. Sinai Scene, July 15, 2005.
36. Newspaper Apogevmatini (Greece), April 17, 2005.
37. Nature, August 2005,18;436:1060.
38. Ontario Institute of Cancer Research (OICR) Annual Report, 2006; pg 9.
39. Socity for Young Clinical Laboratories (SYCL), March 2006.
40. CAP Today, July 2006;20:7.
41. Homemakers Magazine, October 2006; pgs 58-64.
42. Clinical Chemistry News, February 2007;33:2.
43. JAMA, October 2007; pg 1751.
44. Science, November 3, 2009.
45. Nature Medicine 2009;15:1339-1343 [Dec. issue 12].

List of Publications: Books

1. *E.P. Diamandis*, P.A. Siskos, A. Papanastasiou-Diamandi.
   Laboratory Exercises in Clinical Chemistry (~105 pages, in Greek), Athens, 1986.
2. *E.P. Diamandis*, P.A. Siskos, A. Papanastasiou-Diamandi.
   Lectures in Clinical Chemistry (~ 500 pages, in Greek), Athens 1987.

3. *E.P. Diamandis*, T.K. Christopoulos. (Eds.)
   Immunoassay (579 pages). Academic Press, San Diego, CA 1996.
4. *E.P. Diamandis*, H.A. Fritsche, H. Lilja, D.W. Chan, M.K. Schwartz (Eds.)
   Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications (541 pages).
   AACC Press, Washington, DC, 2002.

Book Chapters

1. T.P. Hadjiioannou, D.S. Papastathopoulos and *E.P. Diamandis*. Applications of ion-selective electrodes (ISE) in continuous-flow clinical analysis. In: "Computerization and Automation in Health Facilities". Martin Rubin Editor, pp. 169-196. CRC Press (1984).
2. *E.P. Diamandis* and T.K. Christopoulos. Biochemical markers of malignancy. In: "Clinical Chemistry" A.H.B. Wu, Editor, pp 103-111. Health and Education Resources Inc., 1991.
3. *E.P. Diamandis* and T.K. Christopoulos. Time-resolved fluorescence immunoassays - Principles and applications In: "Immunochemical Assays and Biosensor Technology for the 1990s". R. Nakamura, Y. Kasahara and G. Rechnitz, Editors, pp 251-271. American Society of Microbiology, 1992.
4. *E.P. Diamandis* and T.K. Christopoulos. Time-resolved fluorescence. In: "Non-radioactive labelling and detection of biomolecules" C.Kessler, Editor. pp 188-193. Springer-Verlag 1992.
5. *E.P. Diamandis* and T.K. Christopoulos. Detection of lanthanide chelates and multiple labelling strategies based on time resolved fluorescence. In: "Nonisotopic DNA Probe Techniques". L.J. Kricka, Editor, pp. 263-274. Academic Press, 1992 and pp 377-390, Second Edition, 1995.
6. T.K. Christopoulos and *E.P. Diamandis*, Past, present and future of immunoassays. In: "Immunoassay". *E.P. Diamandis* and T.K. Christopoulos, Editors, pp. 1-3. Academic Press, Inc. 1996.
7. T.K. Christopoulos and *E.P. Diamandis*. Theory of immunoassays. In: "Immunoassay". *E.P. Diamandis* and T.K. Christopoulos, Editors, pp. 25-50. Academic Press, Inc. 1996.
8. T.K. Christopoulos and *E.P. Diamandis*. Immunoassay configurations. In: "Immunoassay". *E.P. Diamandis* and Christopoulos, TK, Editors, pp. 227-236. Academic Press, Inc. 1996.
9. T.K. Christopoulos and *E.P. Diamandis*. Fluorescence immunoassays. In: "Immunoassay". *E.P. Diamandis* and T.K. Christopoulos, Editors, pp. 309-335. Academic Press, Inc. 1996.
10. *E.P. Diamandis*, M.J. Kosravi and T.K. Christopoulos. Development of in-house immunological assays. In: "Immunoassay". *E.P. Diamandis* and T.K. Christopoulos, Editors, pp. 555-568. Academic Press, Inc. 1996.
11. *E.P. Diamandis* and H. Yu. Non-prostatic sources of prostate-specific antigen. In: "The Urologic Clinics of North America": Prostate-specific antigen: the best prostatic Tumour marker. J.E. Oesterling, Editor, Vol. 24; pp. 275-282. W.B. Saunders Co., 1997.
12. D.M. Goldberg, G.J. Soleas, S.E. Hahn, *E.P. Diamandis*, A. Karumanchiri. Identification and assay of trihydroxystilbenes in wine and their biological properties. *In:* Wine: Nutritional and Therapeutic Benefits. Tom R. Watkins, Editor. pp American Chemical Society, 1997.
13. E.P. Diamandis. Tumour Markers: Past, present and future. In: Tumour Markers: Physiology, Pathobiology, Technology and Clinical Applications. *E.P. Diamandis*, H.A. Fritsche, H. Lilja, D.W. Chan, M.K. Schwartz (Eds.), pp 3-8, AACC Press, 2002.
14. A. Haese, C. Becker, *E.P. Diamandis*, H. Lilja. Adenocarcinoma of the prostate. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. *E.P. Diamandis*, H.A. Fritsche, H. Lilja, D.W. Chan, M.K. Schwartz (Eds.), pp 193-237, AACC Press, 2002.
15. G.M. Yousef, *E.P. Diamandis*. Kallikreins as cancer biomarkers. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. *E.P. Diamandis*, H.A. Fritsche, H. Lilja, D.W. Chan, M.K. Schwartz (Eds.), pp 465-469, AACC Press, 2002.

16. T. Kishi, ***E.P. Diamandis***. Neuropsin, human tissue kallikrein 8. In:Handbook of Proteolytic Enzymes 2nd Edn., A.J. Barrett, N.D. Rawlings, J.F. Woessner (Eds.), Vol. 2, #484, pp 1593, Elsevier 2004.
17. ***E.P. Diamandis***, L-Y. Luo. Human tissue kallikrein 10. In:Handbook of Proteolytic Enzymes 2nd Edn., A.J. Barrett, N.D. Rawlings, J.F. Woessner (Eds.), Vol. 2, #485, pp 1593-1595, Elsevier 2004.
18. D.W. Chan, R.A. Booth, ***E.P. Diamandis***. Tumor Markers. In: Tietz Textbook of Clinical Chemistry, 3rd Edition. C.A. Burtis, E.R. Ashwood, D. Bruns (Eds.), pp 245-295, J. Wiley & Sons, 2004.
19. N. Harbeck, V. Magdolen, ***E. Diamandis***, J.S. Ross, M.D. Ronald, E Kates, M. Schmit. Tumour-associated proteolytic factors: Markers for tumour invasion and metastasis. In: Molecular Oncology of Breast Cancer, J. Ross, G. Hortobagyi (Eds.), pp 276-288, Jones and Bartlett 2006.
20. D.W. Chan, R.A. Booth, ***E.P. Diamandis***. Tumor Markers. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition. C.A. Burtis, E.R. Ashwood, D.E. Bruns (Eds), pp 745-795, Elsevier 2007.
21. D-E. van der Merwe, K. Oikonomopoulou, J. Marshall, ***E.P. Diamandis***. Mass spectrometry: uncovering the cancer proteome for diagnostics. In: Genomics in Cancer Drug Discovery and Development. G. Hampton, K. Sikora (Eds.), pp 22-50, Academic Press, 2007.
22. D-E. van der Merwe, ***E.P. Diamandis***. To screen or not to screen? In: Tietz Applied Laboratory Medicine, 2nd Edition. M.G. Scott, A.M. Gronowski, C.S. Eby (Eds.), pp 349-354, J. Wiley & Sons, 2007.
23. Kulasingam V, Smith CR, Batruch I, *Diamandis EP*. Immuno-mass spectrometry: Quantification of low abundance proteins in biological fluids. Methods in Molecular Biology, Human Press [submitted].

Reviews

1981-1989

1. Siskos PA, *Diamandis EP*. Health and safety in university chemical laboratories. In: "The Sixth Panhellenic Chemistry Conference". **Greek Chemists' Association**, Athens 1981;207-18. [in Greek]
2. *Diamandis EP*, Siskos PA. Standardization in analytical chemistry. **Chimica Chronika**, General Edition 1983;48:19-48. [in Greek]
3. *Diamandis EP*. Immunoassays with time-resolved fluorescence spectroscopy. Principles and applications. **Clin Biochem** 1988;21:139-150.
4. *Diamandis EP*, Evangelista RA, Pollak A, Templeton E, Lowden JA. Time-resolved fluoroimmunoassays with europium chelates as labels. **Am Clin Prod Rev** February 1989;26-22.

1990

5. *Diamandis EP*. Detection techniques for immunoassay and DNA probing applications. **Clin Biochem** 1990;23:437-43.
6. *Diamandis EP*. Analytical methodology for immunoassay and DNA hybridization assays – Current status and selected systems – Critical Review. **Clin Chim Acta** 1990;194;19-50.
7. *Diamandis EP*, Christopoulos TK. Europium chelate labels in time-resolved fluorescence immunoassays and DNA hybridization assays. **Anal Chem** 1990;62;1149A-57A.

1991

8. *Diamandis EP*, Christopoulos TK. The biotin-(strept)avidin system: Principles and applications in biotechnology. **Clin Chem** 1991;37:625-36.
9. *Diamandis EP*. Multiple labelling and time-resolvable fluorophores. **Clin Chem** 1991;37:1486-91.
10. *Diamandis EP*. Time-resolved fluorometry with lanthanide chelates as labels - In Principles, applications and new developments. **Anal Sciences** 1991;7:785-787.

1992

11. *Diamandis EP*, Christopoulos TK. Immunological assays based on time-resolved fluorometry and lanthanide chelates as labels. **In-Service Training and Continuing Education**. **AACC** 1992;10:9-26.
12. *Diamandis EP*. Oncogenes and Tumour suppressor genes - New biochemical tests. **CRC Crit Rev Clin Lab Sci** 1992;29:269-305.
13. *Diamandis EP*. New Tumour markers based on oncogenes and Tumour suppressor genes. **Clin Chem News** 1992;18:6-7 (Dec. 1992 issue).

1993-1994

14. Goldberg DM, *Diamandis EP*. Models of neoplasia and their diagnostic implications: A historical perspective. **Clin Chem** 1993;39:2360-74.
15. *Diamandis EP*. Fluorescence spectroscopy. **Anal Chem** 1993;65:454R-9R.
16. *Diamandis EP*. An update on prostate specific antigen. **Clin Chem News** 1993;19:6-8 (Oct. 1993 issue).
17. *Diamandis EP*. Time-resolved fluorometry in nucleic acid hybridization and Western blotting techniques. **Electrophoresis** 1993;14:866-75.
18. *Diamandis EP*. The p53 Tumour suppressor gene and its clinical applications. **Clin Chem News** 1994;20 (March 1994 issue).

1995

19. *Diamandis EP*. Clinical applications of the p53 Tumour suppressor gene. **Clin Chim Acta** 1995;237:79-90.
20. Gudgin Dickson EF, Pollak A, *Diamandis EP*. Time-resolved detection of lanthanide luminescence for ultrasensitive bioanalytical assays. **J Photochem Photobiol** 1995; 27: 3-19.
21. Gudgin Dickson EF, Pollack A, *Diamandis EP*. Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. **Pharmacol Therapeutics** 1995;66:207-35.
22. *Diamandis EP*. New diagnostic applications and physiological functions of prostate specific antigen. **Scand J Clin Lab Invest** 1995; 55: 105-112.

1996

23. *Diamandis EP*. Prognostic markers in breast cancer. **Clin Lab News** 1996;22:46-51.
24. *Diamandis EP*. Prostate specific antigen – new applications in breast and other cancers. **Anticancer Res** 1996;16:3983-3986.

1997

25. *Diamandis EP*. Clinical applications of Tumour suppressor genes and oncogenes in cancer. **Clin Chim Acta** 1997;257:157-180.
26. *Diamandis EP*. New diagnostic applications of prostate specific antigen. **Br J Urol** 1997; 79(Suppl): 87-91.
27. Soleas GJ, *Diamandis EP*, Goldberg DM. Resveratrol: A molecule whose time has come? And Gone? **Clin Biochem** 1997;30:91-113.
28. Soleas GJ, *Diamandis EP*, Goldberg DM. Wine as a biological fluid: History, production and role in disease prevention. **J Clin Lab Anal** 1997;11:287-313.

1998-1999

29. Lopez-Otin C, *Diamandis EP*. Breast and prostate cancer: An analysis of common epidemiological, genetic and biochemical features. **Endocr Rev** 1998;19:365-396.
30. *Diamandis EP*. Prostate specific antigen – its usefulness in clinical medicine. **Trends Endocrinol Metab** 1998;9:310-316.
31. *Diamandis EP*. Prostate Cancer – will we win the battle in the next century? **Clin Lab News** (Oct. issue) 1999;25:14-16.

2000

32. Black MH, *Diamandis EP*. The diagnostic and prognostic utility of prostate specific antigen for diseases of the breast. **Breast Cancer Res Treat** 2000;59:1-14.
33. *Diamandis EP*, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family – implications in carcinogenesis. **Trends Endocrinol Metab** 2000;11:54-60.
34. *Diamandis EP*. Prostate-specific antigen: a cancer fighter and a valuable messenger? **Clin Chem** 2000; 46: 896-900.

2001

35. Yousef GM, *Diamandis EP*. The new human tissue kallikrein gene family: Structure, function and association to disease. **Endocr Rev** 2001; 22:184-204.
36. *Diamandis EP*, Yousef GM. Human tissue kallikrein gene family: a rich source of novel disease biomarkers. **Expert Rev Mol Diagn** 2001;1:182-190.
37. Becker C, Noldus J, *Diamandis E*, Lilja H.. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. **Crit Rev Clin Lab Sci** 2001;38:357-399.
38. Scorilas A, Magklara A, Hoffman BR, Bromberg RM, Bjartell A, *Diamandis EP*. Highly sensitive array analysis using time resolved fluorescence and a novel streptavidin-based reagent. **Anal Sci** 2001;17:547-550.

2002

39. Stephan C, Jung K, *Diamandis EP*, Rittenhouse HG, Lein M, Leoning SA. Prostate-specific antigen, its molecular forms and other kallikrein markers for detection of prostate cancer. **Urology** 2002;59:2-8.
40. Diamandis EP. Duties and responsibilities of laboratory scientists. **Clin Chim Acta** 2002;319:111-115.
41. Yousef GM, *Diamandis EP*. Kallikreins, steroid hormones and ovarian cancer: is there a link? **Minerva Endocrinol** 2002;27:157-166.
42. *Diamandis EP*, Yousef GM. Human tissue kallikreins: A family of new cancer biomarkers. **Clin Chem** 2002;48:1198-1205.
43. Yousef GM, *Diamandis EP*. Expanded human tissue kallikrein family - a novel panel of cancer biomarkers. **Tumour Biol** 2002;23:185-192.
44. Yousef GM, *Diamandis EP*. Human tissue kallikreins: A new enzymatic cascade pathway? **Biol Chem** 2002;383:1045-1057.
45. Rosenberg Zand RS, Jenkins DJ, *Diamandis EP*. Flavonoids and steroid hormone-dependent cancers. **J Chromatogr B Analyt Technol Biomed Life Sci** 2002;777:219-232.

2003

46. Yousef GM, *Diamandis EP*. Human kallikreins: common structural features, sequence analysis and evolution. **Current Genomics** 2003;4:147-165.
47. Yousef GM, Kishi T, *Diamandis EP*. Role of kallikrein enzymes in the central nervous system. **Clin Chim Acta** 2003;329:1-8.
48. Yousef GM, *Diamandis EP*. Tissue kallikreins: New players in normal and abnormal cell growth. **Thromb Haemost** 2003;90:7-16.
49. Yousef GM, *Diamandis* EP. An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. **Clin Biochem** 2003;36:443-452.
50. Sotiropoulou G, Rogakos V, Tsetsenis T, Pampalakis G, Zafiropoulos N, Simillides G, Yiotakis A, *Diamandis EP*. Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. **Oncol Res** 2003;13:381-391.
51. Luo LY, Yousef GM, *Diamandis EP*. Human tissue kallikreins and testicular cancer. **APMIS** 2003;111:225-232.

52. Diamandis EP. Human tissue kallikreins: From genes to clinical applications with emphasis on ovarian cancer. **J Clin Ligand Assay** 2003;26:174-176.

2004

53. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: Opportunities and potential limitations. **Mol Cell Proteomics** 2004;3:367-378.

54. *Diamandis EP*, Yousef GM, Olsson AY. An update on human and mouse glandular kallikreins. **Clin Biochem** 2004;37:258-260.

55. Borgoňo CA, Michael IP, *Diamandis EP*. Human tissue kallikreins: physiologic roles and applications in cancer. **Mol Cancer Res** 2004;2:257-280.

56. Borgoňo CA, *Diamandis EP*. The emerging roles of human tissue kallikreins in cancer. **Nat Rev Cancer** 2004;4:876-890.

2005

57. Kurlender L, Borgoňo C, Michael IP, Obiezu C, Elliott MB, Yousef GM, *Diamandis EP*. A survey of alternative transcripts of human tissue kallikrein genes. **Biochim Biophys Acta** 2005;1755:1-14.

58. Yousef M, Obiezu CV, Luo L-Y, Magklara A, Borgoňo CA, Kishi T, Memari N, Michael P, Sidiropoulos M, Kurlender L, Economopolou K, Kapadia C, Komatsu N, Petraki C, Elliott M, Scorilas A, Katsaros D, Levesque MA, *Diamandis EP*. Human tissue kallikreins: from gene structure to function and clinical applications. **Adv Clin Chem** 2005;39:11-79.

59. Obiezu CV, *Diamandis EP*. Human tissue kallikrein gene family: applications in cancer. **Cancer Lett** 2005;224:1-22.

2006

60. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, *Diamandis EP*, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. **Biol Chem** 2006;387:637-641.

61. Paliouras M, *Diamandis EP*. The kallikrein world: An update on the human tissue kallikreins. **Clin Chem** 2006;387;643-652.

62. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Diamandis EP, Hollenberg MD. Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more **Biol Chem** 2006;387:677-85.

63. Petraki CD, Papanastasiou PA, Karavana VN, *Diamandis EP*. Cellular distribution of human tissue kallikreins: immunohistochemical localization. **Biol Chem** 2006;653-663.

2007

64. van der Merwe DE, Oikonomopoulou K, Marshall J, *Diamandis EP*. Mass spectrometry: uncovering the cancer proteome for diagnostics. **Adv Cancer Res** 2007;96:23-50.

65. Paliouras M, Borgono C, *Diamandis EP*. Human tissue kallikreins: The cancer biomarker family. **Cancer Lett** 2007;249;61-79.

66. Gunawardana CG, *Diamandis EP*. High throughput proteomic strategies for identifying tumour-associated antigens. **Cancer Lett** 2007;249:110-119.

67. Emami N, *Diamandis EP*. Human tissue kallikreins: A road under construction. **Clin Chim Acta** 2007;381:78-84.

68. Stephan C, Jung K, Lein M, *Diamandis EP*. PSA and other tissue kallikreins for prostate cancer detection. **Eur J Cancer** 2007;43:1918-1926.

69. Rabien A, Kristiansen G, *Diamandis EP*, Jung K, Stephan C. Aricle in German. **Urologe A** 2007;46:1070-1071.

70. Yousef GM, Denic N, Wadhwa J, Chandracanth, Smith T, Elms F, *Diamandis EP*. Intravagal ectopic parathyroid presenting as a vocal cord paralysis: Case report and review of literature. **J Otolaryngology** 2007;36:E93-95.

71. Emami N, *Diamandis EP*. New insights into the functional mechanisms and clinical applicatons of the kallikrein-related peptidase family. **Mol Oncol** 2007;1:269-287.

2008

72. Kulasingam V, *Diamandis EP*. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. **Nat Clin Pract Oncol** 2008;5:588-599.

73. Prassas I, *Diamandis EP*. Novel therapeutic applications of cardiac glycosides. **Nat Rev Drug Discov** 2008;7:926-935.

74. Kulasingam V, Diamandis EP. Tissue culture-based breast cancer biomarker discovery platform. **Int J Cancer** 2008;123:2007-2012.

75. Emami N, *Diamandis EP*. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. **Clin Chem** 2008;54:1600-1607.

76. *Diamandis EP*, Hoffman B, Sturgeon CM. National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. **Clin Chem** 2008;54:1935-1939.

77. Sturgeon CM, Duffy MJ, Stenman U-H, Lilja H, Brũnner N, Chan DW, Babaian RJ, Bast RC, Dowel B, Esteva F, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee G, Lamerz RN, Looijenga L, Molina R, Nielsen HJ, Rittenhouse HG, Semjonow A, Shih I-M, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman B, *Diamandis EP*. National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the Use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. **Clin Chem** 2008;54:e11-e79.

78. Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF, Liotta LA, Petricoin EF, Schmitt M, Semmes OJ, Sölétormos G, van der Merwe E, *Diamandis EP*. National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the Use of tumor markers in clinical practice: quality requirements. **Clin Chem** 2008;54:e1-e10.

79. Sardana G, Dowell B, *Diamandis EP*. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. **Clin Chem** 2008;54:1951-1960.

80. Eissa A, *Diamandis EP*. Human tissue kallikreins as promiscuous medulators of homeostatic skin barrier functions. **Biol Chem** 2008;389:669-680.

81. Yousef GM, *Diamandis EP*. KLK5 (Kallikrein-related peptidase 5). Atlas Genet Cytogenet Oncol Haematol. June 2008. URL : http://AtlasGeneticsOncology.org/Genes/KLK5ID41085ch19q13.html

82. Hansen KK, Oikonomoupou K, Baruch A, Ramachandran R, BeckP, *Diamandis EP*, Hollenberg MD. Proteinases as hormones: targets and mechanisms for proteolytic signaling. **Biol Chem** 2008;389:971-982.

83. Hollenberg MD, Oikonomopoulou K, Hansen KK, Saiffeddine M, Ramachandran R, *Diamandis EP*. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. **Biol Chem** 2008; 389:643-51.

2009

84. Yousef GM, *Diamandis EP*. The human kallikrein gene family: new biomarkers for ovarian cancer. **Cancer Treat Res** 2009;149:165-187.

85. Gunawardana CG, Memari N, *Diamandis EP*. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. **Clin Biochem** 2009;42:426-429.

86. Sotiropoulou G, Pampalakis G, *Diamandis EP*. Functional roles of human kallikrein-related peptidases. **J Biol Chem** 2009;284:32989-32994.

87. Sturgeon CM, Duffy MJ, Hoffma B, Lamerz RM, Fritsche HA, Gaarenstroom K, Bonfrer JMG, Ecke T, Grossman HB, Hayes P, Hoffmann R-T, Lerner S, Lohe F, Louhimo JM, Sawczuk I, Taketa K, *Diamandis EP*. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in liver, bladder, cervical and gastric cancers. [**Clin Chem**].

88. Makawita S, *Diamandis EP*. The bottleneck in the biomarker pipeline and prospects for candidate verification through multiple reaction monitoring-based approaches. **Clin Chem** [in press].

89. Oikonomopoulou K, *Diamandis EP,* Hollenberg MD. Kallikrein-related peptidases: proteolysis and signalling in cancer, the new frontier. [**Biol Chem**].

90. Pavlou MP, *Diamandis EP*. The cancer cell secretome: A good source for discovering biomarkers? [**J Proteomics].**

Original Research Papers

1977

1. Hadjiioannou TP, *Diamandis EP*. Analytical study of a new picrate-selective membrane electrode. **Anal Chim Acta** 1977;94;443-447.

2. *Diamandis EP*, Hadjiioannou TP. Titrimetric determination of thiourea and silver with a picrate ion-selective electrode. **Mikroch Acta** (Wien) 1977;2;255-260.

3. *Diamandis EP*, Koupparis MA, Hadjiioannou TP. Kinetic potentiometric determination of creatinine in urine with a picrate ion-selective electrode. **Microchem J** 1977;22:498-504.

1980

4. *Diamandis EP*, Hadjiioannou TP. Titrimetric determination of iodide, hexacyanoferrate (II), thiourea, cationic surfactants and of picrate with a picrate ion-selective electrode. **Mikroch Acta** (Wien) 1980;II:27-38.

5. Papastathopoulos DS, *Diamandis EP*, Hadjiioannou TP. Flow-through electrode unit for liquid membrane electrodes. **Anal Chem** 1980;52:2100-104.

6. *Diamandis EP*, Efstathiou CE, Hadjiioannou TP. Automatic determination of ethylene glycol in anti-freeze solutions with a periodate sensitive flow-through electrode. **Analyst** 1980;105:1203-1207.

7. *Diamandis EP*, Hadjiioannou TP. Analytical study of new creatininium and tetramethylammonium cation-selective membrane electrodes. **Anal Lett** 1980;13(B15);1317-1332.

1981

8. *Diamandis EP*, Hadjiioannou TP. Catalytic determination of selenium with a picrate-selective electrode. **Anal Chim Acta** 1981;123:143-150.

9. *Diamandis EP*, Hadjiioannou TP. Potentiometric determination of some common alkaloids with a picrate-selective electrode. **Anal Chim Acta** 1981;123:341-345.

10. Efstathiou CE, *Diamandis EP,* Hadjiioannou TP. Potentiometric determination of nicotine in tobacco products with a nicotine-sensitive liquid membrane electrode. **Anal Chim Acta** 1981;127:173-180.

11. *Diamandis EP*, Athanasiou-Malaki E, Papastathopoulos DS, Hadjiioannou TP. Construction and analytical applications of liquid membrane electrodes for atropine and novatropine. **Anal Chim Acta** 1981;128:239-244.

12. *Diamandis EP*, Papastathopoulos DS, Hadjiioannou TP. Continuous-flow serum albumin determination by reaction with picrate ions, with use of a flow-through picrate ion electrode. **Clin Chem** 1981;27:427-430.

13. *Diamandis EP*, Hadjiioannou TP. Kinetic potentiometric determination of creatinine in serum with a picrate ion-selective membrane electrode. **Clin Chem** 1981;27:455-457.

1982

14. *Diamandis EP*, Hadjiioannou TP. Continuous-flow potentiometric determination of creatinine in urine with a picrate ion-selective electrode. **Microchem J** 1982;27:512-518.

15. Lazarou LA, *Diamandis EP*, Hadjiioannou TP. Spectrophotometric study of the iron(II)-induced perbromate-iodide reaction. Automatic reaction rate method for the ultramicrodetermination of iron. **Chimica Chronica**, New Series, 1982;11:3-10.

16. *Diamandis EP*, Hadjiioannou TP. Continuous-flow determination of reducing sugars and sucrose in natural and industrial products with periodate oxidation and a periodate-sensitive flow-through electrode. **Analyst** 1982;107:1471-1478.

17. Koupparis MA, *Diamandis EP*, Malmstadt HV. Total calcium and magnesium determined in serum with an automated stopped-flow analyzer. **Clin Chem** 1982;28:2149-2152.

18. Christopoulos TK, *Diamandis EP*, Hadjiioannou TP. Potentiometric titration of organic cations with sodium tetraphenylborate and a liquid membrane tetraphenylborate ion-selective electrode. **Anal Chim Acta** 1982;143:143-151.

1983

19. *Diamandis EP*, Hadjiioannou TP. Study of the stoichiometry and the kinetics of the Jaffe reaction with a picrate ion-selective electrode. **Microchem J** 1983;28:399-408.

20. *Diamandis EP*, Efstathiou CF, Papastathopoulos DS, Hadjiioannou TP. Continuous-flow determination of reducing sugars in serum by reaction with periodate ions, with use of a flow-through periodate-sensitive electrode. **Microchem J** 1983;28:227-234.

21. *Diamandis EP*, Koupparis MA, Hadjiioannou TP. Kinetic studies with ion-selective electrodes: Determination of creatinine in urine with a picrate ion selective electrode. A laboratory experiment. **J Chem Educ** 1983;60:74-76.

22. Koupparis MA, *Diamandis EP*, Malmstadt HV. Automated determination of crude protein, phosphorus, calcium, iron and magnesium in feeds by using stopped-flow analyzer. **J Assoc Off Anal Chem** 1983;66:188-196.

23. Siskos PA, *Diamandis EP*, Gillieron E, Colbert JC. Potentiometric titration of sulfate, sulphite and dithionate mixtures with use of a lead ion-selective electrode. **Talanta** 1983;30:980-982.

24. Papanastasiou-Diamandi A, Siskos PA, *Diamandis EP*. A direct kinetic fluorometric method for the enzymic determination of lactate in plasma. **Clin Chim Acta** 1983;129:359-364.

25. Papanastasiou-Diamandi A, *Diamandis EP*, Siskos PA. Direct enzymic fluorometric method for the determination of individual bile acids in bile. **Clin Chim Acta** 1983;134:17-23.

26. *Diamandis EP*, Christopoulos TK. Potentiometric titration of pharmaceutical compounds in formulations with sodium tetraphenylborate. **Anal Chim Acta** 1983;152:281-284.

1984

27. Papanastasiou-Diamandi A, *Diamandis EP*, Soldin SK. Enzymic measurement of primary bile acids and the primary bile acid ratio in serum with the IL-Multistat III fluorescence/light scattering centrifugal analyzer. **Clin Biochem** 1984;17:242-248.

28. Ellis G, *Diamandis EP*, Giesbrecht E, Allen L. An automated "high pressure" liquid chromatographic assay for hemoglobin A_{1C}. **Clin Chem** 1984;30:1746-1752.

29. Mitsana-Papazoglou A, *Diamandis EP*, Hadjiioannou TP. Construction and analytical applications of an improved liquid-membrane electrode for salicylate. **Anal Chim Acta** 1984;159:393-396.

1985

30. *Diamandis EP*, Papanastasiou-Diamandi A, Soldin SJ. Digoxin immunoreactivity in cord and maternal serum and placental extracts. Partial characterization of immunoreactive substances by high performance liquid chromatography and inhibition of Na^+-K^+- ATPase. **Clin Biochem** 1985;18:48-55.

31. Mitsana-Papazoglou A, Christopoulos TK, *Diamandis EP*, Hadjiioannou TP. Construction of ion-selective electrodes for chlorpromazine, amitriptyline, propantheline and meperidine. Analytical study and application to pharmaceutical analysis. **Analyst** 1985;110:1091-1094.

32. Koupparis MA, *Diamandis EP*, Malmstadt HV. Automated stopped-flow analyzer in clinical chemistry: Determination of albumin with bromcresol green and purple. **Clin Chim Acta** 1985;149:225-235.

33. Christopoulos TK, Mitsana-Papazoglou A, *Diamandis EP*. Ion-selective electrodes for the determination of ionization constants of sparingly soluble organic bases in aqueous solutions. Application to chlorpromazine and amitriptyline. **Analyst** 1985;110:1497-1500.

34. *Diamandis EP*, Papanastasiou-Diamandi A, Christopoulos TK, Hadjiioannou TP. Continuous-flow potentiometric determination of a-amylase activity in serum and urine. **Microchem J** 1985;32:183-190.

1986

35. Gritzapis PC, *Diamandis EP*, Hadjiioannou TP. Determination of the second ionization constant of 3,5-dinitrosalicylic acid (DNSH) and the instability constant of DNS-Fe^{+} and titrimetric determination of thiourea with a 3,5-dinitrosalicylate-selective electrode. **Microchem J** 1986;33:62-70.

36. Sarantonis EG, *Diamandis EP*, Karayannis MI. Kinetic study of the reaction between trinitrobenzenesulfonic acid (TNBS) and aminoacids with a trinitrobenzenesulfonate ion-selective electrode. **Anal Biochem** 1986;155:129-134.

37. Christopoulos TK, *Diamandis EP*. A general method for the assay of binders. Application to the potentiometric determination of albumin in human serum, plasma and whole blood. **Clin Biochem** 1986;19:151-160.

1987

38. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Effect of incubation time and temperature on the interference of digoxin-like immunoreactive substances in digoxin immunoassays. **Ther Drug Monitor** 1987;9:461-463.

39. Christopoulos TK, *Diamandis EP*. New flow-through units for solid-state, liquid and PVC-matrix membrane ion-selective electrodes to minimize streaming potentials. **Analyst** 1987;112:1293-1298.

40. Mitsana-Papazoglou A, *Diamandis EP*, Hadjiioannou TP. Ion-selective electrodes for the H-receptor antagonists cimetidine and ranitidine. **J Pharm Sci** 1987;76:485-491.

41. Mitsana-Papazoglou A, Christopoulos TK, *Diamandis EP*, Koupparis MA. Dissolution studies of drug formulations using ion-selective electrodes as sensors in air-segmented continuous flow analyzer. **J Pharm Sci** 1987;76:724-730.

42. Khosravi MJ, *Diamandis EP*. Immunofluorometry of choriogonadotropin by time-resolved fluorescence spectroscopy, with a new europium chelate as label. **Clin Chem** 1987;33:1994-1999.

43. Chan MA, Bellem AC, *Diamandis EP*. Time-resolved immunofluorometric assay for alpha-fetoprotein in serum and amniotic fluid, with a novel detection system. **Clin Chem** 1987;33:2000-2003.

1988

44. Christopoulos TK, *Diamandis EP*. Use of a sintered glass crucible for easy construction of liquid-membrane ion-selective electrodes. **J Chem Educ** 1988;65:648.

45. Reichstein E, Shami Y, Ramjeesingh M, *Diamandis EP*. Laser-Excited time-resolved solid-phase fluoroimmunoassays with the new europium chelate 4, 7 bis (chlorosulfophenyl)-1, 10 phenanthroline-1,9 dicarboxylic acid as label. **Anal Chem** 1988;60:1069-1074.

46. Evangelista RA, Pollak A, Allore B, Templeton EF, Morton RC, *Diamandis EP*. A new europium chelate for protein labelling and time-resolved fluorometric applications. **Clin Biochem** 1988;21:173-178.

47. *Diamandis EP*, Bhayana V, Conway K, Reichstein E, Papanastasiou-Diamandi A. Time-resolved fluoroimmunoassay of cortisol in serum with a europium chelate as label. **Clin Biochem** 1988;21:291-296.

48. *Diamandis EP*, D'Costa M. Selective determination of urinary free cortisol by liquid chromatography after solid-state extraction. **J Chromatogr Biomed Appl** 1988;426:25-32.

49. Khosravi MJ, Chan MA, Bellem AC, *Diamandis EP*. A sensitive time-resolved immunofluorometric assay of ferritin in serum with monoclonal antibodies. **Clin Chim Acta** 1988;175:267-276.

50. *Diamandis EP*, Morton RC. Time-resolved fluorescence using a europium chelate of 4, 7-bis (chlorosulfophenyl)-1, 10 phenanthroline-2, 9-dicarboxylic acid (BCPDA). Labelling procedures and applications in immunoassays. **J Immunol Methods** 1988;112:43-52.

51. Khosravi MJ, Morton RC, *Diamandis EP*. Sensitive, rapid procedure for time-resolved immunofluorometry of lutropin. **Clin Chem** 1988;34:1640-1644.

1989

52. Reichstein E, Morton R, *Diamandis EP*. Sensitive time-resolved immunofluorometric assay of thyrotropin in serum. **Clin Biochem** 1989;22:23-29.

53. *Diamandis EP*, Morton RC, Reichstein E, Khosravi MJ. Multiple fluorescence labeling with europium chelators. Application to time-resolved fluoroimmunoassays. **Anal Chem** 1989;61:48-53.

54. Papanastasiou-Diamandi A, Bhayana V, *Diamandis EP*. A simple time-resolved fluoroimmunoassay of total thyroxine in serum. **Ann Clin Biochem** 1989;26:238-243.

55. Tan YK, Khosravi MJ, *Diamandis EP*. Time-resolved immunofluorometric assay of thyroxine-binding globulin in serum. **J Immunoassay** 1989;10:413-428.

56. Christopoulos TK, *Diamandis EP*. Potentiometric measurements in air-segmented streams without debubbling. **Anal Chem** 1989;61:504-508.

57. Papanastasiou-Diamandi A, Conway K, *Diamandis EP*. Digoxin immunoassay with monoclonal and polyclonal antibodies using time-resolved fluorometry. **J Pharm Sci** 1989;78:617-621.

58. Kahan I, Papanastasiou-Diamandi A, D'Costa M, *Diamandis EP*. Measurement of serum prolactin by a simple and rapid time-resolved immunofluorometric assay. **Clin Chem Enzym Comms** 1989;1:293-303.

59. Bhayana V, *Diamandis EP*. A double monoclonal time-resolved immunofluorometric assay of carcinoembryonic antigen in serum. **Clin Biochem** 1989;22:433-438.

60. *Diamandis EP*, Papanastasiou-Diamandi A, Lustig V, Khosravi MJ, Tan A. Time-resolved immunofluorometric assay of human pancreatic isoamylase in serum, with use of two monoclonal antibodies. **Clin Chem** 1989;35:1915-1920.

61. Khosravi MJ, *Diamandis EP*. Time-resolved immunofluorometry of follitropin in serum. A new and highly sensitive procedure. **Clin Chem** 1989;35:181.

62. Diamandis EP. A time-resolved fluorescence immunoassay system especially suitable for research applications. **Clin Chem** 1989;35:491.

1990

63. Papanastasiou-Diamandi A, Christopoulos TK, *Diamandis EP*. Effect of solid-phase blocking on the background signal in a time-resolved fluorescence immunoassay system based on labelled streptavidin. **Clin Chem Enzym Comms** 1990;2:177-181.

64. Kahan I, Papanastasiou-Diamandi A, Ellis G, Makela S, McLaurin J, D'Costa M, *Diamandis EP*. Sensitive time-resolved fluorescence immunoassay of somatotropin in serum. **Clin Chem** 1990;36:503-508.

65. Loucari-Yiannakou E, Yiannakou L, Souvatzoglou A, *Diamandis EP*. Radioimmunoassay of digoxin in serum using monoclonal antibodies and assessment of interference by digoxin-like immunoreactive substances (DLIS). **Ther Drug Monitor** 1990;12:195-200.

66. *Diamandis EP*, Ogilvie RR. Ultrasensitive time-resolved immuno- fluorometry of human albumin in urine using monoclonal antibodies - A new assay for microalbuminuria. **Ann Clin Biochem** 1990;27:232-237.

67. Shankaran P, Reichstein E, Khosravi MJ, *Diamandis EP*. Detection of IgG and IgM antibody to rubella virus by time-resolved immunofluorometry. **J Clin Microbiol** 1990;28:573-579.

68. Christopoulos TK, *Diamandis EP*. Binding studies using ion-selective electrodes - Examination of the picrate-albumin interaction as a model system. **Anal Chem** 1990;62:360-367.

69. Morton RC, *Diamandis EP*. Streptavidin-based macromolecular complex labelled with a europium chelator suitable for time-resolved fluorescence immunoassay applications. **Anal Chem** 1990;62:1841-1845.

70. Christopoulos TK, Lianidou ES, *Diamandis EP*. Ultrasensitive time- resolved fluorescence method for α-fetoprotein. **Clin Chem** 1990;36:1497-1502.

71. Lianidou ES, Christopoulos TL, *Diamandis EP*. Assay of creatine kinase isoenzyme MB in serum with time-resolved immunofluorometry. **Clin Chem** 1990;36:1679-1683.

1991

72. Christopoulos TK, *Diamandis EP*. Ultrasensitive determination of europium using microsecond time-resolved fluorometry. **Analyst** 1991;116:627-630.

73. *Diamandis EP*, Christopoulos TK. Time-resolved immunofluorometric detection of antigens separated by high performance liquid chromatography and coated to polystyrene. **Biotechniques** 1991;10:646-648.

74. Christopoulos TK, *Diamandis EP*, Wilson G. Quantification of nucleic acids on nitrocellulose membranes with time-resolved fluorometry. **Nucleic Acids Res** 1991;19:6015-6019.

1992

75. Kakabakos SE, Christopoulos TK, *Diamandis EP*. Multianalyte immunoassay based on spatially distinct fluorescent areas quantified by laser-excited solid-phase time-resolved fluorometry. **Clin Chem** 1992;38:338-342.

76. *Diamandis EP*, Christopoulos TK, Bean CC. Quantitative Western blot analysis and spot immunodetection using time-resolved fluorometry. **J Immunol Methods** 1992;147:251-259.

77. Christopoulos TK, *Diamandis EP*. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. **Anal Chem** 1992;64:342-346.

78. Papanastasiou-Diamandi A, Christopoulos TK, *Diamandis EP*. Ultrasensitive thyrotropin immunoassay based on enzymatically amplified time-resolved fluorescence with a terbium chelate. **Clin Chem** 1992;38:545-548.

79. *Diamandis EP*, Grass L, Uldall R, Mendelssohn D, Maini D. An enzymatic method for measuring serum mannitol and its use in hemodialysis patients. **Clin Biochem** 1992;25: 457-462.

80. *Diamandis EP*. Europium and terbium chelators as candidate substrates for enzyme-labeled time-resolved fluorometric immunoassays**. Analyst** 1992;117:1879-1884.

81. Hassapoglidou S, *Diamandis EP*. Antibodies to the p53 Tumour suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. **Clin Biochem** 1992;25:445-449.

1993

82. Chan AW, *Diamandis EP*, Krajden M. Quantification of polymerase chain reaction products in agarose gels with a fluorescent europium chelate as label and time-resolved fluorescence spectroscopy. **Anal Chem** 1993;65:158-163.

83. *Diamandis EP*, Hassapoglidou S, Bean CC. Evaluation of non-isotopic labeling and detection techniques for nucleic acid hybridization. **J Clin Lab Analysis** 1993;7:174-179.

84. Hassapoglidou S, *Diamandis EP*, Sutherland DJA. Quantification of p53 protein in Tumour cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. **Oncogene** 1993;8:1501-1509.

85. Yu H, *Diamandis EP***.** Ultrasensitive time-resolved immunofluorometric assay of prostate specific antigen in serum and preliminary clinical studies. **Clin Chem** 1993;39:2108-2114.

86. Angelopoulou K, *Diamandis EP*. Autoantibodies against the p53 Tumour suppressor gene product quantified in cancer patient serum with time-resolved immunofluorometry. **Cancer J** 1993;6:315-321.

1994

87. Levesque MA, *Diamandis EP*, Yu H, Sutherland DJA. Quantitative analysis of mutant p53 protein in breast Tumour cytosols and study of its association with other biochemical prognostic indicators in breast cancer. **Breast Cancer Res Treat** 1994;30:179-195.

88. Angelopoulou K, *Diamandis EP*, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 Tumour suppressor gene protein in various cancers. **Int J Cancer** 1994;58:480-487.

89. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, *Diamandis EP*. Immunological quantification of advanced glycosylation end products in the serum of patients on hemodialysis or continuous ambulatory peritoneal dialysis. **Kidney Int** 1994;46:216-222.

90. Wang T, *Diamandis EP*, Lane A, Baines AD. Variable selectivity of the Hitachi chemistry analyzer chloride ion-selective electrode toward interfering ions. **Clin Biochem** 1994;27:37-41.

91. Yu H, *Diamandis EP*, Sutherland DJA. Immunoreactive prostate specific antigen levels in female and male breast Tumours and its association with steroid hormone receptors and patient age. **Clin Biochem** 1994;27:75-79.

92. Yu H, *Diamandis EP,* Levesque MA, Sismondi P, Zola P, Katsaros D. Ectopic production of prostate specific antigen by a breast Tumour metastatic to the ovary. **J Clin Lab Analysis** 1994;8:251-253.

93. Goldberg DM, Yan J, Ng E, *Diamandis EP*, Karumanchiri A, Soleas G, Waterhouse AL. Direct injection gas chromatographic mass spectrometric assay for trans-resveratrol. **Anal Chem** 1994;66:3959-3963.

94. Monne M, Croce CM, Yu H, *Diamandis EP*. Molecular characterization of prostate specific antigen mRNA expressed in breast Tumours. **Cancer Res** 1994;54:6344-6347.

95. Yu H, *Diamandis EP*, Zarghami N, Grass L. Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. **Breast Cancer Res Treat** 1994;32:291-300.

96. *Diamandis EP*, Yu H, Sutherland DJA. Detection of prostate specific antigen immunoreactivity in breast Tumours. **Breast Cancer Res Treat** 1994;32:301-310.

97. Marriott G, Heidecker M, *Diamandis EP*, Marriott YY. Time-resolved delayed luminescence image microscopy using an europium ion chelate complex. **Biophys J** 1994;67:957-965.

1995

98. Yu H, *Diamandis EP*. Prostate specific antigen in milk of lactating women. **Clin Chem** 1995;41:54-58.

99. Levesque M, Yu H, D'Costa M, *Diamandis EP*. Prostate specific antigen expression by various Tumours. **J Clin Lab Analysis** 1995;9:123-128.

100. Yu H, *Diamandis EP*. Prostate specific antigen immunoreactivity in amniotic fluid. **Clin Chem** 1995;41:204-210.

101. Yu H, *Diamandis EP*. Measurement of serum prostate specific antigen levels in females and in prostatectomized males with an ultrasensitive immunoassay technique. **J Urol** 1995;153:1004-1008.

102. Levesque M, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, *Diamandis EP*. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. **Cancer** 1995;75:1327-1338.

103. Yu H, *Diamandis EP*, Monne M, Croce CM. Oral contraceptive-induced expression of prostate specific antigen in the female breast. **J Biol Chem** 1995;270:6615-6618.

104. Soleas GJ, Goldberg DM, *Diamandis EP*, Karumanchiri A, Yan J, Ng E. A derivatized gas chromatographic-mass spectrometric method for the analysis of both isomers of resveratrol in juice and wine. **Am J Enol Vitic** 1995;46:346-352.

105. Yu H, *Diamandis EP*, Prestigiacomo AF. Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of Tumour doubling time after radical prostatectomy. **Clin Chem** 1995;41:430-434.

106. Zarghami N, Yu H, *Diamandis EP*, Sutherland DJA. Quantification of creatine kinase BB isoenzyme in Tumour cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. **Clin Biochem** 1995;28:243-253.

107. Yu H, Giai M, *Diamandis EP*, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P. Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. **Cancer Res** 1995;55:2104-2110.

108. Pace-Asciak CR, Hahn SE, *Diamandis EP*, Soleas G, Goldberg DM. The red wine phenolics *trans*-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. **Clin Chim Acta** 1995;235:207-219.

109. Yu H, *Diamandis EP*, Levesque M, Asa S, Monne M, Croce CM. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. **Cancer Res** 1995;55:1603-1606.

110. Goldberg DM, Karumanchiri A, Ng E, Yan J, *Diamandis EP*, Soleas GJ. Direct gas chromatographic-mass spectrometric method to assay-cis-resveratrol in wines: Preliminary survey of its concentration in commercial wines. **J Agric Food Chem** 1995;43:1245-1250.

111. Levesque MA, Clark GM, Yu H, *Diamandis EP*. Immunofluorometric analysis of p53 protein and prostate specific antigen in breast Tumours and their association with other prognostic indicators. **Br J Cancer** 1995;72:720-727.

112. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, *Diamandis EP*. Prostate specific antigen in serum of women with breast cancer. **Br J Cancer** 1995;72:728-731.

113. Goldberg DM, Yan J, Ng E, *Diamandis EP*, Karumanchiri A, Soleas G, Waterhouse A. A global survey of *trans*-resveratrol concentrations in commercial wines. **Am J Enol Vitic** 1995;46:159-165.

114. Soleas GJ, Goldberg DM, Karumanchiri A, *Diamandis EP*, Ng E. Influences of viticultural and oenological factors on changes in *cis*- and *trans*-resveratrol in commercial wines. **J Wine Res** 1995;6:107-121.

115. Levesque M, Yu H, D'Costa M, Tadross L, *Diamandis EP*. Immunoreactive prostate specific antigen in lung Tumours. **J Clin Lab Anal** 1995;9:375-379.

116. Levesque MA, D'Costa M, Tadross L, *Diamandis EP*. Time-resolved immunofluorometric assay of p53 protein. **Clin Chem** 1995;41:1720-1729.

117. Galvan B, Christopoulos TK, *Diamandis EP*. Detection of prostate specific antigen mRNA by reverse-transcription polymerase chain reaction and time-resolved fluorometry. **Clin Chem** 1995;41:1705-1709.

118. Zarghami N, Katsaros D, Yu H, *Diamandis EP*. Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma. **Can J Oncol** 1995;5:401-407.

119. Goldberg DM, Ng E, Karumanchiri A, Yan J, *Diamandis EP*, Soleas GJ. Assay of resveratrol glucosides and isomers in wine by direct-injection high-performance liquid chromatography. **J Chromatography A** 1995;708:89-98.

1996

120. Zarghami N, Giai M, Yu H, Katsaros D, *Diamandis EP*. Creatine kinase BB isoenzyme levels in Tumour cytosols and survival of breast cancer patients. **Br J Cancer** 1996;73:386-390.

121. Zarghami N, *Diamandis EP*. Detection of prostate specific antigen mRNA and protein in breast Tumours. **Clin Chem** 1996;42:361-366.

122. Randell E, *Diamandis EP*, Ellis G. Serum prostate specific antigen measured in children from birth to age 18 years. **Clin Chem** 1996;42:420-423.

123. *Diamandis EP*, Yu H, Lopez-Otin C. Prostate specific antigen – a new constituent of breast cyst fluid. **Breast Cancer Res Treat** 1996;38:259-264.

124. Ferguson RA, Yu H, Kalyvas M, Zammit S, *Diamandis EP*. Ultrasensitive detection of prostate specific antigen by a time-resolved immunofluorometric assay and the Immulite® Immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. **Clin Chem** 1996;42:675-684.

125. Hoffman BR, Yu H, *Diamandis EP*. Assay of prostate specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. **Clin Chem** 1996;42:536-544.

126. Melegos D, *Diamandis EP*. Diagnostic value of molecular forms of prostate specific antigen for female breast cancer. **Clin Biochem** 1996;29:193-200.

127. Goldberg DM, Garovic-Kocic V, *Diamandis EP*, Pace-Asciak CR. Wine: does the colour count? **Clin Chim Acta** 1996;246:183-193.

128. Melegos DN, Yu H, *Diamandis EP*. Prostaglandin D_2 synthase: a component of human amniotic fluid and its association with fetal abnormalities. **Clin Chem** 1996;42:1042-1050.

129. Pace-Asciak CR, Rounova O, Hahn SE, *Diamandis EP*, Goldberg DM. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. **Clin Chim Acta** 1996;246:163-182

130. Goldberg DM, Ng E, Yan J, Karumanchiri A, Soleas GJ, *Diamandis EP*. Regional differences in resveratrol isomer concentrations of wines from various cultivars. **J Wine Res** 1996;7:13-24.

131. Goldberg DM, Tsand E, Karumanchiri A, *Diamandis EP*, Soleas G, Ng E. Method to assay the concentrations of phenolic constituents of biological interest in wines. **Anal Chem** 1996;68:1688-1694.

132. James GK, Pudek M, Berean DW, *Diamandis EP*, Archibald BL. Salivary duct carcinoma secreting prostate specific antigen. **Am J Clin Pathol** 1996;106:242-247.

133. Yu H, *Diamandis EP*, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue**. Breast Cancer Res Treat** 1996;40:171-178.

134. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. **Br J Cancer** 1996;74:1242-1247.

135. Levesque MA, D'Costa M, *Diamandis EP*. P53 protein is absent from the serum of patients with lung cancer. **Br J Cancer** 1996;74:1434-1440.

136. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, *Diamandis EP*. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathological features and survival**. Cancer** 1996;78:2146-2152.

137. Melegos DN, Yu H, Allen LC, *Diamandis EP*. Prostate specific antigen in amniotic fluid of normal and abnormal pregnancies. **Clin Biochem** 1996;29:555-562.

138. Melegos DN, *Diamandis EP*, Oda H, Urade Y, Hayaishi O. Immunofluorometric assay of prostaglandin D synthase in human tissue extracts and fluids. **Clin Chem** 1996;42:1984-1991.

139. Oesterling JE, Tekchandani AH, Martin SK, Bergstralh EJ, Reichstein ER, *Diamandis EP*, Yemoto C, Stamey TA. The periurethral glands do not significantly influence the serum prostate specific antigen concentration. **J Urol** 1996;155:1658-1660.

140. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G, Ross EA, Yu H, *Diamandis EP*. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. **Cancer Epidemiol Biomarkers Prevent** 1996;5:967-970.

141. Goldberg DM, NG E, Karumanchiri A, *Diamandis EP*, Soleas GJ. Resveratrol glucosides are important components of commercial wines. **Am J Enol Vitic** 1996;47:415-520.

1997

142. Angelopoulou K, Stratis M, *Diamandis EP*. Humoral immune response against p53 protein in patients with colorectal carcinoma. **Int J Cancer** 1997;70:46-51.

143. Zarghami N, Grass L, *Diamandis EP*. Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. **Br J Cancer** 1997;75:579-588.

144. Angelopoulou K, *Diamandis EP*. Detection of the TP53 Tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. **Eur J Cancer** 1997;33:115-121.

145. Yu H, *Diamandis EP*, Wong P-Y, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels between 0.001-01 ug/L. **J Urol** 1997;157:913-918.

146. Melegos D, Yu H, Ashok M, Wang C, Stanczyk F, *Diamandis EP*. Prostate specific antigen in female serum, a potential new marker of androgen excess. **J Clin Endocrinol Metab** 1997;82:777-780.

147. Levesque MA, Tadross L, *Diamandis EP*, D'Costa M. Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. **Am J Clin Pathol** 1997;107:308-316.

148. Howarth DJC, Aronson IB, *Diamandis EP*. Immonohistochemical localization of prostate specific antigen in benign and malignant breast tissues. **Br J Cancer** 1997;75:1646-1651.

149. Soleas GJ, Goldberg DM, Ng E, Karumanchiri A, Tsang E, *Diamandis EP*. Comparative evaluation of four methods for assay of cis-and trans-resveratrol. **Am J Enol Vitic** 1997;48:169-176.

150. Zarghami N, Levesque M, D'Costa M, Angelopoulou K, *Diamandis EP*. Frequency of expression of prostate specific antigen mRNA in lung Tumours. **Am J Clin Pathol** 1997;108:184-190.

151. Tsuyuki D, Grass L, *Diamandis EP*. Frequent detection of mutations in the 5′ flanking region of the prostate-specific antigen gene in female breast cancer. **Eur J Cancer** 1997;33:1851-1853.

152. Zarghami N, D'Costa M, Tsuyuki D, Asa SL, *Diamandis EP*. Expression of the prostate specific antigen gene by lung tissue. **Clin Cancer Res** 1997;3:1201-1206.

153. Melegos DN, Freedman MS, *Diamandis EP*. Prostaglandin D synthase concentration in cerebrospinal fluid and serum of patients with neurological disorders. **Prostaglandins** 1997;54:463-474.

154. *Diamandis EP*, Nadkarni S, Bhaumik B, Abdelrahman A. Melegos DN, Borchert G, Black M, Alonso M, Salas A, de los Toyos JR, Sampedro A, Lopez-Otin C. Immunofluorometric assay of pepsinogen C and preliminary clinical applications. **Clin Chem** 1997;43:1365-1371.

155. Zarghami N, Grass L, Sauter ER, *Diamandis EP*. Prostate specific antigen levels in serum during the menstrual cycle. **Clin Chem** 1997;43:1862-1867.

156. Lianidou ES, Melegos DN, *Diamandis EP*. BRCA1 Tumour suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. **Clin Biochem** 1997;30:425-432.

157. Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, *Diamandis EP*. Molecular forms of prostate specific antigen in the serum of women with benign and malignant breast diseases. **Br J Cancer** 1997;76:1087-1094.

158. Soleas GJ, Tomlinson G, *Diamandis EP*, Goldberg DM. Relative contributions of polyphenolic constituents to the antioxidant status of wines: development of a predictive model. **J Agric Food Chem** 1997;45:3995-4003.

159. Degenhardt TP, Grass L, Reddy S, Thorpe SR, *Diamandis EP*, Baynes JW. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl)lysine is increased in uremia**. Kidney Int** 1997;52:1064-1067.

160. Soleas GJ, *Diamandis EP*, Karumanchiri A, Goldberg DM. A multiresidue derivatization gas chromatographic assay for fifteen phenolic constituents with mass selective detection. **Anal Chem** 1997;69:4405-4409.

1998

161. Angelopoulou K, Levesque MA, Katsaros D, *Diamandis EP*. Exon 5 of the p53 gene is a target for deletions in ovarian cancer. **Clin Chem** 1998;44:72-77.

162. Levesque MA, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, *Diamandis EP*. Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. **Int J Cancer** 1998;79:147-152.

163. Griniatsos J, *Diamandis EP*, Gioti J, Karyda I, Vassilopoulos PP, Agnanti N. Correlation of prostate specific antigen immunoreactivity (IR-PSA) to other prognostic factors in female breast cancer. **Anticancer Res** 1998;18:683-688.

164. Lambert-Messerlian GM, Canick JA, Melegos DN, *Diamandis EP*. Increased concentrations of prostate specific antigen in maternal serum from pregnancies affected by fetal Down Syndrome. **Clin Chem** 1998;44:205-208.

165. Randell E, *Diamandis EP*, Goldberg DM. Changes in serum carbohydrate-deficient transferrin and gammaglutamyl transferase after moderate wine consumption in healthy males. **J Clin Lab Anal** 1998;12:92-97.

166. Sauter ER, Babb J, Daly M, Engstrom PF, Ehya H, Malik J, *Diamandis EP***.** Prostate-specific antigen production in the female breast: Association with progesterone. **Cancer Epidermiol Biomarkers Prevent** 1998;7:315-320.

167. Kogan I, Ballinger J, Redshaw R, *Diamandis EP*, Melegos DN,Kuba R, Rauth AM. Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice**. Breast Cancer Res Treat** 1998;48:73-80.

168. Luo L, Herbrick J-A, Scherer SW, Beatty B, Squire J, *Diamandis EP*. Structural characterization and mapping of the normal epithelial cell-specific 1 gene. **Biochem Biophys Res Commun** 1998;247:580-586.

169. Yu H, Levesque MA, Clark GM, *Diamandis EP*. Prognostic value of prostate-specific antigen for women with breast cancer: A large U.S. cohort study. **Clin Cancer Res** 1998;4:1489-1497.

170. Katsaros D, Melegos DN, *Diamandis EP*. Prostate specific antigen production by breast Tumours after induction with oral contraceptives. **Clin Biochem** 1998;31:285-288.

171. Angelopoulou K, *Diamandis EP*. Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: application to breast and ovarian Tumours**. J Clin Lab Anal** 1998;12:250-256.

172. Bharaj BS, Angelopoulou K, *Diamandis EP***.** Rapid sequencing of the p53 gene with a new automated DNA sequencer. **Clin Chem** 1998;44:1397-1403.

173. Levesque MA, Yu H, Clark GM, *Diamandis EP*. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. **J Clin Oncol** 1998;16:2641-2650.

174. Levesque MA, D'Costa M, Spratt EH, Yaman MM, *Diamandis EP*. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. **Int J Cancer** 1998;79:494-501.

175. Rosenberg RS, Grass L, Jenkins DJA, Kendall CWC, *Diamandis EP*. Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines. **Biochem Biophys Res Commun** 1998;248:935-939.

176. Lianidou ES, Angelopoulou A, Katsaros D, Durando A, Massobrio M, *Diamandis EP*. Fragment analysis of the p53 gene in ovarian Tumours. **Clin Biochem** 1998;31:551-553.

177. Angelopoulou K, Prody C, *Diamandis EP*. A candidate new gene on human chromosome 5q12 contains a motif that is found in transcriptional co-activators. **Clin Biochem** 1998;31:687-688.

178. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. Insulin-like growth factor-binding protein-3 and breast cancer survival. **Int J Cancer** 1998;79:624-628.

179. Rao PN, Wang Z, Cessac JW, Rosenberg RS, Jenkins DJA, *Diamandis EP*. New 11β-Aryl substituted steroids exhibit both progestational and antiprogestational activity. **Steroids** 1998;63:523-530.

1999

180. Melegos DN, Grass L, Pierratos A, *Diamandis EP*. Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. **Urology** 1999;53:32-37.

181. Foekens JA, *Diamandis EP*, Yu H, Look MP, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. **Br J Cancer** 1999;79:888-894.

182. Borchert GH, Yu H, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, *Diamandis EP*. Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. **J Clin Lab Anal** 1999;13:75-81.

183. *Diamandis EP*, Helle SJ, Yu H, Melegos DN, Lundgren S, Lonning PE. Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. **Cancer** 1999;85:891-898.

184. Luo L, *Diamandis EP*. Amplification of human genomic DNA sequences with polymerase chain reaction using a single oligonucleotide primer. **J Clin Lab Anal** 1999;13:69-74.

185. Majumdar S, *Diamandis EP***.** The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. **Br J Cancer** 1999;79:1594-1602.

186. Borchert GH, Melegos DN, Yu H, Giai M, Roagna R, Ponzone R, Sgro L, *Diamandis EP*. Quantification of pepsinogen C and prostaglandin D synthase in breast cyst fluid and their potential utility for cyst type classification. **Clin Biochem** 1999;32:39-44.

187. *Diamandis EP*, Arnett WP, Foussias G, Pappas H, Ghandi S, Melegos DN, Mullen B, Yu H, Srigley J, Jarvi K. Seminal plasma biochemical markers and their association with semen analysis findings. **Urology** 1999;53:596-603.

188. Jenkins DJA, Kendall CWC, Vidgen E, Agarwal S, Rao AV, Rosenberg RS, *Diamandis EP*, Novokmet R, Mehling CC, Perera T, Griffin LC, Thompson LU, Cunnane SC. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures and *ex vivo* androgen and progestin activity: a controlled crossover trial. **Am J Clin Nutr** 1999;69:395-402.

189. Black MH, Grass L, Leinonen J, Stenman U-H, *Diamandis EP*. Characterization of monoclonal antibodies for prostate-specific antigen and development of highly sensitive free prostate-specific antigen assays. **Clin Chem** 1999;45:347-354.

190. Lianidou ES, Levesque MA, Katsaros D, Angelopoulou K, Yu H, Genta F, Arisio R, Massobrio M, Bharaj B, *Diamandis EP*. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma. **Anticancer Res** 1999;19:749-756.

191. Scorilas A, *Diamandis EP*, Levesque MA, Papanastasiou-Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, López-Otin C. Immunoenzymatically determined pepsinogen C concentration in breast Tumour cytosols: an independent favorable prognostic factor in node-positive patients. **Clin Cancer Res** 1999;5:1778-1785.

192. Black MH, Magklara A, Obiezu CV, Melegos DN, *Diamandis EP*. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. **Clin Chem** 1999;45:790-799.

193. Wald NJ, Hackshaw AK, *Diamandis EP*, Melegos DN. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. International Prenatal Screening Group. **Prenat Diagn** 1999;19:674-676.

194. Yousef GM, Luo L-Y, *Diamandis EP*. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. **Anticancer Res** 1999;19:2843-2852.

195. Angelopoulou K, Borchert G, Melegos DN, Lianidou E, Lilja H, *Diamandis EP*. Characterization of the BRCA1-like immunoreactivity of human seminal plasma. **Urology** 1999; 54:753-762.

196. Bharaj BS, Vassilikos EJ, *Diamandis EP*. Rapid and accurate determination of $(CAG)_n$ repeats in the androgen receptor gene using polymerase chain reaction and automated fragment analysis. **Clin Biochem** 1999;32:327-332 .

197. Yu H, Levesque MA, Clark GM, *Diamandis EP*. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination **Br J Cancer** 1999; 81:490-495.

198. Rosenberg Zand RS, Jenkins DJ, *Diamandis EP*. Development and evaluation of a competitive time-resolved immunofluorometric assay for the estrogen-regulated protein pS2**. J Clin Lab Anal** 1999; 13:241-245.

199. Magklara A, Scorilas A, López-Otin C, Vizoso F, Ruibal A, *Diamandis EP*. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. **Clin Chem** 1999; 45:1774-1780.

200. Yousef GM, Obiezu CV, Luo LY, Black MH, *Diamandis EP*. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. **Cancer Res** 1999;59:4252-4256.

201. Magklara A, Scorilas A, Catalona WJ, *Diamandis EP*. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. **Clin Chem** 1999;45:1960-1966.

202. Yousef GM, *Diamandis EP*. The new kallikrein-like gene KLK-L2: Molecular characterization, mapping, tissue expression and hormonal regulation. **J Biol Chem** 1999;274:37511-37516.

203. Yousef GM, Luo L-Y, Scherer SW, Sotiropoulou G, *Diamandis EP*. Molecular characterization of zyme/proteaseM/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. **Genomics** 1999;62: 251-259.

204. Sauter ER, Ehya H, Babb J, *Diamandis EP*, Daly M, Klein-Szanto A, Sigurdson E, Hoffman J, Malick J, Engstrom PF. Biologic markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. **Br J Cancer** 1999;81:1222-1227.

2000

205. Black MH, Giai M, Ponzone R, Sismondi P, Yu H, *Diamandis EP*. Serum total and free prostate specific-antigen for breast cancer diagnosis in women. **Clin Cancer Res** 2000;6:467-473.

206. Levesque MA, D'Costa M, *Diamandis EP*. p21WAF1 protein expression determined by quantitative immunoassay in relation to non-small-cell lung cancer aggressiveness. **J Cancer Res Clin Oncol** 2000;126:48-52.

207. Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, *Diamandis EP*. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast Tumours and in normal breast secretions. **Br J Cancer** 2000;82:361-367.

208. Angelopoulou K, Yu H, Bharaj B, Giai M, *Diamandis EP*. p53 gene mutation, Tumour p53 protein overexpression and serum p53 autoantibody generation in patients with breast cancer. **Clin Biochem** 2000;33:53-62.

209. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren L, Yu H, *Diamandis EP*. Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. **J Urol** 2000;163:802-805.

210. Scorilas A, Yu H, Soosaipillai AR, Gregorakis AK, *Diamandis EP*. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. **Clin Chim Acta** 2000;292:127-138.

211. Yousef GM, *Diamandis EP*. The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). **Genomics** 2000;65:184-194.

212. Jenkins DJA, Kendall CWC, Garsetti M, Rosenberg-Zand RS, Jackson C-J, Agarwal S, Rao AV, *Diamandis EP*, Parker T, Faulkner D, Vuksan V, Vidgen E. Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity -- a controlled crossover trial. **Metabolism** 2000;49:537-543.

213. Yu H, Bharaj B, Vassilikos EJK, Giai M, *Diamandis EP*. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer . **Breast Cancer Res Treat** 2000;59:153-161.

214. Nam RK, *Diamandis EP*, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papanastasiou P, Jewett MAS, Narod SA. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. **J Clin Oncol** 2000;18:1036-1042.

215. Yousef GM, Scorilas A, *Diamandis EP*. Genomic organization, mapping, tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. **Genomics** 2000;63:88-96.

216. Yousef GM, Chang A, *Diamandis EP*. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. **J Biol Chem** 2000;275:11891-11898.

217. Luo LY, Grass L, *Diamandis EP*. The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. **Anticancer Res** 2000;20:981-986.

218. Bharaj B, Scorilas A, Giai M, *Diamandis EP*. TA repeat polymorphism of the 5alpha-reductase gene in breast cancer. **Cancer Epidemiol Biomarkers Prevent** 2000;9:387-393.

219. Rosenberg Zand RS, Grass L. Magklara A, Jenkins DJA, *Diamandis EP*. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? **Breast Cancer Res Treat** 2000;60:1-8.

220. Obiezu CV, Giltay EJ, Magklara A, Scorilas A, Gooren LJG, Yu H, Howarth DJC, *Diamandis EP*. Serum and urinary prostate-specific antigen and urinary human glandular kallikrein concentrations are significantly increased after testosterone administration in female-to-male transsexuals. **Clin Chem** 2000;46:859-862.

221. Magklara A, Grass L, *Diamandis EP*. Differential steroid hormone regulation of human glandular kallikerin (hK2) and prostate specific antigen (PSA) in breast cancer cell lines. **Breast Cancer Res Treat** 2000;59:263-270.

222. Obiezu CV, Yousef G, *Diamandis EP*. Identification of exon 1 of prostase/KLK-L1 gene. **Clin Biochem** 2000:33:221-222.

223. Vassilikos EJK, Yu H, Trachtenberg J, Nam RK, Narod SA, Bromberg IL, *Diamandis EP*. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. **Clin Biochem** 2000;33:115-123.

224. Scorilas A, *Diamandis EP*. Polyvinylamine-streptavidin complexes labeled with a europium chelator: a universal detection reagent for solid-phase time resolved fluorometric applications. **Clin Biochem** 2000; 33:345-350.

225. Bharaj B, Scorilas A, *Diamandis EP*, Giai M, Levesque MA, Sutherland DJ, Hoffman BR. Breast cancer prognostic significance of a single nucleotide polymorphism in the proximal androgen response element of the prostate specific antigen gene promoter. **Breast Cancer Res Treat** 2000;61:111-119.

226. Zand RS, Jenkins DJ, *Diamandis EP*. Steroid hormone activity of flavonoids and related compounds. **Breast Cancer Res Treat** 2000;62:35-49.

227. Foussias G, Yousef GM, *Diamandis EP*. Identification and molecular characterization of a novel member of the Siglec family (SIGLEC-9). **Genomics** 2000;67:171-178.

228. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, *Diamandis EP*. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. **Urology** 2000;56:527-532.

229. Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, *Diamandis EP*. Evidence for a dose-response effect between p53 (but not $p21^{WAF1/Cipl}$) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. **Clin Cancer Res** 2000;6:3260-3270.

230. Magklara A, Cheung CC, Asa SL, *Diamandis EP*. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. **Clin Chim Acta** 2000;300:171-180.

231. Yousef GM, Scorilas A, Magklara A, Soosaipillai A, *Diamandis EP.* The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family — genomic characterization, mapping, tissue expression and hormonal regulation. **Gene** 2000;254:119-128.

232. *Diamandis EP*, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. **Clin Biochem** 2000;33:369-375.

233. Yousef GM, Chang A, Scorilas A, *Diamandis EP*. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. **Biochem Biophys Res Commun** 2000;276:125-133.

234. Scorilas A, Bjartell A, Lilja H, Moller C, *Diamandis EP*. Streptavidin-polyvinylamine conjugates labeled with a europium chelate: applications in immunoassay, immunohistochemistry and microarrays. **Clin Chem** 2000;46:1450-1455.

235. Yousef GM, Magklara A, *Diamandis EP*. KLK12 is a novel serine protease and a new member of the human kallikrein gene family — differential expression in breast cancer. **Genomics** 2000;69:331-341.

236. *Diamandis EP*, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG, Wain H. New nomenclature for the human tissue kallikrein gene family. **Clin Chem** 2000;46:1855-1858.

237. *Diamandis EP*, Yousef GM, Soosaipillai AR, Bunting P. Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. **Clin Biochem** 2000;33:579-583.

238. Luo L-Y, *Diamandis EP*. Preliminary examination of time-resolved fluorometry for protein array applications. **Luminescence** 2000;15:409-413.

239. Foussias G, Yousef GM, *Diamandis EP*. Molecular characterization of SIGLEC8 variant containing cytoplasmic tyrosine-based motifs, and mapping of the SIGLEC8 gene. **Biochem Biophys Res Commun** 2000;278:775-781.

240. Scorilas A, Black MH, Talieri M, *Diamandis EP*. Genomic organization, physical mapping and expression analysis of the human protein arginine methyltransferase 1 gene. **Biochem Biophys Res Commun** 2000;278:349-359.

241. *Diamandis EP*, Yousef GM, Petraki C, Soosaipillai AR. Human kallikrein 6 as a biomarker of Alzheimer's disease. **Clin Biochem** 2000; 33:663-667.

242. Obiezu CV, *Diamandis EP*. An alternatively spliced variant of KLK4 expressed in prostatic tissue. **Clin Biochem** 2000; 33:599-600.

243. Comay D, Cauch-Dudek K, Hemphill D, *Diamandis E*, Wanless I, Heathcote EJ. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis? **Digestive Dis Sci** 2000;45:2018-2021.

2001

244. Yousef GM, Scorilas A, Jung K, Ahsworth LK, *Diamandis EP*. Molecular cloning of the human kallikrein 15 gene (KLK15): Up-regulation in prostate cancer. **J Biol Chem** 2001;276:53-61.

245. Luo LY, Soosaipillai A, *Diamandis EP*. Molecular cloning of a novel human gene on chromosome 4p11 by immunoscreening of an ovarian carcinoma cDNA library. **Biochem Biophys Res Commun** 2001; 280:401-406.

246. Katsaros D, Yu H, Levesque MA, Danese S, Genta F, Richiardi G, Fracchioli S, Khosravi MJ, Diamandi A, Gordini G, *Diamandis EP*, Moassobrio M. IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. **Eur J Cancer** 2001;37:478-485.

247. Scorilas A, Bharaj B, Giai M, *Diamandis EP*. Codon 89 ploymorphism in the human 5α-reductase gene in primary breast cancer. **Br J Cancer** 2001;84:760-767.

248. Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, *Diamandis EP*. Levels of insulin-like growth factor-I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. **Urology** 2001;57:471-475.

249. Kim H, Scorilas A, Katsaros D, Yousef GM, Massobrio M, Fracchioli S, Piccinno R, Gordini G, *Diamandis EP*. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. **Br J Cancer** 2001;84:643-650.

250. Luo LY, Grass L, Howarth DJC, Thibault P, Ong H, *Diamandis EP***.** Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. **Clin Chem** 2001; 47:237-246.

251. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, *Diamandis EP*. Molecular cloning, physical mapping and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved bh2 domain of the bcl-2 family. **Genomics** 2001;72:217-222.

252. Luo L-Y, Bunting P, Scorilas A, *Diamandis EP*. Human kallikrein 10: a novel tumour marker for ovarian carcinoma? **Clin Chim Acta** 2001;306:111-118.

253. Magklara A, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Danese S, *Diamandis EP*. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. **Clin Cancer Res** 2001;7:806-811.

254. Yousef GM, Magklara A, Chang A, Jung K, *Diamandis EP*. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. **Cancer Res** 2001;61:3425-3431.

255. Obiezu CV, Scorilas A, Magklara A, Thornton MH, Wang CY, Stanczyk FZ, *Diamandis EP*. Prostate specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. **J Clin Endocrinol Metab** 2001;86:1558-1561.

256. Foussias G, Taylor SM, Yousef GM, Tropak MB, Ordon MH, *Diamandis EP*. Cloning and molecular characterization of two splice variants of a new putative member of the Siglec-3-like subgroup of Siglecs. **Biochem Biophys Res Commun** 2001;284:887-899.

257. Yousef GM, Ordon MG, Foussias G, *Diamandis EP*. Molecular characterization, tissue expression and mapping of a novel Siglec-like gene (SLG2) with three splice variants. **Biochem Biophys Res Comm** 2001;284:900-910.

258. Yousef GM, Diamandis M, Jung K, *Diamandis EP*. Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. **Genomics** 2001;74:385-395.

259. Soleas GJ, Angelini M, Grass L, *Diamandis EP*, Goldberg DM. Absorption of *trans*-resveratrol in rats. **Methods Enzymol** 2001;335:145-154.

260. Scorilas A, Kyriakopoulou L, Katsaros D, *Diamandis EP*. Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. **Br J Cancer** 2001;85:190-198.

261. Luo L-Y, Rajpert-De Meyts E, Jung K, *Diamandis EP*. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate Tumour suppressor gene in normal and malignant testicular tissue. **Br J Cancer** 2001;85:220-224.

262. Scorilas A, Yousef GM, Jung K, Rajpert-de Meyts E, Carsten S, *Diamandis EP*. Identification and characterization of a novel human testis-specific kinase substrate gene which is downregulated in testicular Tumours. **Biochem Biophys Res Comm** 2001;285:400-408.

263. Yousef GM, Bharaj BS, Yu H, Poulopoulos J, *Diamandis EP*. Sequence analysis of the human kallikrein gene locus identifies a unique polymorphic minisatellite element. **Biochem Biophys Res Commun** 2001;285:1321-1329.

264. Soleas GJ, *Diamandis EP*, Goldberg DM. The world of resveratrol. **Adv Exp Med Biol** 2001;492:159-182.

265. Obiezu CV,Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, *Diamandis EP*. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. **Clin Cancer Res** 2001;7:2380-2386.

266. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Piccinno R, Rigault de la Longrais IA, Howarth DJ, *Diamandis EP*. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. **Clin Cancer Res** 2001;7:2372-2379.

267. Sidiropoulos M, Chang A, Jung K, *Diamandis EP*. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. **Br J Cancer** 2001;85:393-397.

268. Soleas GJ, Goldberg DM, Grass L, Levesque M, *Diamandis EP*. Do wine polyphenols modulate p53 gene expression in human cancer cell lines? **Clin Biochem** 2001;34:415-420.

269. Shimizu-Okabe C, Yousef GM, *Diamandis EP*, Yoshida S, Shiosaka S, Fahnestock M. Expression of the kallikrein gene family in normal and Alzheimer's disease brain. **Neuroreport** 2001;12:2747-2751.

270. Rosenberg Zand RS, Jenkins DJ, *Diamandis EP*. Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. **Clin Chim Acta** 2001;31:213-219.

271. Petraki CD, Karavana VN, Skoufogiannis PT, Little SP, Howarth DJ, Yousef GM, *Diamandis EP*. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. **J Histochem Cytochem** 2001;49:1431-1442.

272. Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, *Diamandis EP*, Katsaros D. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. **Cancer Res** 2001;61:7811-7818.

273. Chang A, Yousef GM, Jung K, Rajpert-De Meyts E, *Diamandis EP*. Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: different expression in the human testis and testicular cancer. **Anticancer Res** 2001;21:147-152.

2002

274. *Diamandis EP*, Okui A, Mitsui S, Luo LY, Soosaipillai A, Grass L, Nakamura T, Howarth DJ, Yamaguchi N. Human Kallikrein 11: A new biomarker of prostate and ovarian carcinoma. **Cancer Res** 2002;62:295-300.

275. Rosenberg Zand RS, Jenkins DJA, Brown TJ, *Diamandis EP*. Flavonoids can block PSA production by breast and prostate cancer cell lines. **Clin Chim Acta** 2002;317:17-26.

276. Bharaj BB, Luo L-Y, Jung K, Stephan C, *Diamandis EP*. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular and ovarian cancers. **Prostate** 2002;51:35-41.

277. Sauter ER, Tichansky DS, Cervoneva I, *Diamandis EP*. Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer. **Environ Health Perspect** 2002;110:241-246.

278. Yousef G, Ordon M, Foussias G, *Diamandis EP*. Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new signlec pseudogenes. **Gene** 2002;286:259-270.

279. Chang A, Yousef GM, Scorilas A, Grass L, Sismondi P, Ponzone R, *Diamandis EP*. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favorable prognosis in breast cancer. **Br J Cancer** 2002;86:1457-1464.

280. Lin R, Nagai Y, Sladek R, Bastien Y, Ho J, Petrecca K, Sotiropoulou G, *Diamandis EP*, Hudson TJ, White JH. Expression of profiling in aquamous carcinoma cells reveals pleiotropic effects of vitamin D(3) analog EB1089 signalling on cell proliferation, differential, and immune system regulation. **Mol Endocrinol** 2002;16:1243-1256.

281. Scorilas A, Levesque MA, Ashworth LK, *Diamandis EP*. Cloning, physical mapping and structural characterization of the human alpha(A)-Adaptin gene. **Gene** 2002;289:191-199.

282. Soleas G, Grass L, Josephy PD, Goldberg DM, *Diamandis EP*. A comparison of the anticarcinogenic properties of four wine polyphenols. **Clin Biochem** 2002;35:119-124.

283. Yousef GM, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, *Diamandis EP*. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. **Prostate** 2002;51:126-132.

284. Zarghooni M, Soosaipillai A, Grass L, Scorilas A, Mirazimi N, *Diamandis EP*. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. **Clin Biochem** 2002;35:225-231.

285. Sauter ER, Chervoneva I, Diamandis A, Khosravi JM, Litwin S, Diamandis EP. Prostate-specific antigen and insulin-like growth factor binding protein-3 in nipple aspirate fluid are associated with breast cancer. **Cancer Det Prev** 2002;26:149-157.

286. Luo L-Y, *Diamandis EP*, Look MP, Soosaipillai AP, Foekens JA. Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. **Br J Cancer** 2002;86:1790-1796.

287. Magklara A, Brown TJ, *Diamandis EP*. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. **Int J Cancer** 2002;100:507-514.

288. Mahmoud AAH, Yousef GM, Al-Hifzi I, *Diamandis EP*. Cocayne syndrome in three sisters with varying clinical presentation. **Am J Med Gen** 2002;111:81-85.

289. Stephan C, Cammann H, Semjonow A, *Diamandis EP*, Wymenga LF, Lein M, Sinha P, Leoning SA, Jung K. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. **Clin Chem** 2002;48:1279-1287.

290. Yousef GM, Scorilas A, Kyriakopoulou L, Rendel L, Diamandis M, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P, *Diamandis EP*. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. **Clin Chem** 2002;48:1241-1250.

291. Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, Howarth DH, *Diamandis EP*. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. **Clin Chem** 2002;48:1232-1240.

292. Petraki CD, Karavana VN, Luo L-Y, *Diamandis EP*. Human kallikrein 10 expression in normal tissues by immunohistochemistry. **J Histochem Cytochem** 2002;50:1247-1261.

293. Luo LY, Herrera I, Soosaipillai A, *Diamandis EP*. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. **Br J Cancer** 2002;87:339-343.

294. Sauter ER, Welch T, Magklara A, Klein G, *Diamandis EP*. Ethnic variation in kallikrein expression in nipple aspirate fluid. **Int J Cancer** 2002;100:678-682.

295. Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Biglia N, Abd Ellatif M, *Diamandis EP*. The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. **Br J Cancer** 2002;87:1294-1300.

296. Yousef GM, Borgoño CA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P, *Diamandis EP*. Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. **Br J Cancer** 2002;87:1287-1293.

297. Yousef GM, Obiezu CV, Jung K, Stephan C, Scorilas A, *Diamandis EP*. Differential expression of kallikrein gene 5 in cancerous and normal testicular tissues. **Urology** 2002;60:714-718.

298. Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, Colgan T, Puopolo M, Giardina G, Massobrio M, *Diamandis EP*. Immunofluorometric quantitation and histochemical localisation of

kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. **Br J Cancer** 2002;87:763-771.

299. Brauer PM, McKeown-Eyssen GE, Jazmaji V, Logan AG, Andrews DF, Jenkins D, Marcon N, Saibil F, Cohen L, Stern H, Baron D, Greenberg G, *Diamandis E*, Kakis G, Singer W, Steiner G. Familial aggregation of diabetes and hypertension in a case-control study of colorectal neoplasia. **Am J Epidemiol** 2002;156:702-713.

300. Petraki CD, Karavana VN, Revelos KI, Luo L-Y, *Diamandis EP*. Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. **Histochem J** 2002;34:313-322.

2003

301. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Dristiansen G, Hauptmann S, Bharaj BS, Nakamura T, Leoning SA, *Diamandis EP*. Quantitative analysis of kallikrein 15 (KLK15) gene expression in prostatic tissue. **J Urol** 2003;169:361-364.

302. Kapadia C, Chang A, Sotiropoulou G, Yousef GM, Grass L, Soosaipillai A, Xing X, Howarth DH, *Diamandis EP*. Human kallikrein 13: Production and purification of recombinant protein, monoclonal and polyclonal antibodies and development of a sensitive and specific immunofluorometric assay. **Clin Chem** 2003;49:77-86.

303. Kishi T, Grass L, Soosaipillai A, Scorilas A, Shimizu-Okabe C, *Diamandis EP*. Human kallikrein 8: Immunoassay development and identification in tissue extracts and biological fluids. **Clin Chem** 2003;49:87-96.

304. Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, *Diamandis EP*. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. **Clin Biochem** 2003;36:135-143.

305. Luo L-Y, Katsaros D, Scorilas A, Fracchioli S, Bellino R, van Gramberen M, de Bruijn H, Henrik A, Stenman U-H, van der Zee AGJ, Vergote I, *Diamandis EP*. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. **Cancer Res** 2003;63:807-811.

306. *Diamandis EP*, Scorilas A, Fracchioli S, van Gramberen M, de Bruijn H, Henrik A, Soosaipillai A, Grass L, Yousef GM, Stenman U-H, Massobrio M, van der Zee AGJ, Vergote I, Katsaros D. Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. **J Clin Oncol** 2003;21:1035-1043.

307. Yousef GM, Scorilas A, Nakamura T, Ellatif Said M, Ponzone R, Biglia N, Maggiorotto M, Roagna R, Sismondi P, *Diamandis EP*. The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. **Breast Cancer Res Treat** 2003;78:149-158.

308. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, *Diamandis EP*. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. **Br J Cancer** 2003;88:1101-1103.

309. Yousef GM, Fracchioli S, Scorilas A, Borgono CA, Iskander L, Puopolo M,, Massobrio M, *Diamandis EP*, Katsaros D. Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. **Am J Clin Pathol** 2003;119:345-355.

310. Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F, *Diamandis EP*. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. **The Prostate** 2003;54:220-229.

311. Petraki CD, Karavana VN, *Diamandis EP*. Human kallikrein 13 expression in normal tissues: An immunohistochemical study. **J Histochem Cytochem** 2003;51:493-501.

312. Hutchinson S, Luo L-Y, Yousef GM, Soosaipillai A, *Diamandis EP*. Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. **Clin Chem** 2003;49:746-751.

313. Yousef GM, Polymeris M-E, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, *Diamandis EP*. Parallel overexpression of seven kallikrein genes in ovarian cancer. **Cancer Res** 2003;63:2223-2227.

314. Nakamura T, Stephan C, Scorilas A, Yousef GM, Jung K, *Diamandis EP*. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. **Urology** 2003;61:1042-1046.

315. Kollara A, *Diamandis EP*, Drown TJ. Secretion of endogenous kallikrein 2 and 3 by androgen receptor-transfected PC-3 prostate cancer cells. **J Steroid Biochem Mol Biol** 2003;84:493-502.

316. Scorilas A, Chiang PM, Katsaros D, Yousef GM, *Diamandis EP*. Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors. **Gene** 2003;310:79-89.

317. Talieri M, *Diamandis EP*, Katsaros N, Gourgiotis D, Scorilas A. Expression of BCL2L12, a new member of apoptosis-related genes, in breast Tumours. **Thromb Haemost** 2003;89:1081-1088.

318. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Mysliwiec M, Schmitt M, *Diamandis EP*. Human kallikrein 8, a novel biomarker for ovarian carcinoma. **Cancer Res** 2003;63:2771-2774.

319. Yousef GM, Stephan C, Ad Ellatif M, Scorilas A, Jung K, Kristiansen G, Jung M, *Diamandis EP*. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. **The Prostate** 2003;56:287-393.

320. Borgoño CA, Fracchioli S, Yousef GM, Rigault De La Longrais IA, Luo L-Y, Soosaipillai A, Puopolo M, Grass L, Scorilas A, *Diamandis EP*, Katsaros D. Favourable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. **Int J Cancer** 2003.106:605-610.

321. Nam RK, Zhang WW, Trachtenberg J, *Diamandis EP*, Toi A, Emami M, Ho M, Sweet J, Evans A, Jewett MA, Narod SA. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. **J Clin Oncol** 2003;21:2312-2319.

322. Yousef GM, Kopolovic AD, Elliott M, *Diamandis EP*. Genomic overview of serine proteases. **Biochem Biophys Res Commun** 2003;305:28-36.

323. Yousef GM, Scorilas A, Katsaros D, Fracchioli S, Iskander L, Borgoño C, Rigault de la Longrais IA, Puopolo M, Massobrio M, *Diamandis EP*. Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. **J Clin Oncol** 2003;21:3119-3126.

324. Yousef GM, Kapadia C, Polymeris M-E, Borgono C, Hutchinson S, Wasney GA, Soosaipillai A, *Diamandis EP*. The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. **Biochim Biophys Acta** 2003;1628:88-96.

325. Yousef GM, Polymeris M-E, Grass L, Soosaipillai A, Chan P-C, Scorilas A, Borgono C, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, *Diamandis EP*. Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. **Cancer Res** 2003; 63:3958-3965.

326. Magklara A, Mellati AA, Wasney GA, Little SP, Sotiropoulou G, Becker GW, *Diamandis EP*. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity and regulation by inhibitors. **Biochem Biophys Res Commun** 2003;307:948-955.

327. Luo L-Y, Grass L, *Diamandis EP*. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. **Clin Chim Acta** 2003;337:115-126.

328. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai AR, *Diamandis EP*. The usefulness of serum human kallikrein11 (hK11) for discriminating between prostate cancer and benign prostatic hyperplasia. **Cancer Res** 2003;63:6543-6546.

329. Petraki CD, Gregorakis AD, Papanastasiou PA, Karavana VN, Luo LY, *Diamandis EP*. Immunohistochenmical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. **Prostate Cancer Prostatic Dis** 2003;6:223-227.

330. Borgoño CA, Grass L, Soosaipillai A, Yousef GM, Petraki CD, Howarth HC, Fracchioli S, Katsaros D, *Diamandis EP*. Human kallikrein 14: A new potential biomarker for ovarian and breast cancer. **Cancer Res** 2003;63:9032-9041.

331. *Diamandis EP*, Borgoño CA, Scorilas A, Yousef GM, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. **Tumour Biol** 2003;24:299-309.

2004

332. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Leoning SA, *Diamandis EP*. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. **J Urol** 2004;171:187-191.

333. Talieri M, *Diamandis EP*, Gourgiotis D, Mathioudaki K, Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast Tumours: a new potential biomarker for prognosis of breast carcinoma. **Thromb Haemost** 2004;91:180-186.

334. Kapadia C, Yousef GM, Mellati AA, Magklara A, Wasney GA, *Diamandis EP*. Complex formation between human kallikrein 13 and serum protease inhibitors. **Clin Chim Acta** 2004;339:157-167.

335. Sauter ER, Lininger J, Magklara A, Hewett JE, *Diamandis EP*. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. **Int J Cancer** 2004;108:588-591.

336. Papageorgiou PC, Pourdjabbar A, Amfilochiadis AA, *Diamandis EP*, Boomsma F, Osmond DH. Are cardiovascular and sympathoadrenal effects of human "new pressor protein" preparations attributable to human coagulation {beta}-FXIIa? **Am J Physiol Heart Circ Physiol** 2004;286:H837-H846.

337. Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, *Diamandis EP*. Kallikrein gene downregulation in breast cancer. **Br J Cancer** 2004;90:167-172.

338. Scorilas A, Borgoňo CA, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. **J Clin Oncol** 2004;22:678-685.

339. *Diamandis EP,* Scorilas A, Kishi T, Blennow K, Luo LY, Soosaipillai A, Rademaker AW, Sjogren M. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. **Clin Biochem** 2004;37:230-237.

340. Kishi T, Soosaipillai A, Grass L, Little SP, Johnstone EM, *Diamandis EP***.** Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. **Clin Chem** 2004;50:709-716.

341. Yousef GM, Borgoňo CA, Popalis C, Yaboub GM, Polymeris M-E, Soosaipillai A, *Diamandis EP*. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. **Anticancer Res** 2004;24:43-51.

342. Sauter E, Klein G, Wagner-Mann C, *Diamandis EP*. Prostate-specific antigen expression in nipple aspirate fluid is associated with advanced breast cancer. **Cancer Det Prev** 2004;28:27-31.

343. Yousef GM, Elliott MB, Kopolovic AD, Serry E, *Diamandis EP*. Sequence and evolutionary analysis of the human trypsin subfamily of serine peptidases. **Biochim Biophys Acta** 2004;1698:77-86.

344. Antoniou A, Papanastasiou P, Stephanidis A, *Diamandis E*, Androulakakis PA. Assessment of serum prostate specific antigen in childhood. **BJU Int** 2004;93:838-840.

345. Pampalakis G, Kurlender L, *Diamandis EP*, Sotiropoulou G. Cloning and characterization of novel isoforms of the human kallikrein 6 gene. **Biochem Biophys Res Commun** 2004;320:54-61**.**

346. Kurlender L, Yousef GM, Memari N, Robb J-D, Michael IP, Borgoňo C, Katsaros D, Stephen C, Jung K, *Diamandis EP*. Differential expression of a human kallikrein 5 *(KLK5)* splice variant in ovarian and prostate cancer. **Tumour Biol** 2004;25:149-156.

347. Yousef GM, Borgoňo CA, Michael IP, Davidian C, Stephan C, Jung K, *Diamandis EP*. Molecular cloning of a new gene which is differentially expressed in breast and prostate cancers. **Tumour Biol** 2004:25:122-133.

348. Kapadia C, Ghosh CM, Grass L, *Diamandis EP*. Human kallikrein 13 involvement in extracellular matrix degradation. **Biochem Biophys Res Commun** 2004;323:1084-1090.

349. *Diamandis EP*, Borgoňo CA, Scorilas A, Harbeck N, Dorn J, Schmitt M. Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. **Clin Biochem** 2004;37:823-829.

350. Yousef GM, Borgoňo CA, Michael IP, *Diamandis EP*. Cloning of a kallikrein pseudogene. **Clin Biochem** 2004;37:961-967**.**

351. Ghosh MC, Grass L, Soosaipillai A, Sotiropoulou G, *Diamandis EP*. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. **Tumour Biol** 2004;25:193-199.

352. Yousef GM, White NMA, Michael I, Memari N, Robb J-D, Katsaros D, Stephan C, Jung K, *Diamandis EP*. The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer. **Tumour Biol** 2004;25:221-227.

353. Yousef GM, Borgoňo CA, White NMA, Robb J-D, Michael IP, Oikonomopoulou K, Khan S, *Diamandis EP*. Insilico analysis of the human kallikrein gene 6. **Tumour Biol** 2004;25:282-289.

354. Tran N, Bharaj BS, *Diamandis EP*, Smith M, Li BD, Yu H. Short tandem repeat polymorphism and cancer risk: influence of laboratory analysis on epidemiologic findings. **Cancer Epidemiol Biomarkers Prev** 2004;13:2133-2140.

2005

355. Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, Stephan C, Jung K, *Diamandis EP*. Intron retention: a common splicing event within the human kallikrein gene family. **Clin Chem** 2005;51:506-515.

356. Felber LM, Borgono CA, Cloutier SM, Kundig CM, Kishi T, Chagas JR, Jichlinski P, Gygi CM, Leisinger H-J, *Diamandis EP*, Deperthes D. Enzymatic profiling of human kallikrein 14 using phage- display substrate technology. **Biol Chem** 2005;386:291-298.

357. Santin AD, *Diamandis EP*, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. **Clin Cancer Res** 2005;11:3320-3325.

358. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Ghosh M, Wasney G, *Diamandis EP*. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. **J Biol Chem** 2005;280:14628-14635.

359. Komatsu N, Saijoh K, Toyama T, Ohka R, Otsuki N, Hussack G, Takehara H, *Diamandis EP*. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. **Br J Dermatol** 2005;153:274-281.

360. Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, *Diamandis EP*. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. **BJU Int** 2005;96:521-527.

361. Yousef GM, White NMA, Michael IP, Cho JC, Robb JD, Kurlender L, Khan S, *Diamandis EP*. Identification of new splice variants and differential expresson of the human kallikrein 10 gene, a candidate cancer biomarker. **Tumour Biol** 2005;26:227-235.

362. Obiezu CV, Shan SJ, Soosaipilla A, Luo LY, Grass L, Sotiropoulou G, Petraki CD, Papanastasiou PA, Levesque MA, *Diamandis EP*. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. **Clin Chem** 2005;51:1432-1442.

363. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, *Diamandis EP*, Hellstrom I, Mok SC, Liu J, Bast RC Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. **Gynecol Oncol** 2005;99:267-277.

364. Sidiropoulos M, Pampalakis G, Sotiropoulou G, Katsaros, D, *Diamandis EP*. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. **Tumour Biol** 2005;26:324-336.

365. Yousef GM, Ejeckam GC, Best LM, *Diamandis EP*. Collecting duct carcinoma associated with oncocytoma: **Int Braz J Urol** 2005;31:465-467.

366. Komatsu N, Saijoh K, Sidiropoulos M, Tsai B, Levesque MA, Elliott MB, Takehara K, *Diamandis EP*. Quantification of human tissue kallikreins in the stratum corneum: dependence on age and gender. **J Invest Dermatol** 2005;125:1182-1189.

367. Schmitt M, Magdolen V, Mengele K, Reuning U, Foekens J, *Diamandis EP*, Harbeck N. Fibrinolytics, enzyme inhibitors and cancer survival. Haematol Repts 2005;1:28-33.

2006

368. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, *Diamandis EP*. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. **Tumour Biol** 2006;27:1-7.

369. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, *Diamandis EP,* Hampton GM, Russell PJ, Giles GG, Breit SN. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. **Clin Cancer Res** 2006;12:89-96.

370. Simon I, Zhou S, Corral L, *Diamandis EP*, Sarno MJ, Wolfert RL, Kim NW. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. **Cancer Res** 2006;66:1570-1575.

371. Fritzsche F, Gansukh T, Borgono C, Burkhardt M, Pahl S, Mayordomo E, Winzer KJ, Weichert W, Denkert C, Jung K, Stephan C, Dietel M, *Diamandis EP*, Dahl E, Kristiansen G. Expression of human kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status. **Br J Cancer** 2006;94:540-547.

372. Darling MR, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human Kallikrein 6 expression in salivary gland tumors. **J Histochem Cytochem** 2006;54:337-342.

373. Luo L-Y, Shan SJC, Elliott MB, Soosaipillai A, *Diamandis EP*. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. **Clin Cancer Res** 2006;12:742-750.

374. Prezas P, Scorilas A, Yfanti C, Viktorov P, Agnanti N, *Diamandis EP*, Talieri M. The role of human tissue kallikreins 7 and 8 in intracranial malignancies. **Biol Chem** 2006;387;1607-1612.

375. Elliott MB, Irwin DM, *Diamandis EP*. In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. **Genomics** 2006;88:591-599.

376. Oikonomopoulou K, Hansen K,K, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, *Diamandis EP*, Hollenberg MD. Proteinase-activated receptors, targets for kallikrein signalling. **J Biol Chem** 2006;281:32095-32112.

377. Shan SJ, Scorilas A, Katsaros D, Rigault de la Longrais I, Massobrio M, *Diamandis EP*. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. **Clin Chem** 2006;52:1879-1886.

378. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors. **Int J Biol Markers** 2006;21:201-205.

379. Dorn J, Harbeck N, Kates R, Magdolen V, Grass L, Soosaipillai A, Schmalfeldt B, *Diamandis EP*, Schmitt M. Disease processes may be reflected by correlations among tissue kallikreins proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma. **Biol Chem** 2006;387:1121-1128.

380. Slagter MH, Gooren LJG, Scorilas A, Petraki CD, *Diamandis EP*. Effects of long-term androgen administration on breast tissue of female-to-male transsexuals. **J Histochem Cytochem** 2006;54:905-910.

381. Slagter MH, Scorilas A, Gooren LJG, de Ronde W, Soosaipillai A, Giltay EJ, Paliouras M, *Diamandis EP*. Effect of testosterone administration on serum and urine kallikrein concentrations in female-to-male transsexuals. **Clin Chem** 2006;52:1546-1551.

382. Slagter MH, Gooren LJG, de Ronde W, Soosaipillai A, Scorilas A, Giltay EJ, Paliouras M, *Diamandis EP*. Serum and urine tissue kallikrein concentrations in male-to-female transsexuals treated with anti-androgens and estrogens. **Clin Chem** 2006;52:1356-1365.

383. Oikonomopoulou K, Hansen KK, Saiffeddine M, Vergnolle N, Tea I, Blaber M, Blaber SI, Scarisbrick I, *Diamandis EP*, Hollenberg MD. Kallikrein-mediated cell signallying: targeting proteinase-activated receptors (PARs). **Biol Chem** 2006;387:817-824.

384. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A, Wittock R, Robinson K, Alexander JS, Birch-Machin MA, Abdel-Malak M, Froberg MK, *Diamandis EP*, Thayer RE. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. **J Mol Diagn** 2006;8:312-319.

385. Prezas P, Arlt MJ, Viktorov P, Soosaipillai A, Holzscheiter L, Schmitt M, Talieri M, *Diamandis EP*, Krűger A, Magdolen V. Overexpression of the human tissue kallikrein genes KLK4, 5, 6 and 7 increases the malignant phenotype of ovarian cancer cells. **Biol Chem** 2006;387:807-811.

386. Stephan C, Meyer HA, Cammann H, Nakamura T, *Diamandis EP*, Jung K. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. **Biol Chem** 2006;387:801-805.

387. Pampalakis G, *Diamandis EP*, Sotiropoulou G. The epigenetic basis for the aberrant expression of kallikreins in human cancers. **Biol Chem** 2006;387:795-799.

388. Obiezu CV, Michael IP, Levesque MA, *Diamandis EP*. Human kallikrein 4: enzymatic activity, inhibition and degradation of extracellular matrix proteins. **Biol Chem** 2006;387:749-759.

389. Memari N, Grass L, Nakamura T, Karakucuk I, *Diamandis EP*. Human tissue kallikrein 9: production of recombinant proteins and specific antibodies. **Biol Chem** 2006;387:833-740.

390. Kishi T, Cloutier SM, Kűndig C, Deperthes D, *Diamandis EP*. Activation and enzymatic characterization of recombinant human kallikrein 8. **Biol Chem** 2006;387:723-731.

391. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. **Cancer Res** 2006;66:5540-5541.

392. Felber LM, Kűndig C, Borgoňo CA, Chagas JR, Tasinato A, Jichlinski P, Gygi CM, Leisinger HJ, *Diamandis EP*, Deperthes D, Cloutier SM. Mutant recombinant serpins as highly specific inhibitors of human kallikrein 14. **FEBS J** 2006;273:2505-2514.

393. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, *Diamandis EP*. Human tissue kallikrein 5 is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. **J Biol Chem** 2006;281:12743-12750.

394. Santin AD, *Diamandis EP*, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. **Am J Obstet Gynecol** 2006;194:1296-302.

395. Soleas GJ, Grass L, Josephy PD, Goldberg DM, *Diamandis EP*. A comparison of the anticarcinogenic properties of four red wine polyphenols. **Clin Biochem** 2006;39:492-497.

396. Stephan C, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, *Diamandis EP*, Meyer H, Cammann H, Jung K. Three new serum markers for prostate cancer detection within a percent free PSA-based artifical neural network. **Prostate** 2006;66:651-659.

397. Darling MR, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 13 expression in salivary gland tumors. **Intl J Biol Markers** 2006;21:106-110.

398. Borgoňo CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 8 protein is a favourable prognostic marker in ovarian cancer. **Clin Cancer Res** 2006;12:1487-1493.

399. Stephan C, Jung K, Nakamura T, Yousef GM, Kristiansen G, *Diamandis EP*. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. **Int J Urol** 2006;13:238-243.

400. Darling MR, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 6 expression in salivary gland tumors. **J Histochem Cytochem** 2006;54:337-342.

401. Simon I, Zhuo S, Corral L, *Diamandis EP*, Sarno MJ, Wolfert RL, Kim NW. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. **Cancer Res** 2006;66:1570-1575.

402. Luo LY, Shan SJ, Elliott MB, Soosaipillai A, *Diamandis EP*. Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. **Clin Cancer Res** 2006;12:742-750.

403. Brown DA, Stepham C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, *Diamandis EP*, Hampton GM, Russell PJ, Giles GG, Breit SN. Measurement of serum levels of macrophage inhibitory cytokine I combined with prostate-specific antigen improves prostate cancer diagnosis. **Clin Cancer Res** 2006;12:89-96.

404. Luo L-Y, Soosaipillai A, Grass L, *Diamandis EP*. Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients. **Tumour Biol** 2006;27:227-234.

405. Oikonomopoulou K, Scorilas A, Michael IP, Grass L, Soosaipillai A, Rosen B, Murphy J, *Diamandis EP*. Kallikreins as markers of disseminated tumour cells in ovarian cancer – a pilot study. **Tumour Biol** 2006;27:104-114.

406. Petraki CD, Gregorakis AK, Vaskamatzis MM, Papanastasiou PA, Yousef GM, Levesque MA, *Diamandis EP*. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. **Tumour Biol** 2006;27:1-7.

407. Williams D, Bowden P, Stacey C, McDonell M, Kowalski P, Kowalski JM, Evans K, *Diamandis EP*, Siu KWM, Marshall J. Comparison of methods to examine the endogenous peptides of fetal serum. **Clin Proteomics** 2006;2:.

2007

408. Shaw JL, Grass L, Sotiropoulou G, *Diamandis EP*. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identificationof KLK15 in tissues and biological fluids. **Clin Biochem** 2007;40:104-110.

409. Borgoňo CA, Michael IP, Shaw JL, Luo LY, Ghosh MC, Soosaipillai A, Grass L, Katsaros D, *Diamandis EP*. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. **J Biol Chem** 2007;282:2405-2422.

410. Shan SJ, Scorilas A, Katsaros D, *Diamandis EP*. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. **Br J Cancer** 2007;96:362-372.

411. Komatsu N, Saijoh K, Otsuki N, Kishi T, Michael IP, Obiezu CV, Borgono CA, Takehara K, Jayakumar A, Wu HK, Clayman GL, *Diamandis EP*. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. **Clin Chim Acta** 2007;377:228-236.

412. Paliouras M, *Diamandis EP*. Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. **Breast Cancer Res Treat** 2007;102:7-18.

413. Borgoňo CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, *Diamandis EP*. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. **J Biol Chem** 2007;282:3640-3652.

414. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, *Diamandis EP*, Remzi M, Djavan B, Wildhagen MF, Blijenberg BG, Finne P, Stenman U-H, Jung K, Meyer HA. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. **World J Urol** 2007;25:95-103.

415. Sardana G, Marshall J, *Diamandis EP*. Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. **Clin Chem** 2007;53:429-437.

416. Dorn J, Schmitt M, Kates R, Schmalfeldt B, Kiechle M, Scorilas A, *Diamandis EP*. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. **Clin Cancer Res** 2007;13:1742-1748.

417. Memari N, Jiang W, *Diamandis EP*, Luo L-Y. Enzymatic properties of human kallikrein-related peptidase 12 (KLK12). **Biol Chem** 2007;388:427-435.

418. Shih IeM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Műller-Holzner E, Gastl G, Zhang Z, *Diamandis EP*. Ovarian cancer specific kallikrein profile in effusions. **Gynecol Oncol** 2007;105:501-507.

419. Komatsu N, Saijoh K, Kuk C, Shirasaki F, Takehara K, *Diamandis EP*. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. **Br J Dermatol** 2007;156:875-883.

420. Komatsu N, Saijoh K, Kuk C, Liu AC, Khan S, Shirasaki F, Takehara K, *Diamandis EP*. Human tissue kallikreins expression in the stratum corneum and serum of atopic dermatitis patients. **Exp Dermatol** 2007;16:513-519.

421. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, *Diamandis EP*. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. **Gynecol Oncol** 2007;106:334-341.

422. Shaw JL, Smith CR, *Diamandis EP*. Proteomic analysis of human cervico-vaginal fluid. **J Proteome Res** 2007;6:2859-2865.

423. Shaw JL, *Diamandis EP*. Distribution of 15 human kallikreins in tissues and biological fluids. **Clin Chem** 2007;53:1423-1432.

424. Memari N, *Diamandis EP*, Earle T, Campbell A, Van Dekken H, Van der Kwast TH. Human kallikrein-related peptidase 12: Antibody generation and immunohistochemical localization in prostatic tissues. **Prostate** 2007;67:1465-1474.

425. McIntosh MW, Liu Y, Drescher C, Urban N, *Diamandis EP*. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. **Clin Cancer Res** 2007;13:4422-4428.

426. Cho CK, Shan SJ, Winsor EJ, *Diamandis EP*. Proteomic analysis of human amniotic fluid. **Mol Cell Proteomics** 2007;6:1406-1415.

427. Kulasingam V, *Diamandis EP*. Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines. **Biol Chem** 2007;388:1113-1119.

428. Yousef GM, Denic N, Wadhwa J, Chandracanth, Smith T, Elms F, *Diamandis EP*. Intravagal ectopic parathyroid presenting as a vocal cord paralysis: Case report and review of literature. **J Otolaryngol** 2007;36:E93-95.

429. Zheng Y, Katsaros D, Shan SJC, Rigault de la Longrais I, Porpiglia M, Scorilas A, Kim NW, Wolfert RL, Simon I, Li L, Feng Z, *Diamandis EP*. A multiparametric panel for ovarian cancer diagnosis, prognosis and response to chemotherapy. **Clin Cancer Res** 2007;13:6984-6992.

430. Borgono CA, Gavigan J-A, Valves J, Bowles B, Harris JL, Sotiropoulou G, *Diamandis EP*. Defining the extended substrate specificity of kallikrein 1-related peptidases. **Biol Chem** 2007;388:1215-1225.

431. Kulasingam V, *Diamandis EP*. Proteomics analysis of conditioned media from three breast cancer cell lines: A mine for biomarkers and therapeutic targets. **Mol Cell Proteomics** 2007;6:1997-2011.

432. Goard CA, Bromberg IL, Elliott MB, Diamandis EP. A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (*KLK*) locus. **Mol Oncol** 2007;1:303-312.

2008

433. Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A, *Diamandis EP*, Escott N, Skehan A, Prowse O, Thayer RE, Froberg MK, Wilson MJ, Maragh S, Jakupciak JP, Wagner PD, Srivastava S, Dakubo GD, Parr RL. Mitochondrial genome deletion aids in the identification of false- and true- negative prostate needle core biopsy specimens. **Am J Clin Pathol** 2008;129:57-66.

434. Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, *Diamandis EP*. "Product Ion Monitoring" assay for for prostate-specific antigen in serum using a linear Ion-trap. **J Proteome Res** 2008;7:640-647.

435. Emami N, *Diamandis EP*. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade: Possible function in seminal plasma and skin. **J Biol Chem** 2008;283:3031-3041.

436. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, *Diamandis EP*, Goodglick L. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. **Clin Cancer Res** 2008;14:1355-1362.

437. Heshmat S, Mullen B, Jarvi K, Soosaipillai A, *Diamandis EP*, Hamilton RJ, Lo KC. Seminal plasma lipocalin-type prostaglandin D synthase: a potential new marker for the diagnosis of obstructive azoospermia. **J Urol** 2008;79:1077-1080.

438. Paliouras M, *Diamandis EP*. Intracellular signaling pathways regulate hormone-dependent human kallikrein gene expression. **Tumour Biol** 2008;29:63-75.

439. Rabien A, Fritzsche F, Jung M, *Diamandis EP*, Leoning SA, Dietel M, Jung K, Stephan C, Kristiansen G. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. **Tumour Biol** 2008;29:1-8.

440. Planque C, Bléchet, Ayadi-Kaddour A, Heuzé-Vourc'h N, Dumont P, Guyétant S, *Diamandis EP*, El Mezni F, Courty Y. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung. **Biol Chem** 2008;389:781-786.

441. Scarisbrick IA, Linbo R, Vandell AG, Keegan M, Blaber SI, Blaber M, Sneve D, Lucchinetti CF, Rodriguez M, *Diamandis EP*. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. **Biol Chem** 2008;389:739-745.

442. Paliouras M, Diamandis EP. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. **Biol Chem** 2008;389:773-780.

443. Emami N, Deperthes D, Malm J, *Diamandis EP*. Major role of the human klk14 in seminal clot liquefaction. **J Biol Chem** 2008;283:19561-19569.

444. Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Kowalski D, *Diamandis EP*, Dimopoulos MA. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. **Ann Oncol** 2008;19:1271-1277.

445. Komatsu N, Saijoh K, Jayakumar A, Clayman GL, Tohyama M, Suga Y, Mizuno Y, Tsukamoto K, Taniuchi K, Takehara K, *Diamandis EP*. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. **J Invest Dermatol** 2008;128:1148-1159.

446. Chow T-F C, Crow M, Earle T, El-Said H, *Diamandis EP*, Yousef GM. Kallikreins as microRNA targets: An *in silico* and experimental-based analysis. **Biol Chem** 2008;389:731-738.

447. Sardana G, Jung K, Stepham C, *Diamandis EP*. Proteomic analysis of conditioned media from PC3, LNCaP and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. **J Proteome Res** 2008;7:3329-3338.

448. Oikonomopoulou K, Hansen KK, Baruch A, Hollenberg MD, *Diamandis EP*. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids. **Biol Chem** 2008;389:747-756.

449. Sharma N, Oikonomopoulou K, Ito K, Renaux B, *Diamandis EP*, Hollenberg MD, Rancourt DE. Substrate specificity determination of mouse implantation serine proteinase and human kallikrein-related peptidase 6 by phage display. **Biol Chem** 2008;389:1097-1105.

450. Oikonomopoulou K, Li L, Zheng Y, Simon I, Wolfort RL, Valik D, Nekulov M, Simickova M, Frgala T, *Diamandis EP*. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. **Br J Cancer** 2008;99:1103-1113.

451. Rŭckert F, Henning M, Petraki CD, Wehrum D, Distler M, Denz A, Schröder M, Dawelbait G, Kalthoff H, Saeger H-D, *Diamandis EP*, Pilarsky C, Grűtzmann R. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. **Br J Cancer** 2008:99:1484-1492.

452. Paliouras M, *Diamandis EP*. Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10,11 and 14 in breast cancer cells via a membrane bound androgen receptor. **Mol Oncol** 2008;1:413-424.

453. Prassas I, Paliouras M, Datti A, *Diamandis EP*. High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: Implications for cancer therapies. **Clin Cancer Res** 2008;14:5778-5784.

454. Bayani J, Paliouras M, Planque C, Shan SJC, Graham C, Squire JA, *Diamandis EP*. Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. **Mol Oncol** 2008;2:250-260.

455. Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, *Diamandis EP*, Dimopoulos MA. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). **Cancer Sci** 2008;99:2224-2229.

456. Shaw JLV, Petraki C, Watson C, Bocking A, *Diamandis EP*. Role of tissue kallikrein-related peptidases in cervical mucus remodeling and host defense. **Biol Chem** 2008; 389:1513-1522.

457. Shaw LV, *Diamandis EP*. Regulation of human tissue kallikrein-related peptidase expression by steroid hormones in 32 cell lines. **Biol Chem** 2008;389:1409-1419.

458. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, *Diamandis EP*. Human kallikrein 8 expression in salivary gland tumors. **Head & Neck Pathol** 2008;2:169-174.

2009

459. Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp R, *Diamandis EP*, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. **Thromb Haemost** 2009;101:541-546.

460. Talieri M, Mathioudaki K, Prezas P, Alexopoulou DK, *Diamandis EP*, Xynopoulos D, Ardavanis A, Arnogiannaki N, Scorilas A. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer.**Thromb Haemost** 2009;101:741-747.

461. Chen Y, Yazdanpanah M, Hoffman BR, *Diamandis EP*, Wong P-Y. Rapid determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry and a split sample comparision with three automated immunoassays. **Clin Biochem** 2009;42:484-490.

462. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, *Diamandis EP*. Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. **Mol Cell Proteomics** 2009;8:791-798.

463. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, *Diamandis EP*. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. **Mol Cell Proteomics** 2009;8:661-669.

464. Cherny DZ, Konvalinka A, Zinman B, *Diamandis EP*, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW, Miller JA. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: A pilot study. **Diabetes Care** 2009;32:91-93.

465. Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, *Diamandis EP*. Activated leukocyte cell adhesion molecule: A novel biomarker for breast cancer. **Int J Cancer** 2009;125:9-14.

466. Talieri M, Li L, Zheng Y, Alexopoulou DK, Soosaipillai A, Scorilas A, Xynopoulos D, *Diamandis EP*. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. **Br J Cancer** 2009;100:1659-1665.

467. Christensen E, Pintile M, Evans KR, Lenarduzzi M, Menard C, Catton CN, *Diamandis EP*, Bristow RG. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. **Clin Cancer Res** 2009;15:5576-5583.

468. Sardana G, *Diamandi EP*. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer. **Clin Biochem** 2009;42:1483-1486.

469. Emami N, Scorilas A, Soosaipillai A, Earle T, Mullen B, *Diamandis EP*. Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: Their relation to sperm motility. **Biol Chem** 2009;390:921-929.

470. Strojnik T, Kavalar R, Zajc I, *Diamandis EP*, Oikonomopoulou K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. **Anticancer Res** 2009;29:3269-3279.

471. Gunawardana G, Kuk C, Smith CR, Batruch I, Soosaipillai A, *Diamandis EP*. Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. **J Proteome Res** 2009;8:4705-4713.

472. Oikonomopoulou K, Soosaipillai A, *Diamandis EP*. Evaluation of prostate-specific antigen as a novel biomarker for Hsp90 inhibition. **Clin Biochem** 2009;42:1705-1712.

In Press

1. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP. Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines. **Mol Cell Proteomics**.
2. Pampalakis G, *Diamandis EP*, Katsaros D, Sotiropoulou G. Down-regulation of dicer expression in ovarian cancer tissues provides a new potential biomarker. **Clin Biochem** .
3. Emami N, *Diamandis EP*. Potential role of multiple members of the kallikrein-related peptidase family of serine proteases in activating latent TGFβ1 in semen. **Biol Chem** [Epub ahead of print].
4. Kuk, C, Gunawardana CG, Soosaipillai A, Kobayashi H, Li L, Zheng Y, *Diamandis EP*. Nidogen-2: A new serum biomarker for ovarian cancer. **Clin Biochem** [Epub ahead of print].
5. Chen Y, Yazdanpanah M, Wang Y, Hoffman BR, *Diamandis EP*, Wong P-Y. Direct measurement of serum free testosterone by ultrafiltration followed by liquid chromatography tandem mass spectrometry. [**Clin Chem**].

Submitted

1. Rabien A, Fritzsche F, Jung M, *Diamandis EP*, Leoning SA, Dietel M, Jung K, Kristiansen G, Stephan C. KLK15 is an independent prognostic factor for patient outcome after radical prostatectomy. [**Tumor Biol**].
2. Zheng Y, Li L, Talieri M, Alexopoulou DK, Soosaipillai A, Scorilas A, Xynopoulos D, *Diamandis EP*. A multiparametric tissue kallikrein-related peptidase panel for colorectal cancer. [**Clin Cancer Res**].
3. Pavlou M, Kulasingam V, Sauter ER, Kliethermes B, *Diamandis EP*. The nipple aspirate fluid proteome of normal volunteers and patients with breast cancer. [**Clin Chem (Special Issue)**].
4. Drabovich A, *Diamandis EP*. Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. [**J Proteome Res**].
5. Cho C-K, Soosaipillai A, *Diamandis EP*. Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. [**Mol Cell Proteomics**].
6. Oikonomoupou K, Batruch I, Smith CR, Soosaipillai A, *Diamandis EP*, Hollenberg MD. Functional proteomics of kallikrein-related peptidases in ovarian cancer ascites fluid. [**Biol Chem**].
7. Dorn J, Gerte T, Gkazepis A, Harlozinska A, Sedlaczek, *Diamandis EP*, Schuster T, Sagner S, Madgolen V, Kremer M, Kiechle M, Schmitt M. Circulating biomarker tissue kallikrein-related peptidases KLK5 impacts ovarian cancer patients' vurvival. [**Clin Chem**].

Editorials/Commentaries

1994

1. Goldberg DM, *Diamandis EP.* Clinical chemistry: Death or transfiguration? **Eur J Lab Med** 1994;2:157-159.

1995

2. *Diamandis EP*, Yu H. Prostate cancer, prostate specific antigen and the polymerase chain reaction. **Clin Chem** 1995;41:177-179.
3. *Diamandis EP*, Yu H. New biological functions of prostate specific antigen? **J Clin Endocrinol Meta**b 1995;80:1515-1517.

1996

4. Diamandis EP. Automation of molecular diagnostics. **Clin Chem** 1996;42:7-8.
5. *Diamandis EP*, Yu H, Melegos DN. Ultrasensitive prostate specific antigen assays and their clinical application. **Clin Chem** 1996;42:853-857.

2000

6. *Diamandis EP*. Sequencing by microarray technology — a powerful new tool for molecular diagnostics. **Clin. Chem** 2000;46:1523-1525.

2001

7. *Diamandis EP*. Signal amplification in time-resolved fluorometry. **Clin Chem** 2001;47:380-381.

2002

8. *Diamandis EP*. Cancer diagnostics: discovery and clinical applications – Introduction. **Clin Chem** 2002;48:1145-1146.

2003

9. Diamandis EP. Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? C**lin Chem** 2003;49:1272-1278.

2004

10. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: Drawing attention to potential problems. **J Natl Cancer Inst** 2004;96:353-356.
11. Diamandis EP. How are we going to discover new cancer biomarkers? A proteomic approach for bladder cancer. **Clin Chem** 2004;50:793-795.
12. Diamandis EP. Immunoassay interference: A relatively rare but still important problem. **Clin Biochem** 2004;37:331-332.
13. Diamandis EP. Proteomic patterns to identify ovarian cancer: 3 years on. **Expert Rev Mol Diagn** 2004;4:575-577.
14. Hoffman BR, *Diamandis EP*. Recent advances in cancer biomarkers. **Clin Biochem** 2004;37:503-504.

2005

15. *Diamandis EP*, van der Merwe D-E. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. **Clin Cancer Res** 2005;11:963-965.
16. Schmitt M, Magdolen V, Mengele K, Reuning U, Foekens J, *Diamandis EP*, Harbeck N. Fibrinolytics, enzyme inhibitors and cancer survival. **Haematologica Reports** 2005;1:28-33.

2006

17. Diamandis EP. Lost in (the Business of) Translation: Invest in the Youth. **Clin Cancer Res** 2006;12:669.
18. Diamandis EP. Validation of breast cancer biomarkers identified by mass spectrometry. **Clin Chem** 2006;52:771-772.
19. *Diamandis EP*, Deperthes D, Lundwall A. The first international symposium on kallikreins. **Biol Chem** 2006;387:635-636.
20. Diamandis EP. Peptidomics for cancer diagnosis: Present and future. **J Proteome Res** 2006;5:2079-2082.
21. Diamandis EP. Quality of the scientific literature: all that glitters is not gold. **Clin Biochem** 2006;39:1109-1111.

2007

22. Diamandis EP. Oncopeptidomics: a useful approach for cancer diagnosis. **Clin Chem** 2007;53:1004-1006.
23. Evans KR, Hoffman BR, *Diamandis EP*. Cancer Biomarkers. **Cancer Lett** 2007;249:1-2.

2009

24. *Diamandis EP*, Hanash S, Lopez M, Carr SA, Petricoin EF 3rd. Protein quantificatin by mass spectrometry: Is it ready for prime time? **Clin Chem** 2009;55:1427-1430.
25. Pavlou M, *Diamandis EP*. The search for new prostate cancer biomarkers continues. **Clin Chem** 2009;55 :1277-1279.
26. Diamandis EP. Journal impact factor : it will go away soon. **Clin Chem Lab Med** 2009;47 :1317-1318.
27. *Diamandis EP*, Voelkerding KV, Drmanac R, Angus D, McPherson J. Next-generaton sequencing: A new revolution in molecular diagnostics? **Clin Chem** 2009;55:2088-2092.
28. Diamandis EP. Early prostate cancer antigen-2 *(EPCA-2): A controversial prostate cancer biomarker? **Clin Chem** [in press].

Letters to the Editor

1982

1. *Diamandis EP,* Efstathiou CE, Hadjiioannou TP. Stability of the composite solution Mercury (II)-TPTZ-Iron (II) used for the automated determination of serum chloride. **Clin Chem** 1982;28:254.

1984

2. *Diamandis EP,* Ellis G, Daneman D, Allen LC. Liquid Chromatography of glycated hemoglobins with the Daiichi HA-8110 automated analyzer. **Clin Chem** 1984;30:503-504.

3. *Diamandis EP*, Hoffman BR. Total Mg^{2+} measured in serum and urine in the Technicon RA-1000 Random Access Analyzer by use of modified manual calmagite procedure. **Clin Chem** 1984;30:1262.

1995

4. *Diamandis EP*, Levesque M. Assessment of p53 protein overexpression by non-immunohistochemical methods. **J Pathol** 1995;175:93-94.

5. *Diamandis EP*, Yu H. Prostate specific antigen and lack of specificity for prostate cells. **Lancet** 1995;345:1186.

1996

6. *Diamandis EP*, Yu H. Clinical usefulness of prostate specific antigen. **J Urol** 1996;154:294.

7. *Diamandis EP.* BRCA1 protein products: antibody specificity, functional motifs and secreted Tumour suppressors. **Nature Genetics** 1996;13:268.

8. *Diamandis EP*, Yu H. Does prostate cancer start at puberty? **J Clin Lab Anal** 1996;10:468-469.

1997

9. Borchert GH, Giai M, *Diamandis EP*. Elevated levels of prostate specific antigen in serum of women with fibroadenomas and breast cysts. **J Natl Cancer Inst** 1997;89:587-588.

10. Melegos DN, Freedman MS, *Diamandis EP*. Prostate specific antigen in cerebrospinal fluid. **Clin Chem** 1997;43:855.

11. *Diamandis EP*. Clinical application of ultrasensitive prostate specific antigen assays. **J Natl Cancer Inst** 1997;89:1077.

1998

12. *Diamandis EP*. Prostate-specific antigen or human kallikrein 3? Recent developments. **Tumour Biol** 1998;19:65-68.

13. Melegos DN, *Diamandis EP*. Is prostate-specific antigen present in female serum? **Clin Chem** 1998;44:691-692.

14. Zaviacic C, Ablin RJ, • Response, *Diamandis EP*. The Female Prostate. **J Natl Cancer Inst** 1998;90:713-714.

15. *Diamandis EP*. Induction of prostate-specific antigen expression by synthetic progestins in patients with prostate and breast cancer. **Mayo Clin Proc** 1998;73:706-707.

16. Yu H, *Diamandis EP*, Hoffman B. Elevated estradiol and testosterone levels and risk for breast cancer. **Ann Intern Med** 1999;131:715.

1999

17. *Diamandis EP*. β-trace protein as indicator of glomerular filtration rate: • Response: **Urology** 1999;54:941-942.

2000

18. Rosenberg-Zand RS, Jenkins DJA, *Diamandis EP*. Genistein: a potent natural antiandrogen. **Clin Chem** 2000;46:887-888 .

19. *Diamandis EP*. Elevated serum prostate-specific antigen levels in a woman with metastatic breast cancer. **New Engl J Med** 2000;343:890-891.

2001

20. Sauter ER, *Diamandis EP*. Prostate-specific antigen levels in nipple aspirate fluid. **J Clin Oncol** 2001;19:3160.

2002

21. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. **Lancet** 2002;360:170-171.

2003

22. Diamandis EP. Serum proteomic patterns for detection of prostate cancer. **J Natl Cancer Inst** 2003;95:489-490.

2004

23. Diamandis E.P. **Re:** Diagnostic potential of serum proteomic patterns in prostate cancer. **J Urol** 2004;171:1244-1245.

24. Diamandis EP. Identification of serum amyloid A protein as a potentially useful biomarker for nasopharyngeal cancinoma. **Clin Cancer Res** 2004;10:5293-5294.

25. Diamandis EP. OvaCheck: doubts voiced soon after publication. **Nature** 2004;430:611.

2005

26. Diamandis EP. Validation of breast cancer biomarkers identified by mass spectrometry. **Clin Chem** [in press].

2006

27. Komatsu N, Tsai B, Siriropoulos M, Saijoh K, Levesque MA, Takehara K, *Diamandis EP*. Quantification of eight human tissue kallikreins in the stratum corneum and sweat. **J Invest Dermatol** 2006;126:925-929.

28. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Wu HK, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, *Diamandis EP*. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. **J Invest Dermatol** 2006;126:2338-2342.

29. *Diamandis EP*, Kulasingam V, Sardana G. Differential exoprotease activities confer tumor-specific serum peptidome. **J Clin Invest** 2006 [http://www.jci.org/cgi/eletters/116/1/271].

2007

30. Diamandis EP. POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma? **Clin Biochem** 2007;40:1437-1439.

Science Fiction

2009

1. Diamandis EP. How to win Wimbledon championships: Creating Beklof and Vamos. **Clin Chem** [submitted].
2. Diamandis EP. A conversation with Phedias and Pericles about the Elgin Marbles and other matters. **Clin Chem** [in press].

Patents

PATENTS AWARDED

	Inventor (s)	Country	Title	Patent No.	Date Awarded
1	Diamandis EP, Lowden JA.	USA	Immunoassay methods and reagents and methods for producing the latter.	5,089,423	Feb. 18, 1992
2	Diamandis EP.	USA	Europium and terbium chelators for time-resolved fluorometric assays.	5,312,922	May 17, 1994
3	Diamandis EP, Dunn JM, Stevens JK	USA	Method, reagents and kit for diagnosis and targeted screening for p53 mutations.	5,552,283 6,071,726	Sept. 3, 1996 June 6, 2000
4	Diamandis EP.	USA	Detection of prostate-specific antigen in amniotic fluid, maternal serum and breast milk.	5,679,534	Oct. 21, 1997
5	Diamandis EP.	USA	Detection of prostate-specific antigen in breast Tumours.	5,688,658 5,723,302 6,261,766	Nov. 18, 1997 Mar. 3, 1998 July 17, 2001
6	Diamandis EP.	USA	Europium and terbium chelators for time-resolved fluorometric assays.	5,854,008	Dec. 29, 1998
7	Diamandis EP, Redshaw R	USA	Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen.	6,068,830 6,274,118	May 30, 2000 Aug. 14, 2001
8	Yousef GM, Diamandis EP.	USA	Human kallikrein-like genes	7,022,497	Apr. 4, 2006
9	Diamandis EP, Lowden AJ	CAN	Immunoassay methods and reagents and	1,300,007	May 5, 1992

	Inventor (s)	Country	Title	Patent No.	Date Awarded
		US	methods for producing the latter.	5,089,423	Feb 18, 1992
10	Diamandis EP, Morton RC	CAN	Multiple fluorescence labelling with europium chelators.	1,308,022	Sept. 29, 1992
11	Diamandis EP, Morton RC	CAN	Multiple fluorescence labelling with europium chelators.	1,330,061	Jun. 7, 1994
12	Diamandis EP	CAN	Detection of prostate-specific antigen in breast tumors	2,161,778	Jun. 7, 2002
13	Diamandis EP	USA	Methods for detecting Alzheimer's disease	6,962,793	Nov 8, 2005
14	Yousef GM, Diamandis EP	USA EURO	Novel human kallikrein-like genes	7,022,497 11/319,952	Apr 4, 2006 Nov 22, 2006
15	Yousef GM, Diamandis EP.	EURO FRAN GR BRIT ITAL SPAIN SWITZ US GER	Novel kallikrein gene (KLK15)	1309703 1309703 1309703 1309703 1309703 1309703 7,199,229 60120712.2.08	Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Jun 14, 2006 Apr 3, 2007 Jun 14, 2006
16	Diamandis EP.	JAP EUR FRAN GR BRIT ITAL SPAIN SWITZ GER	Diagnostic methods for ovarian carcinoma (KLK6).	2002-538164 1330652 1330652 1330652 1330652 1330652 60129151.4-08	Oct 13, 2004 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007 Jun 27, 2007
17	Diamandis EP.	USA	Monitoring prostate and ovarian cancer (KLK11)	10/478,333	Oct 14, 2004
18	Yousef GM, Diamandis EP.	EURO USA	Method for detecting ovarian cancer (KLK9).	02767026.4 10/492,740	Jul 14, 2004 Aug 11, 2005
19	Kishi T, Diamandis EP.	USA	Methods for detecting ovarian cancer (kallikrein 8).	10/510/321	Dec 29, 2005
20	Diamandis EP.	USA	Detection of nerurodegenerative diseases.	10/868,490	May 19, 2005
21	Yousef GM, Diamandis EP.	USA	Methods for detecting breast and ovarian cancer (hK5).	10/526,029	Apr 6, 2006
22	Yousef GM, Diamandis EP.	USA	Methods for detecting endocrine cancer (hK13), as a biomarker	10/526,111	Jul 20, 2006
23	Diamandis EP.	USA	Methods for detecting prostate cancer (hK11 and PSA).	10/529,088	Aug 4, 2006
24	Diamandis EP.	USA EURO	Methods for detecting endocrine cancer (hK12, hK14 & hK15).	10/529,163 03753165.4	Oct 5, 2006 Jun 29, 2005
25	Diamandis EP.	USA	Multiple marker assay for detection of ovarian cancer (CA125 & kallikreins 5,6,7,8,10 and 11)	10/544,944	Jun 22, 2006
26	Diamandis EP, Petraki CD.	USA	Assay for detection of renal cell carcinoma (kallikreins 5,6,10 and 11)	10/546,435	Jun 26, 2006
27	Diamandis EP.	EURO	Diagnostic methods for ovarian carcinoma (KLK6).	1,330,652	Jul 6, 2007

PATENTS PENDING

	Inventor (s)	Country	Title	Application #	Date Filed
1	Yousef GM, Diamandis EP.	CAN JAP US	Novel kallikrein gene (KLK15)	2,418,422 2002-519613 11/729,560	Aug 10, 2001 Aug 10, 2001 Mar 29, 2007
2	Diamandis EP.	USA	Diagnostic methods for ovarian carcinoma (KLK6).	10/399,013	Apr 10, 2003
3	Luo L-Y, Diamandis EP.	USA	Detection of ovarian cancer (KLK10).	10/415,222	Apr 25, 2003

	Inventor (s)	Country	Title	Application #	Date Filed
		JAP EURO		2002-539815 01982020.8 02727132.9	Oct 26, 2001 Nov 1, 2001 May 24, 2002
4	Diamandis EP.	CAN AUSTR JAP EURO	Method of detecting and monitoring ovarian cancer (1st Prov.) and Method of detecting and monitoring prostate and ovarian cancer (KLK11) (2nd Prov.).	2,448,355 2002-257464 2003-500566	May 24, 2002 May 24, 2002 May 24, 2002
5	Yousef GM, Diamandis EP.	CAN JAP KOREAN	Method for detecting ovarian cancer (KLK9).	2,463,920 2003-536454 10-2004-7005644	Oct 16. 2002 Oct 16, 2002 Oct 16, 2001
6	Diamandis EP.	USA	Localization of disorders associated with kallikreins (hK6).		Oct. 16, 2002
7	Yousef GM, Diamandis EP.	CAN	Methods for detecting endocrine cancer (hK13), as a biomarker	2,497,061	Aug 28, 2003
8	Diamandis EP.	CAN EURO	Methods for detecting prostate cancer (hK11 and PSA).	2.498,147 03753166.2	Sept 26, 2003 Sept 26, 2003
9	Diamandis EP.	CAN	Methods for detecting endocrine cancer (hK12, hK14 & hK15).	2,499,261	Sept 26, 2003
10	Kishi T, Diamandis EP.	EURO CAN	Methods for detecting ovarian cancer (kallikrein 8).	03709529.6 2,481,093	Apr 4, 2003 Apr 4, 2003
11	Diamandis EP.	CAN	Multiple marker assay for detection of ovarian cancer (CA125 & kallikreins 5,6,7,8,10 and 11)	2,516,591	Feb 26, 2004
12	Diamandis EP.	USA	Kallikrein 14 markers for cancer.		Feb. 27, 2003
13	Diamandis EP, Petraki CD.	CAN	Assay for detection of renal cell carcinoma (kallikreins 5,6,10 and 11)	2,516,588	Feb 26, 2004
14	Diamandis EP, Petraki CD.	USA	Assay for detection of prostate cancer.		Feb. 27, 2003
15	Diamandis EP.	USA	Inhibitors of kallikrein 6.		Feb. 27, 2003
16	Diamandis EP.	CAN	Detection of nerurodegenerative diseases.	2,468,651	Jun 14, 2004
17	Yousef GM, Diamandis EP	CAN EUR US	Novel human kallikrein-like genes	2,362,885 06076156.6 11/319,952	Mar 9, 2000 Mar 9, 2000 Dec 28, 2005
18	Chu C-W, Diamandis EP	USA	Methods and compositions for the identification and diagnosis of diseases and/or conditions of the breast (hK6 & CA15)	60/652,636	Feb 14, 2005
19	Diamandis EP, Kulasingam V	USA	Methods for the detection of breast cancer	60/985,861	Nov 6, 2007

GenBank Submissions

No.	Description	Authors	Accession#	Submitted	Latest Update
1-41	Sequence 1-41 from patent US 5552283	Diamandis,E., Dunn,J.M. and Stevens,J.K.	125682-125722	07-OCT-1996	05-JUL-2002
42	HSU90205 Human lung carcinoma (E.P.Diamandis) Homo sapiens cDNA, MRNA sequence	Diamandis,E.P.	U90205	29-JUL-1997	29-JUL-1997
43	Homo sapiens chromosome 5 external transcribed spacer, complete sequence	Diamandis,E.P. and Prody,C.A.	AF038385	11-DEC-1997	28-SEP-2001
44	Homo sapiens kallikrein 10 (KLK10) gene, complete cds	Luo,L.Y. and Diamandis,E.P.	AF055481	24-MAR-1998	30-AUG-2000
45	Kallikrein 10 [Homo sapiens]	Luo,L.Y. and Diamandis,E.P.	AAC14266	24-MAR-1998	30-AUG-2000
46	Stratum corneum chymotryptic enzyme [Homo sapiens]	Yousef,G.M., Scorilas,A. and Diamandis,E.P.	AAD49718	30-DEC-1999	18-SEP-2000
47-48	Kallikrein-like protein 5-related protein 1, 2 [Homo sapiens]	Yousef,G.M., Magklara,A. and Diamandis,E.P.	AAF06065, AAF06066	01-NOV-1999	27-JUN-2000
49	Homo sapiens testis-specific kinase substrate (TSKS) gene, complete cds	Scorilas,A., Yousef,G. and Diamandis,E.P.	AF200923	31-OCT-1999	17-AUG-2001
50	Homo sapiens stratum corneum chymotryptic enzyme gene, complete cds	Yousef,G.M., Scorilas,A. and Diamandis,E.P.	AF166330	07-JUL-1999 30-DEC-1999	18-SEP-2000
51	Homo sapiens trypsin-like serine protease (TLSP) gene, complete cds	Yousef,G.M., Scorilas,A. and Diamandis,E.P.	AF164623	01-JUL-1999	26-JUN-2000
52	Trypsin-like serine protease [Homo sapiens]	Yousef,G.M., Scorilas,A. and Diamandis,E.P.	AAD47815	01-JUL-1999	26-JUN-2000
53	Homo sapiens kallikrein-like protein 6 (KLKL6) gene, complete cds	Yousef,G.M. and Diamandis,E.P.	AF161221	21-JUN-1999	19-JAN-2000
54	Kallikrein-like protein 6 [Homo sapiens]	Yousef,G.M. and Diamandis,E.P.	AAD50773	21-JUN-1999	19-JAN-2000
55	Kallikrein 14 precursor (Kallikrein-like protein 6) (KLK-L6)	Yousef,G.M. and Diamandis,E.P.	Q9P0G3	~JUN-1999	15-JUN-2002
56	Homo sapiens kallikrein-like serine protease gene, complete cds	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AF149289	08-MAY-1999	26-JUN-2000
57	Kallikrein-like serine protease; zyme; protease M; neurosin [Homo sapiens]	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AAD51475	08-MAY-1999	26-JUN-2000

No.	Description	Authors	Accession#	Submitted	Latest Update
58	Homo sapiens kallikrein-like protein 5 gene, alternative splice products, complete cds	Yousef,G.M., Magklara,A. and Diamandis,E.P.	AF135025	13-MAR-1999 01-NOV-1999	27-JUN-2000
59	Homo sapiens sialic acid-binding immunoglobulin-like lectin-9 (SIGLEC9) gene, complete cds	Yousef,G.M., Foussias,G. and Diamandis,E.P.	AF135027	13-MAR-1999 04-NOV-1999	03-AUG-2000
60	Homo sapiens kallikrein-like protein 4 KLK-L4 gene, complete cds	Yousef,G.M. and Diamandis,E.P.	AF135024	13-MAR-1999 19-OCT-1999	26-JUN-2000
61	Homo sapiens kallikrein-like protein 2 KLK-L2 gene, complete cds	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AF135028	13-MAR-1999	27-JUN-2000
62	Homo sapiens kallikrein-like protein 1 KLK-L1 gene, complete cds	Yousef,G.M., Luo,L.Y. and Diamandis,E.P.	AF135023	13-MAR-1999	27-OCT-1999
63	Kallikrein-like protein 3 [Homo sapiens]	Yousef,G.M., Grass,L. and Diamandis,E.P.	AAD26427	13-MAR-1999	24-SEP-2001
64	Kallikrein-like protein 3 splice variant 1 [Homo sapiens]	Yousef,G.M., Grass,L. and Diamandis,E.P.	AAG22845	13-MAR-1999	24-SEP-2001
65	Homo sapiens kallikrein-like protein 3 (KLK9) gene, complete cds, alternatively spliced	Yousef,G.M., Grass,L. and Diamandis,E.P.	AF135026	13-MAR-1999	24-SEP-2001
66	AF098797 Human Homo sapiens genomic clone PAC 42H21, genomic survey sequence	Luo LY	AF098797	20-JAN-1999	01-MAR-2001
67-70	Acid phosphatase variant 1,2,3 [Homo sapiens]	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AAK09393 - AAK09396	16-NOV-2000	06-JUL-2001
71	Homo sapiens testicular acid phosphatase (ACPT) gene, complete cds, alternatively spliced products	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AF321918	16-NOV-2000	06-JUL-2001
72	Homo sapiens alpha-adaptin A related protein (AP2A1) gene, complete cds, alternatively spliced	Scorilas,A. and Diamandis,E.P.	AF289221	25-JUL-2000	10-JUN-2002
73	Homo sapiens Bcl-2 related proline-rich protein (BCL2L12) gene, complete cds, alternatively spliced	Scorilas,A. and Diamandis,E.P.	AF289220	24-JUL-2000	10-APR-2001
74	Bcl-2 related proline-rich protein [Homo sapiens]	Scorilas,A. and Diamandis,E.P.	AAG29496	24-JUL-2000	10-APR-2001
75	Sialic acid binding immunoglobulin-like lectin 8 long splice variant [Homo sapiens]	Foussias,G., Yousef,G.M. and Diamandis,E.P.	AAG00573	14-JUL-2000	08-DEC-2000
76	Homo sapiens sialic acid binding immunoglobulin-like lectin 8 long splice variant (Siglec8) gene, complete cds	Foussias,G., Yousef,G.M.and Diamandis,E.P.	AF287892	14-JUL-2000	08-DEC-2000
77	Testis-specific kinase substrate [Homo sapiens]	Scorilas,A., Yousef,G. and Diamandis,E.P.	AAF12819	19-JUN-2000 10-AUG-2000	17-AUG-2001
78	Sialic acid-binding immunoglobulin-like lectin-like short splice variant [Homo sapiens]	Foussias,G., Taylor,S.M., Yousef,G.M., Tropak,M.B., Ordon,M.H. and Diamandis,E.P.	AAK51233	14-JUN-2000	05-SEP-2001
79	Homo sapiens sialic acid-binding immunoglobulin-like lectin-like splice variants (SLG) gene, complete cds, alternatively spliced	Foussias,G., Taylor,S.M., Yousef,G.M., Tropak,M.B., Ordon,M.H. and Diamandis,E.P.	AF277806	14-JUN-2000	05-SEP-2001
80	Homo sapiens kallikrein serine protease 1 (KLK1) gene, complete cds	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AF277050	12-JUN-2000	18-JUL-2000
81	Kallikrein serine protease 1 [Homo sapiens]	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AAF86333	12-JUN-2000	18-JUL-2000
82	Homo sapiens ser/arg-rich pre-mRNA splicing factor SR-A1 (SR-A1) gene, complete cds	Scorilas,A. and Diamandis,E.P.	AF254411	08-APR-2000	25-JUL-2000
83	HSC 00056 RPCI-11 Human Male BAC Library Homo sapiens genomic clone 3H_NH0288H01, genomic survey sequence	Scherer, S.W. Tsui, L.C., Diamandis, E.	AZ081612	05-APR-2000	07-APR-2000
84	HSC 00055 RPCI-11 Human Male BAC Library Homo sapiens genomic clone H_NH0288H01, genomic survey sequence	Scherer, S.W. Tsui, L.C., Diamandis, E.	AZ081611	05-APR-2000	07-APR-2000
85	Homo sapiens serine protease kallikrein/ovasin/neuropsin type (KLK8) gene, complete cds, alternatively spliced	Magklara,A., Yousef,G.M. and Diamandis,E.P.	AF251125	09-MAR-2000	30-APR-2001
86	Serine protease kallikrein/ovasin/neuropsin type 4 [Homo sapiens]	Magklara,A., Yousef,G.M. and Diamandis,E.P.	AAF79145	09-MAR-2000	30-APR-2001
87-90	KLK15 splice variant 1, 2, 3 [Homo sapiens]	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AAG09469 - AAG09472	06-MAR-2000	03-JAN-2001
91	Homo sapiens KLK15 (KLK15) gene, complete cds, alternatively spliced	Yousef,G.M., Diamandis,M.E. and Diamandis,E.P.	AF242195	06-MAR-2000	03-JAN-2001
92	Homo sapiens protein arginine N-methyltransferase 1 (HRMT1L2) gene, complete cds, alternatively spliced	Scorilas,A., Black,M.H. and Diamandis,E.P.	AF222689	07-JAN-2000	10-APR-2001
93	Homo sapiens carcinoembryonic antigen-like proteins (CEAL1) gene, complete dcs, alternatively spliced	Scorilas, A, Chiang PM, Katsaros D, Yousef GM and Diamandis EP.	AF406955	07 AUG 2001	11 JUL 2003
94	Homo sapiens sialic acid binding Ig-like lectin 5 (SIGLEC5) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040820	18-JUN-2001	23-APR-2002
95	Homo sapiens CD33 antigen (CD33) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040541	15-JUN-2001	21-APR-2002

No.	Description	Authors	Accession#	Submitted	Latest Update
96	Homo sapiens sialic acid binding immunoglobulin-like lectin 6 (SIGLEC6) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040542	15-JUN-2001	21-APR-2002
97	Homo sapiens SIGLECP2 pseudogene, complete sequence	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040545	15-JUN-2001	21-APR-2002
98	Homo sapiens SIGLECP1 pseudogene, complete sequence, alternatively spliced	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040544	15-JUN-2001	21-APR-2002
99	Homo sapiens sialic acid binding immunoglobulin-like lectin 7 (SIGLEC7) gene, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY040543	15-JUN-2001	21-APR-2002
100	Homo sapiens siglec-like protein (SLG2) gene and alternatively spliced variants, complete cds	Yousef,G.M., Ordon,M.H. and Diamandis,E.P.	AY029277	06-APR-2001	06-SEP-2001
101-140	Sequence 1-41 from patent US 6071726	Diamandis,E., Dunn,J.M. and Stevens,J.K.	AR097377 - AR097417	14-FEB-2001	05-JUL-2002
141	Homo sapiens YKLK1 pseudogene, complete sequence	Yousef GM, Borgono CA and Diamandis EP.	AY302756	19 MAY 2003	11 JUL 2003
142	Homo sapiens cancer-associated gene protein gene, complete cds.	Yousef GM, Borgono CA, Davidian CT, Michael I and Diamandis EP.	AY279382	19 APR 2003	11 JUL 2003
143	Homo sapiens kallikrein 15 is oform 5 preproprotein (KLK15) mRNA, complete cds; alternatively spliced	Michael IP, Yousef GM, Du DC and Diamandis EP.	AY373373	24 AUG 2003	22 SPET 2003
144	Homo sapiens kallikrein 15 is oform 6 preproprotein *KLK15) mRNA	Michael IP, Yousef GM, Du DC and Diamandis EP.	AY373374	24 AUG 2003	22 SEPT 2003
145	Homo sapiens kallikrein 14 (KLK14), mRNA	Yousef GM, BorgonoCA, Scorilas A, Ponzone R, Biglia N, Iskander L, Polymeris ME, Roagna R, Sismondi P and Diamandis EP.	NM_022046	05 OCT 2003	
146	Homo sapiens kallikrein 5 isoform e preproprotein (KLK5) mRNA complete cds, alternatively spliced	Michael IP, Kurlender L, Du DC, Diamandis EP.	Bankit 582787	9 NOV-2003	
147	Homo sapiens kallikrein 9 and kallikrein 8 bicistronic mRNA, partial sequence.	Michael IP, Elliott MB, Diamandis EP.	AY566267	3 MAR 2003	27 MAR 2004
148	Homo sapiens kallikrein 9 splice variant 2 (KLK9) mRNA, complete cds; alternatively spliced (incomplete 3' UTR)	Kurlender LE, Michael IP, Diamandis EP.	Bankit 602379	16 FEB 2004	
149	Homo sapiens kallikrein 10 splice variant 3 (KLK10) gene, complete cds, alternatively spliced.	Yousef GM, White NMA, Robb J-D, Kurlender L, Diamandis EP.	AY561634	28 FEB 2004	22 MAR 2004
150	Homo sapiens kallikrein 10 (KLK10) Mrna, complete cds.	Yousef GM, White NMA, Robb J-D, Kurlender L, Diamandis EP.	AY561635	28 FEB 2004	22 MAR 2004
151	Homo sapiens kallikrein 9 and kallikrein 8 bicistronic mRNA – partial sequence A	Michael IP and Diamandis EP	Bankit 748383	23 OCT 2005	
152	Homo sapiens kallikrein 9 and kallikrein 8 bicistronic mRNA – partial sequence B	Michael IP and Diamandis EP	Bankit 761216	23 OCT 2005	
153	KLK11 (Kallikrein-related peptidase 11)	Luo Liu-Ying and Diamandis EP	NM_006853 /144947	MAR 2008	

Abstracts

1978

1. Hadjiioannou TP, Koupparis MA, *Diamandis EP*. New Chloramine-T and picrate ion-selective electrodes. **Proc Analyt Div Chem Soc**, March, 1978, p.78-80.

1980

2. *Diamandis EP*, Papastathopoulos DS. Hadjiioannou TP. Automated serum albumin determination based on the reaction with picrate ions using a flow-through picrate ion-electrode. **Proc of the 1st Balkan Chemistry Days**. Athens (1980) p.157.

3. Papastathopoulos DS, *Diamandis EP*, Hadjiioannou TP. A new flow- through electrode unit for liquid membrane electrodes. **Proc of the 1st Balkan Chemistry Days**. Athens (1980) p.159.

1982

4. Christopoulos TK, *Diamandis EP*, Hadjiioannou TP. Semiautomatic potentiometric titrations of drugs with sodium tetraphenylborate and a tetraphenylborate ion-selective electrode. **Proc of the 1st Panhellenic Pharmaceutical Conference**, Athens, 1982.

1983

5. Sarantonis E, Karayannis MI, *Diamandis EP*. The TNBS-Ion electrode. Some applications in kinetic methods of analysis. Abstracts of the First International Symposium of Kinetics **in Analytical Chemistry**, Cordoba, Spain, September 27-30, 1983, p.12.

1984

6. Ellis G, *Diamandis EP*, Giesbrecht E, Allen LC. An automated HPLC method for hemoglobin A**. Clin Chem** 1984;30:978, #198. [AACC]
7. Papanastasiou-Diamandi A, *Diamandis EP*, Soldin SJ. Enzymatic measurement of primary bile acids in serum with the IL-Multistat III fluorescence Light Scattering centrifugal analyzer. **Clin Chem** 1984;30:971, #159. [AACC]
8. *Diamandis EP*, D'Costa M. Improved liquid chromatographic determination of urinary free cortisol after solid-state extraction. **Clin Chem** 1984;30:1042, #520. [AACC]
9. *Diamandis EP*, Hoffman B, Pollard A. Hemoglobin measurement in serum and gastric aspirates based on peroxidase activity, automated on the Technicon. RA-1000 Random Access Analyzer. **Revista Brasileira de Analises Clinicas** 1984;16:127. [IFCC]

1985

10. Papanastasiou-Diamandi A, *Diamandis EP*, Souvatzoglou A. Solid-state extraction of digoxin-like substances from human urine. **Clin Biochem** 1985;18:202, #9. [CSCC]
11. Christopoulos TK, *Diamandis EP*. Assay of albumin in serum based on specific ion binding and ion-selective electrode (ISE) potentiometry. **Clin Biochem** 1985;18:202, #009. [CSCC]
12. Christopoulos TK, *Diamandis EP*. Assay of albumin in serum based on specific ion-binding and ion-selective electrode potentiometry. **Clin Chem** 1985;31:904, #8. [AACC]

1986

13. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Assay of catecholamines in urine and serum with high performance liquid chromatography and electrochemical detection. **Proc of the 13th Panhellenic Conference of the Greek Endocrinology Society**, Athens, April 1986. [in Greek]
14. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Isolation and purification of digoxin like immunoreactive substances from cord blood serum. **Proc of the 13th Panhellenic Conference** of the Greek Endocrinology Society, Athens, April 1986. [in Greek]
15. Christopoulos TK, *Diamandis EP*. Application of ion-selective electrodes for the study of the binding of ions to albumin. **Proc of the 11th Panhellenic Chemistry Conference**, Athens, December 1986. [in Greek]
16. Christopoulos TK, *Diamandis EP*. New types of ion-selective electrodes for continuous-flow clinical analysis. **Proc of the 11th Panhellenic Chemistry Conference**, Athens, December 1986. [in Greek]
17. Mitsana-Papazoglou A, Christopoulos TK, *Diamandis EP*, Koupparis MA. Ion-selective electrodes for the direct monitoring of the release of the active ingredients in dissolution studies of drugs. Automation with a continuous-flow system. **Proc of the 11th Panhellenic Chemistry Conference**, Athens, December 1986. [in Greek]
18. *Diamandis EP*, Yiannakou L, Souvatzoglou A. Extraction, purification and characterization of digoxin-like immunoreactive substances (DLIS) from cord blood plasma. **Clin Chem** 1986;32:1080. [AACC & CSCC]

1987

19. Chan MA, *Diamandis EP*. A time-resolved fluoroimmunoassay for the determination of alpha-fetoprotein in serum. **Clin Chem** 1987;33:919, #190. [AACC]
20. Chan MA, Bellem AC, *Diamandis EP*. A time-resolved fluoroimmunoassay for alpha-fetoprotein in serum and amniotic fluid. **Clin Biochem** 1987;20:285, #10. [CSCC]
21. *Diamandis EP*, Reichstein E, Ramjeesingh M. Labelling strategies in time-resolved fluoroimmunoassays and immunofluorometric assays. **Clin Biochem** 1987;20:285, #11. [CSCC]

22. Chan MA, Bellem AC, *Diamandis EP*. A time-resolved fluoroimmunoassay for ferritin in serum. **Clin Biochem** 1987;20:294, #36. [CSCC]

23. *Diamandis EP*, Reichstein E, Conway K. Cortisol assay in serum with competitive immunoassay and time-resolved fluorescence spectroscopy. **Clin Biochem** 1987;20:294, #37. [CSCC]

24. Khosravi MJ, *Diamandis EP*. Determination of human chorionic gonadotropin by a time-resolved immunofluorometric assay. **Clin Biochem** 1987;20:294, #38. [CSCC]

25. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Effect of steroid hormones on the assessment of the level of digoxin like immunoreactive substances. **Proc of the 14th Panhellenic Conference** of the Greek Endocrinology Society. Athens 1987. [in Greek]

1988

26. Yiannakou L, *Diamandis EP*, Souvatzoglou A. Extraction, immunoprecipitation and calculation of the cross-reactivity and concentration of digoxin-like immunoreactive substances (DLIS) in cord blood plasma. **Proc of the 8th International Congress of Endocrinology**. Tokyo, Japan 1988.

27. *Diamandis EP*, Morton RC. Protein labeling with the fluorescent probe, 4,7-bis(chlorosulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic acid (BCPDA), procedures and applications in immunoassays. **Clin Chem** 1988;34:1155, #013. [AACC]

28. *Diamandis EP*, Evangelista RA, Pollak A, Templeton EF, Lowden JA. Time-resolved fluoroimmunoassays with europium chelates as labels. A new generation of alternative immunoassays. **Clin Chem** 1988;34:1155, #014. [AACC]

29. *Diamandis EP*, Morton RC, Reichstein E, Khosravi MJ. Multiple fluorescent labeling of streptavidin for highly sensitive time resolved immunoassays. **Clin Chem** 1988;34:1157, #021. [AACC]

30. Papanastasiou-Diamandi A, Bhayana V, *Diamandis EP*. A non-isotopic total thyroxine immunoassay with time-resolved fluorescence and a monoclonal antibody. **Clin Chem** 1988;34:1210, #281. [AACC]

31. Reichstein E, Morton RC, *Diamandis EP*. A sensitive assay for TSH with time-resolved fluorescence and monoclonal antibodies. **Clin Chem** 1988;34:1216, #309. [AACC]

32. Khosravi MJ, *Diamandis EP*. Time-resolved immunofluorometry of lutropin. A highly sensitive and rapid procedure. **Clin Chem** 1988;34:1221, #336. [AACC]

33. Kahan I, Papanastasiou-Diamandi A, D'Costa M, *Diamandis EP*. A time-resolved immunofluorometric assay for the measurement of prolactin in serum. **Clin Chem** 1988;34:1226, #357. [AACC]

34. Khosravi MJ, Chan MA, Bellem AC, *Diamandis EP*. A sensitive time-resolved immunofluorometric assay of ferritin in serum with monoclonal antibodies. **Clin Chem** 1988;34:1275, #600. [AACC]

35. *Diamandis EP*, Bhayana V, Conway K, Reichstein E, Papanastasiou-Diamandi A. A time-resolved fluoroimmunoassay of cortisol in serum - a rapid non-isotopic assay. **Clin Chem** 1988;34:1216, #312. [AACC]

36. Khosravi MJ, *Diamandis EP*. A sensitive immunoassay of choriogonadotropin (hCG) by time-resolved fluorescence spectroscopy with a new europium chelate as label. **Clin Chem** 1988;34:1220, #327. [AACC]

37. *Diamandis EP*, Evangelista RA, Pollak A, Templeton EF, Lowden JA. A new generation of time-resolved fluoroimmunoassays with europium chelates as labels. **J Biolumin Chemilumin** 1988;2:200, #55LI.

1989

38. Bhayana V, *Diamandis EP*. A solid-phase time-resolved immuno-fluorometric assay for carcinoembryonic antigen (CEA). **Clin Chem** 1989;35:1077, #059. [AACC]

39. *Diamandis EP*, Papanastasiou-Diamandi A, Lustig V, Khosravi MJ, Tan A. A time-resolved immunofluorometric assay of human pancreatic amylase in serum. **Clin Chem** 1989;35:1117, #241. [AACC]

40. Khosravi M, *Diamandis EP*. Time-resolved immunofluorometry of follitropin in serum. **Clin Chem** 1989;35:1138, #344. [AACC]

41. Reichstein E, *Diamandis EP*. Immunoassay of neonatal hTSH in paper discs using time-resolved fluorescence. **Clin Chem** 1989;35:1139, #345. [AACC].

42. Tan A, Khosravi MJ, *Diamandis EP*, Time-resolved immunofluorometric assay for thyroxine-binding globulin in serum. **Clin Chem** 1989;35:1139, #346. [AACC]

43. Shankaran P, Reichstein E, *Diamandis EP*. Immunoassays for rubella antibodies (IgG and IgM) in serum using time-resolved fluorescence. **Clin Chem** 1989;35:1153, #413. [AACC]

44. McLaurin J, Makela SK, *Diamandis EP*, Ellis G. Evaluation of the CyberFluor time-resolved fluorescence immunoassay for human growth hormone in the diagnosis of growth hormone deficiency. **Clin Biochem** 1989;22:260, #M13. [CSCC]

45. Papanastasiou-Diamandi A, Morton RC, Khosravi MJ, *Diamandis EP*. New assay configurations for competitive-type time-resolved fluoroimmunoassays of haptens. **Clin Biochem** 1989;22:260-261, #M14. [CSCC]

46. Morton RC, *Diamandis EP*. A streptavidin based macromolecular complex labeled with a europium chelator as a universal detection system in time-resolved fluorescence immunoassay. **Clin Biochem** 1989;22:261, #M15. [CSCC]

1990

47. Breborowicz A, Rodela H, Pagiantzis J, *Diamandis EP*, Oreopoulos DG. Glucose toxicity to human mesothelial cells in vitro. **Proc of the 10th Annual Conference on Peritoneal Dialysis**, Dallas, TX, February 1990.

48. Breborowicz A, Rodela H, Pagiantzis J, *Diamandis EP*, Oreopoulos DG. Mesothelial cells produce a growth promoting factor. **Proc of the 10th Annual Conference on Peritoneal Dialysis**, Dallas, TX, February 1990.

49. Christopoulos TL, Lianidou ES, *Diamandis EP*. Ultrasensitive analytical methodologies using time-resolved fluorometry and laser-excited solid-phase measurements. **Clin Chem** 1990;36:1094, #0665. [AACC]

50. Lianidou ES, Christopoulos TK, *Diamandis EP*. Creatine kinase isoenzyme MB quantification in serum with time-resolved immunofluorometry. **Clin Chem** 1990;36:1130, #829. [AACC]

51. Wong T, McLaurin J, Makela SK, *Diamandis EP*, Ellis G. Development of a time-resolved fluorescence immunoassay for 17a- hydroxyprogesterone. **Clin Chem** 1990;36:1150, #0925. [AACC]

1991

52. *Diamandis EP*, Kitching R, Christopoulos TK. Enzyme amplified time-resolved fluoroimmunoassays. **Clin Chem** 1991;37:1038, #0612. [AACC]

53. Christopoulos TK, *Diamandis EP*. Applications of time-resolved fluorometry in molecular biology techniques. **Clin Chem** 1991;37:1060, #0716. [AACC]

1992

54. Hassapoglidou S, *Diamandis EP*. The p53 suppressor gene product quantified in cell lines, Tumour tissue and biological fluids using an ultrasensitive time-resolved fluorescence immunoassay. **Clin Biochem** 1992;25:135, #15. [CSCC]

55. Chan A, Krajden M, *Diamandis EP*. Direct and indirect quantification of polymerase chain reaction products with a time-resolved fluorometric scanner. **Clin Biochem** 1992;25:137, #21. [CSCC]

56. Papanastasiou-Diamandi A, Khosravi MJ, Morton RC, *Diamandis EP*. Total thyroxine immunoassay based enzymatically amplified time-resolved fluorometry. **Clin Biochem** 1992;25:148, #53. [CSCC]

57. *Diamandis EP*, Christopoulos TL. Bean CC. Sensitive and quantitative analysis of Western blots by using time-resolved immunofluorometry. **Clin Chem** 1992;38:987, #0224. [AACC]

58. Hassapoglidou S, *Diamandis EP*. Non-isotopic detection techniques for Southern blot analysis of single-copy genes. **Clin Chem** 1992;38:991, #0240. [AACC]

59. *Diamandis EP*, Grass LC, Uldall R, Mendelsohnn D, Maini D. Mannitol in serum of hemodialysis patients measured by fluorometry and mannitol dehydrogenase from Leuconostoc mesenderoides. **Clin Chem** 1992;38:984, #0213. [AACC]

1993

60. Goldberg DM, Yan J, Ng E, *Diamandis EP*, Karumanchiri A, Waterhouse AL, Soleas GJ. A definitive gas-chromatographic mass-spectrometric assay for resveratrol suitable for industrial and biological samples. **Clin Biochem** 1993;26:126-127, #11. [CSCC]

61. Angelopoulou K, *Diamandis EP*, Kellen J, Bunting P, Sutherland D. Prevalence of antibodies against p53 protein in various cancers. **Clin Biochem** 1993;26:128-129, #16. [CSCC]

62. Angelopoulou K, *Diamandis EP*. New methodology for measuring anti-p53 antibodies in human serum. **Clin Biochem** 1993;26:129, #17. [CSCC]

63. Chan A, Krajden M, *Diamandis EP*. Quantification polymerase chain reaction analysis of pathogenic DNA sequence using an internal DNA sequence standard constructed by recombinant DNA methodology. **Clin Biochem** 1993;26:136-137, #35.[CSCC]

64. Chan A, Jiu Z, Krajden M, *Diamandis EP*. Quantitative analysis of polymerase chain reaction products with high performance liquid chromatography and fluorometric detection. **Clin Biochem** 1993;26:137, #36. [CSCC]

65. Morton RC, Papanastasiou-Diamandi A, *Diamandis EP*, Khosravi MJ. Time-resolved enzyme immunoassay for the determination of thyrotropin in serum. **Clin Biochem** 1993;26:139, #42. [CSCC]

66. Papanastasiou-Diamandi A, Morton RC, *Diamandis EP*, Khosravi MJ. A highly sensitive alpha-fetoprotein (AFP) immunoassay based on enzymatically amplified time-resolved fluorometry. **Clin Biochem** 1993;26:140, #44. [CSCC]

67. Goldberg DM, Karumanchiri A, Eng E, *Diamandis EP*, Yan J, Soleas GJ, Waterhouse AL. Resveratrol content of wines assayed by a direct gas chromatographic-mass spectrometric technique. **Am J En**ol **Vitic** 1993;44:344.

68. Soleas GJ, Goldberg DM, *Diamandis EP*, Karumanchiri A, Ng E, Yan J. A gas chromatographic-mass spectrometric method for the analysis of resveratrol in juice and wine samples. **Am J Enol Vitic** 1993;44:344.

1994

69. Katsaros D, Zola P, Sismondi P, Levesque M, *Diamandis EP*. Prognostic value of p53protein accumulation in ovarian carcinomas. **Cancer Res** 1994;35:234, #1399 [AACC].

70. Angelopoulou K, *Diamandis EP*, Bunting PS. Colorectal carcinoma elicits a humoral immune response against p53 mutant protein. **Clin Biochem** 1994;27:201, #10. [CSCC]

71. Goldberg DM, Garovic-Kocic V, *Diamandis EP*, Pace-Asciak CR. Is resveratrol the solution to the French paradox? **Clin Biochem**,1994;27:226, #78. [CSCC]

72. Zarghami N , Grass L, Sutherland DJA, *Diamandis EP*. Creatine kinase isoenzyme BB is associated with the estrogen receptor in breast cancer. **Clin Biochem** 1994;27:231, #95. [CSCC]

73. *Diamandis EP*, He Y, Grass L. Androgens, progestins and tamoxifen induce PSA production in the breast cancer cell line T-47D. **Clin Biochem** 1994;27:232, #96. [CSCC]

74. Yu H, *Diamandis EP,* Sutherland DJA. Detection of prostate specific antigen in breast Tumours. **Clin Biochem** 1994;27:232, #97. [CSCC]

75. Levesque M, *Diamandis EP*, He Y, Sutherland DJA. Quantitative analysis of prostate specific antigen and mutant p53 protein in breast Tumour cytosols: Relationships with other prognostic indicators. **Clin Biochem** 1994;27:232, #98. [CSCC]

76. Yu H , *Diamandis EP*, Giai M, Ponzone R, Sismondi P, Katsaros D. Evaluation of prostate specific antigen as a prognostic and predictive indicator for breast cancer patients. **Eur J Cancer** 1994;30:A548, #16.

77. Goldberg D, Garovic-Kocic V, *Diamandis EP*, Pace-Asciak CR, Roncari DAK. Resveratrol and ethanol are mediators of changes in plasma lipids and lipoproteins. **Atherosclerosis** 1994;109:77, #302.

1995

78. Yu H, *Diamandis EP*, Sutherland DJA. Immunoreactive prostate specific antigen in breast cancer cytosols and its association with steroid hormone receptors. **Cancer Res** 1995;36:245, #1463.

79. Yu H, *Diamandis EP*. Prostate specific antigen (PSA) as a new prognostic marker in female breast cancer: molecular characterization and clinical implication. **Cancer Res** 1995;36:246, #1464.

80. Monne M, Croce CM, Yu H, *Diamandis EP*. Molecular characterization of prostate specific antigen mRNA expressed in breast Tumours. **Cancer Res** 1995;36:249, #1484.

81. *Diamandis EP*. Tumour suppressor genes and oncogenes in cancer: Are the present techniques meeting the challenge? **Eur J Clin Chem Clin Biochem** 1995;33:A121.

82. Melegos DN, Yu H, Allen LC, *Diamandis EP*. Prostate specific antigen in amniotic fluid and maternal serum. **J Clin Ligand Assay** 1995;18:66.

83. Melegos DN, Yu H, Allen LC, *Diamandis EP*. Prostate specific antigen in amniotic fluid and maternal serum. Possible associations with fetal abnormalities. **Clin Chem** 1995;41:S39, #026.

84. Yu H, *Diamandis EP*. Identification of prostate specific antigen in milk of lactating women. **Clin Chem** 1995;41:S39, #027.

85. Goldberg DM, Tham L, *Diamandis EP*, Karumanchiri A, Soleas G. The assay of resveratrol and its distribution in human blood. **Clin Chem** 1995;41:S115, #366.

86. Angelopoulou K, Stratis M, *Diamandis EP*. Humoral immune response against p53 Tumour suppressor gene product in women with ovarian cancer. **Clin Chem** 1995;41:S218, #811.

87. Zarghami N, Giai M, Yu, H, Katsaros D, *Diamandis EP*. Creatine kinase BB isoenzyme levels in Tumour cytosols and survival of breast cancer patients. **Clin Chem** 1995;41:S218, #815.

88. Yu H, *Diamandis EP*, Levesque MA, Asa S, Monne M, Croce CM. Expression of the prostate specific antigen gene in a primary ovarian carcinoma. **Clin Chem** 1995;41:S219, #816.

89. Levesque MA, *Diamandis EP*, Yu H, Zola P, Sismondi P, Giardina G, Katsaros D. Immunofluorometrically quantified p53 protein as a prognostic indictor in ovarian carcinoma**. Clin Chem** 1995;41:S224, #839.

90. Randell EW, Yu H, *Diamandis EP*, Ellis G. Prostate specific antigen in neonates and infants**. Clin Chem** 1995;41:S230, #866.

91. *Diamandis EP,* Levesque MA, Clark GM. Quantitative analysis of mutant p53 proteinin breast carcinoma relationships to other prognostic factors. **Clin Chem** 1995;41:S224, #840.

92. Galvan B, Christopoulos TK, *Diamandis EP*. Design of a time-resolved fluorometric hybridization assay for the messenger-RNA of prostate-specific antigen. **Clin Chem**1995;41:1686, #042. [AACC]

93. Tham L, Goldberg DM, *Diamandis EP*, Karumanchiri A, Soleas GJ. Extraction of resveratrol from human blood. **Clin Biochem** 1995;28:339, #58.

94. Angelopoulou KA, Stratis M, *Diamandis EP*. Serum p53 autoantibodies: Incidence in ovarian carcinoma. **Clin Biochem** 1995;28:340, #61.

95. Levesque MA, Clark GM, *Diamandis EP*. Relationships between mutant p53 protein overexpression and other prognostic indicators in breast cancer. **Clin Biochem** 1995;28:340, #62.

96. Levesque MA, *Diamandis EP*, Yu H, Zola P, Sismondi P, Giardina G, Katsaros D. Prognostic value of immunofluorometrically quantified p53 protein in ovarian carcinoma. **Clin Biochem** 1995;28:340, #63.

97. Zarghami N, Giai M, Yu H, Katsaros D, *Diamandis EP*. Association between breast cancer patient survival and levels of creatine kinase BB in Tumour cytosols. **Clin Biochem** 1995;28:341, #64.

98. Yu H, *Diamandis EP*, Levesque MA, Asa S, Monne M, Croce CM. Prostate specific antigen gene expression in ovarian cancer post-liver transplantation. **Clin Biochem** 1995;28:341, #65.

99. Yu H, *Diamandis EP*. The milk of lactating women contains prostate specific antigen. **Clin Biochem** 1995;28:341, #66.

100. Melegos DN, Yu H, Allen LC, *Diamandis EP*. A possible association between fetal abnormalities and levels of prostate specific antigen in amniotic fluid. **Clin Biochem** 1995;28:341, #67.

101. Hoffman BR, Yu H, *Diamandis EP*. Prostate cancer screening using prostate specific antigen extracted from dried blood on filter paper. **Clin Biochem** 1995;28:342, #68.

1996

102. Sauter ER, Daly M, Linahan K, Ehay H, Engstrom PF, Sorling A, Bonney G, Ross E, Yu H, *Diamandis EP*. Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. **Cancer Res** 1996;37:213, #1458.

103. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. No associations between IGFBP-3 and p53 or PSA in breast cancer. **Cancer Res** 1996;37:189.

104. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. IGF-1, IGF-11, IGFBP-1 and IGFBP-3 as prognostic markers of breast cancer. **Proc 10th Intl Congress Endocrinol** 1996;2:756, #P3-8.

105. *Diamandis EP*. Prostaglandin D_2 synthase in amniotic fluid and maternal serum: possible association with fetal abnormalities. **Prostaglandins** 1996;51:297.

106. Zarghami N, *Diamandis EP*. Concordance between prostate specific antigen mRNA expression and protein in breast tumours. **Clin Chem** 1996;42:S201, #440.

107. D'Costa M, Levesque M, Tadros L, *Diamandis EP*. Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer. **Clin Chem** 1996;42:S262, #694.

108. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, *Diamandis EP*. Associations between PSA and IGF-1, IGF-11, IGFBP-3 in breast cancer. **Clin Chem** 1996;42:S264, #703.

109. Levesque M, D'Costa M, *Diamandis EP*. p53 protein is absent from the serum of patients with lung cancer. **Clin Chem** 1996;42:S262, #695.

110. Melegos DN, Yu H, *Diamandis EP*. Prostaglandin D_2 synthase in amniotic fluid: possible association with fetal abnormalities. **Clin Chem** 1996;42:S238, #593.

111. Melegos DN, *Diamandis EP*. Diagnostic value of molecular forms of prostate specific antigen for female breast cancer. **Clin Chem** 1996;42:S238, #594.

112. Angelopoulou K, *Diamandis EP,* Dunn JM, Jia Q. Fragment analysis of the p53 gene: Method development and clinical applications. **Clin Chem** 1996;42:S202, #443.

113. Zarghami N, Grass L, *Diamandis EP.* Regulation of the prostate specific antigen gene in breast cancer cell lines by steroid hormones. **Clin Chem** 1996;42:S236, #586.

114. Yu H, Levesque MA, Khosravi MJ, Papanastasioudiamandis A, Clark GM, *Diamandis EP*. Associations between PSA and IGF-I, IGF-II, IGFBP-1 and IGFBP-3 in breast cancer. **Clin Chem** 1996;42:S264, #703.

115. Rozenberg RS, *Diamandis EP,* Kendall CWC, Ransom TPP, Jenkins DJA. The effect of plant derived compounds on sex hormone receptors: Implications for hormone-dependent cancer development and treatment. **FASEB J** 1996;10:A491, #2833.

116. *Diamandis EP*, Melegos DN, Oda H, Urade Y, Hayaishi O. Prostaglandin D Synthase: Development of analytical methodology and preliminary clinical studies. **Prostaglandins Leukotrienes and Essential Fatty Acids** 1996;55:57, #187.

1997

117. Kogan I, Ballinger JR, *Diamandis EP*, Melegos DN, Rauth AM. Prostate specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. **Cancer Res** 1997;38:58, #387.

118. Levesque MA, Yu H, Clark GM, *Diamandis EP*. P53 protein accumulation detected by an ELISA technique is a prognostic factor in a large cohort of breast cancer patients. **Cancer Res** 1997;38:255.

119. Sauter E, Zarghami N, *Diamandis EP*, Engstrom P. PSA levels in nipple aspirate fluid are upregulated by progesterone. **Cancer Res** 1997;38:263, #1767.

120. Angelopoulou K, Katsaros D, *Diamandis EP*. The exon 5 of p53 Tumour suppressor gene is a target for deletions in ovarian cancer. **Cancer Res** 1997;38:270, #1815.

121. Yu H, Levesque MA, Clark GM, *Diamandis EP*. Prognostic value of PSA in breast cancer. A large U.S. cohort study. **Cancer Res** 1997;38:437, #2924.

122. Soleas G. *Diamandis EP,* Tomlinson G, Goldberg DM. Identifying the major phenolic antioxidants of wine. **Atherosclerosis** 1997;134:207.

123. Giai M, Ponzone R, Roagna R, Sgro L, Biglia N, Borchert GH, *Diamandis EP,* Sismondi P. Subfractions of prostate specific antigen differ in serum of normal women and women withmalignant and benign breast diseases. **Breast** 1997;6:335, #P919.

124. *Diamandis EP*, Zarghami N, Grass L, Sauter E. Prostate specific antigen levels in serum during the menstrual cycle. Possible regulation by progesterone. **Proc Endocr Soc 79th Annual Meeting** 1997;385, #P2-402.

125. Majumdar S, *Diamandis EP*. Structural characterization of the prostate specific antigen gene from breast Tumours and cell lines. **Clin Biochem** 1997;30:381, #49.

126. Melegos DN, Freedman MS, *Diamandis EP*. Prostaglandin D Synthase in cerebrospinal fluid and serum from patients with various neuropathologies. **Clin Chem** 1997;43:S185, #360.

127. Melegos DN, Freedman MS, *Diamandis EP*. Prostate specific antigen immunoreactivity in cerebrospinal fluid. **Clin Chem**; 1997;43:S185, #361.

128. Black MH, *Diamandis EP*, Grass CL. Ultrasensitive immunofluorometric assay for measuring free prostate specific antigen. **Clin Chem** 1997;43:S223, #541.

129. Levesque MA, Yu H, Clark GM, *Diamandis EP*. ELISA-detected p53 protein in accumulation is a prognostic factor in a large cohort of breast cancer patients. **Clin Chem** 1997;43: S228, #566.

130. Zarghami N, Levesque MA, D'Costa M, Angelopoulou K, *Diamandis EP*. Frequency of prostate specific antigen mRNA expression in lung tumours. **Clin Chem** 1997;43:S231, #582.

131. Majumdar S, *Diamandis EP*. The prostate specific antigen (PSA) gene is not mutated in either breast tumours or breast carcinoma cell lines. **Clin Chem** 1997;43:S268, #751.

132. Angelopoulou K, Yu H, *Diamandis EP*. P53 autoantibodies in sera of breast cancer patients: Association with p53 gene mutations and p53 protein overexpression**. Clin Chem** 1997;43:S271, #770.

133. Lianidou ES, Angelopoulou D, *Diamandis EP*. Identification of deletions and insertions in the p53 gene in ovarian tumours by high resolution fragment analysis and DNA sequencing. **Clin Chem** 1997;43:S272, #771.

134. *Diamandis EP*. Prostate specific antigen: A tumour marker for prostatic and breast carcinoma. **Balkan J Clin Lab** 1997;4:25.

135. Goldberg DM, *Diamandis EP*. The beneficial health effects of wine drinking – a myth or a reality? **Balkan J Clin Lab** 1997;4:41.

1998

136. Levesque MA, Lianidou ES, Angelopoulou K, Yu H, Genta F, Durando A, Massobrio M, Bharaj B, *Diamandis EP*. Mutational analysis versus ELISA for the detection of p53 gene abnormalities in ovarian carcinoma. **Proc AACR** 1998;39:230-231.

137. Katsaros D, Levesque M, Genta F, Durando A, Arisio R, Yu H, *Diamandis EP*, Massobrio M. Prognostic and predictive implications of p53 and WAF1 expression in ovarian cancer. **Proc AACR** 1998;39:231.

138. Sauter ER, Ehya H, Babb J, *Diamandis EP*, Daly M, Klein-Szanto AJP, Sigurdson E, Hoffman J, Malick J, Engstrom PF. Nipple aspirate fluid (NAF) cytology predicts residual disease after diagnostic biopsy. **Proc AACR** 1998;39:228.

139. Yu H, Levesque MA, Khosravi MJ, *Diamandis EP*, Clark GM. Insulin-like growth factor binding protein 3 and breast cancer recurrence. **Proc AACR** 1998;39:232.

140. Sauter ER, Daly MB, Engstrom PF, Melegos DN, Diamandis A, Khosravi MJ, *Diamandis EP*. IGFBP-3 expression in nipple aspirate fluid (NAF) correlates with breast cancer risk. **Proc AACR** 1998;39:233.

141. Majumdar S, *Diamandis EP*. Mutations in the regulatory region of the prostate specific antigen gene from breast tumours and cell lines. **Proc AACR** 1998;39:248.

142. Angelopoulou K, Yu H, *Diamandis EP*. Mutational spectrum of the p53 gene, Tumour p53 protein overexpression and serum p53 autoantibody generation in patients with breast cancer. **Proc AACR** 1998;39:547.

143. Bharaj B, Angelopoulou K, *Diamandis EP*. Rapid sequencing of the p53 gene with the MicroGene Blaster automated DNA sequencer. **Proc AACR** 1998;39:547.

144. Klijin JGM, *Diamandis EP*, Yu H, Look MP, Meijer-van Gelder ME, van Putten WLJ, Foekens JA. Expression of prostate specific antigen correlates with poor response to tamoxifen therapy in recurrent breast cancer. **Proc AACR** 1998;39:553.

145. Black MH, Giai M, Yu H, *Diamandis EP*. Serum prostate specific antigen levels are elevated in females with breast cancer. **Proc AACR** 1998;39:553.

146. Melegos DN, *Diamandis EP*, Helle SI, Yu H, Lundgren S, Lonning PE. Plasma prostate specific antigen levels and prognostic value in patients with metastatic breast cancer following megestrol acetate treatment. **Proc AACR** 1998;39:553.

147. *Diamandis EP*, Kogan I, Prody C, Angelopoulou K, Zarghami N, Herbrick J, Scherer S. Cloning of a novel nucleotide sequence from human lung tissue. **Proc AACR** 1998;39:133.

148. Luo LY, Herbrick J, Scherer S, *Diamandis EP*. Mapping the normal epithelial cell-specific 1 gene to chromosome 19q13. **Proc AACR** 1998;39:133.

149. Katsaros D, Genta F, Durando A, Danese S, Ricchiardi R, Levesque M, *Diamandis EP,* Massobrio M. Prognostic nd predictive value of p53 and WAF1 expression in epithelial ovarian cancer. **Proc ASCO** 1998;17, #1355.

150. Luo L, *Diamandis EP*. Amplification of human genome DNA sequences with polymerase chain reaction using a single oligonucleotide primer. **Proc Oak Ridge Conf**, April 1998.

151. Angelopoulou K, *Diamandis EP*, Zargharmi N, Herbrick J, Scherer S. Cloning of a new gene that is overexpressed in lung cancer cell lines. **Clin Biochem** 1998;31:299.

152. Luo L, Grass, *Diamandis EP*. The normal epithelial cell-specific gene 1 (NES1) resides on chromosome 19q13 and its expression is regulated by steroid hormones. **Clin Biochem** 1998;31:299.

153. Luo L, Grass L, *Diamandis EP*. The normal epithelial cell-specific gene 1 (NES1) resides on chromosome 19q13 and its expression is regulated by steroid hormones. Proc **Endocr Soc** 1998; P3-153.

154. Klijn JGM, *Diamandis EP,* Yu H, Look MP, Gelder MEMV, Van Putten WLJ, Foekens JA. The significance of prostate specific antigen (PSA) in breast cancer. **Eur J Cancer**1998;34:S106.

155. Borcheert GH, Giai M, Ponzone R, Roagna R, Sgro L, *Diamandis EP,* Sismondi P. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. **Eur J Cancer**1998;34:S3.

156. Katsaros D, Genta F, Durando A, Danese S, Ricchiardi R, Levesque M, *Diamandis EP,* Massobrio M. p53 and WAF1 expression in epithelial ovarian cancer: Prognostic and predictive implications. **Eur J Cancer**1998;34:S22.

157. Melegos DN, Grass L, Pierratos A, *Diamandis EP*. Serum prostaglandin D synthase concentration is elevated in humans with renal impairment. **Clin Chem** 1998;44:A20.

158. Levesque MA, D'Costa M, Spratt EH, Yaman MM, *Diamandis EP*. Prognostic significance of quantitatively-analyzed p53 protein accumulation in lung carcinoma. **Clin Chem** 1998;44:A42.

159. *Diamandis EP*, Angelopoulou K, Zarghami N, Herbrick J, Scherer S. Mapping of a novel 5 Kb sequence on human chromosome 5. **Clin Chem** 1998;44:A43.

160. Angelopoulou K, Borchert G, Melegos DN, Lianidou E, Lilja H, *Diamandis EP*. BRCA1-specific antibodies react strongly with a protein present in seminal plasma. **Clin Chem** 1998;44:A43.

161. Reddy PP, Bagli DJ, *Diamandis EP*, Melegos DN, Barrieras D, Merguerian P, McLorie GA, Khoury AE. Prostate specific antigen in the study of dysfunctional voiding. **Pediatrics** 1998;102;839.

1999

162. Yousef GM, Luo LY, *Diamandis EP*, Sotiropoulou G, Herbrick J-A, Scherer SW, Grass L. The zyme/protease M/neurosin gene maps close to the human kallikrein gene family and is hormonally regulated. **Proc AACR** 1999;40:34, #230.

163. Scorilas A, *Diamandis EP*, Levesque MA, Diamandi A, Khosravi MJ, Giai M, Ponzone R, Roagna R, Sismondi P, Lopez-Otin C. Pepsinogen C, an independent favorable prognostic factor in node-positive breast cancer patients. **Proc AACR** 1999;40:205, #1359.

164. Obiezu CV, Black MH, Magklara A, Levesque MA, Sutherland DJA, Tindall DJ, Young CFY, Sauter ER, *Diamandis EP*. Expression of a prostate-associated protein, human glandular kallikrein (hK2) in breast Tumours and in normal breast secretion. **Proc AACR** 1999;40:378, #2505.

165. Yu H, Bharaj B, Giai M, *Diamandis EP*. CAG repeats of the androgen receptor gene in breast cancer and its association with survival. **Proc AACR** 1999;40:380, #2518.

166. Luo LY, Grass L, *Diamandis EP*. The expression of the normal epithelial cell-specific 1 (NES1) gene is regulated by steroid hormones. **Proc AACR** 1999;40:381, #2521.

167. Vassilikos EJK, Yu H, Trachtenberg J, Nam R, Narod S, *Diamandis EP*. How many prostate cancer patients are considered 'cured' after radical prostatectomy? **Proc AACR** 1999;40:381, #2524.

168. Levesque MA, Yu H, Genta F, Massobrio M, Durando A, Bellino R, *Diamandis EP*, Katsaros D. Expression of p53 but not WAF1 is a predictor of response to platinum-based chemotherapy in patients with epithelial ovarian cancer. **Proc AACR** 1999;40:382, #2531.

169. Bharaj B, Vassilikos E, *Diamandis EP*. Rapid and accurate determination of CAG repeat lengths in androgen receptor gene using PCR and automated fragment analysis. **Proc AACR** 1999;40:468, #3094.

170. Angelopoulou K, Borchert G, Lianidou E, Lilja H, *Diamandis EP*. Characterization of a BRCA1-like compound present in human seminal plasma. **Proc AACR** 1999;40:685, #4519.

171. Magklara A, Black MH, Obiezu CV, Melegos DN, *Diamandis EP*. Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity with prostate specific antigen. PSA. **Proc AACR** 1999;40:526, #3467.

172. Arnett WP, Zini A, Jarvi K, *Diamandis EP*. Prostaglandin D synthase in human semen: a marker to differentiate obstructive from non-obstructive. **J Urol** 1999;161:280, #1084.

173. Yousef GM, Luo L-Y, *Diamandis EP*. The human kallikrein gene locus – discovery of six new genes. **IFCC-WorldLab Symp II** – 1999;21, #14.

174. Scorilas A, *Diamandis EP*, Levesque MA, Diamandi A, Koshravi MJ, Giai MJ, Ponzone R, Roagna R, Sismondi P, Lopez-Otin C. Prognostic value of pepsinogen C in breast cancer. **IFCC-WorldLab Symp** 1999;25, #18.

175. *Diamandis EP*. Tumour markers in prostate cancer. **Clin Chem Lab Med** 1999;37:S33.

176. Zarghami NZ, *Diamandis EP*, Grass L. PSA mRNA expression during menstrual cycle is upregulated by progesterone. **Clin Chem Lab Med** 1999;37:S159, #M172.

177. Lianidou ES, Politis I, Angelopoulou K, *Diamandis EP*. A simple SSCP protocol for mutational analysis of p53 gene, optimized and evaluated in respect to DNA sequencing. **Clin Chem Lab Med** 1999;37:S229, #T050.

178. Obiezu CV, Giltay EJ, Yu H, Magklara A, Soosaipillai AR, Gooren LJG, *Diamandis EP*. Serum prostate specific antigen is significantly elevated after testosterone administration in female to male transsexuals. **Endo Society** 1999;02, #OR29-4.

179. Obiezu CV, Giltay EJ, Yu H, Magklara A, Gooren LJ, *Diamandis EP*. Dramatic suppression of serum prostate specific antigen and human glandular kallikrein by anti-androgens in male to female transsexuals. **Endo Society** 1999;521, #P3-382.

180. Goodwin PJ, Ennis M, Madarnas Y, Pritchard KI, Trudeau ME, Hood N, *Diamandis EP*. Fasting insulin as a potential mediator of the adverse prognostic effect of obesity in locoregional breast cancer. **22nd Ann San Antonio Breast Cancer Symp**, December 8 1999.

181. Bharaj B, Scorilas A, Hoffman B, Giai M, *Diamandis* EP. A novel ARE-1 polymorphism in the promoter region of the prostate specific antigen gene in healthy females and women with breast cancer. **Clin Chem** 1999;116, A37.

182. Levesque MA, D'Costa M, *Diamandis EP*. ELISA-determined $p21^{WAF1}$ expression does not correlate with non-small cell lung cancer aggressiveness. **Clin Chem** 1999;45:A111.

183. Scorilas A, Diamandi A, Khosravi MJ, Levesque MA, Lopez-Otin C, De Los Toyos J, Sampedro A, Giai A, Ponzone R, Roagna R, Sismondi P, *Diamandis EP*. Determination of pepsinogen C concentration in breast Tumour cytosols by a highly sensitive immunofluometric assay and its association with other prognostic variables. **Clin Chem** 1999;45:A117.

184. Soleas GJ, Angelini M, *Diamandis EP*, Goldbert DM. The absorption of *trans*-resveratrol in the rat. **Can J Cardiol** 1999;15:210D.

185. Soleas GJ, *Diamandis EP*, Goldberg DM, Grass L. Do alcoholic beverages prevent the development of atherosclerosis in the rabbit? **Can J Cardiol** 1999;15:210D.

186. Scorilas A, Bharaj B, Giai M, *Diamandis EP*. Polymorphisms in the human 5α-reductase gene and breast cancer. **Proc AACR-NCI-EORTC Int Conf** 1999; p 98, #481.

187. Yousef GM, Luo LY, Black MH, *Diamandis EP*. Molecular characterization, mapping, tissue expression and hormonal regulation of KLK-L2, a new member of the kallikrein gene family. **Proc AACR-NCI-EORTC Int Conf** 1999, p 98, #482.

188. Magklara A, Scorilas A, Catalona WJ, *Diamandis EP*. The ratio of human glandular kallikrein (hK2) to free PSA improve the discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately elevated total PSA levels. **Proc AACR-NCI-EORTC Int Conf** 1999, p 98, #483.

189. Yousef GM, Obiezu CV, Luo LY, Black MH, *Diamandis EP*. The new kallikrein-like gene, Prostase/KLK-L1, is expressed in prostate and breast tissues and is hormonally regulated. **Proc AACR-NCI-EORTC Int Conf** 1999, p 99, #484.

190. Diamandis EP. Application of ultrasensitive, third-generation prostate specific antigen assays in breast and prostate cancer. **J Clin Ligand Assay** 1999;22:385.

191. *Diamandis EP*, Angelopoulou K. p53 antibodies. **J Clin Ligand Assay** 1999;22:385.

192. Katsaros D, Levesque MA, Genta F, Durando A, Bellino R, Mano MP, Aidals S, *Diamandis EP*, Massobrio M. Dose-receptor effect between p453 concentrations, survival and respnsiveness in patients with epithelial ovarian cancer treaded with platinum-based chemotherapy. **Proc ASCO** 1999;18 : #1454.

193. Diamandis EP. Application of ultrasensitive, third-generation prostate specific antigen assays in breast and prostate cancer. **J Clin Ligand Assay** 1999;22 :385.

2000

194. Magklara A, Scorilas A, Catalona WJ, *Diamandis EP*. Human glandular kallikrein (hK2) and prostate specific antigen (PSA) in prostate and breast cancer. **Proc AACR** 2000;41:39, #248.

195. Hoffman BR, Scorilas A, *Diamandis EP*, Giai M, Levesque MA, Bharaj B. A prevalent polymorphism in the proximal androgen response element of the prostate specific antigen gene and its implications in breast cancer prognosis. **Proc AACR** 2000;41:93, #596.

196. Katsaros D, Yu H, Francchioli S, Richiardi G, Danese S, Genta F, Levesque MA, Khosravi JM, Papanastasiou-Diamandi A, Gordini G, *Diamandis EP*, Massobrio M. Insulin-like growth factor binding protein-3 (IGFBP-3) is associated with favorable glinicopathological features and survival in patients with epithelial ovarian cancer. **Proc AACR** 2000;41:501, #3195.

197. Sauter ER, Litwin S, Engstrom F. Diamandis A, Khosravi J, *Diamandis EP*. Fragmented insulin-like growth factor binding protein type-3 is inversely associated with breast cancer risk. **Proc AACR** 2000;41:575, #3661.

198. Obiezu CV, Yousef GM, Katsaros D, *Diamandis EP*. Prostase/KLK-L1 is overexpressed in ovarian Tumours. **Proc AACR** 2000;41:684, #4348.

199. Yousef GM, Foussias G, Magklara A, Grass L, *Diamandis EP*. Cloning of KLK-L5, a new member of the kallikrein gene family and its hormonal regulation in breast cancer cell lines. **Proc AACR** 2000;41:747, #4748.

200. Chang A, Yousef GM, *Diamandis EP*. Discovery of a new human kallikrein-like gene, KLK-L4, and the study of its expression in breast cancer. **Proc AACR** 2000;41:747, #4749.

201. Scorilas A, Bharaj B, Hoffman B, Giai M, *Diamandis EP*. The genotypes of the 5α-reductase gene are related with PSA expression and risk in sporadic breast cancer. **Proc AACR** 2000;41:805, #5116.

202. Rosenberg-Zand R, Jenkins DJ, *Diamandis EP*. Antagonist steroid hormone activity of flavonoids and related compounds in an *in vivo* tissue culture system. **Proc AACR** 2000;41:847, #5377.

203. Kim H, Yousef GM, Katsaros D, *Diamandis EP*. Dramatic overexpression of the kallikrein-like gene 2 (KLK-L2), in ovarian carcinomas. **Clin Biochem** 2000;33:230, #16.

204. Luo LY, *Diamandis EP*. Down-regulation of the normal epithelial cell-specific 1 (NES1) gene is associated with unfavorable outcome of prostate cancer. **Clin Biochem** 2000;33:233, #24.

205. Obiezu CV, Scorilas A, Kim H, *Diamandis EP*. Prostase/KLK-L1 is differentially expressed in normal/benign versus malignant ovarian tissues. **Clin Biochem** 2000;33:234, #27.

206. Rosenberg Zand RS, Jenkins DJA, *Diamandis EP*. Anti-androgen activity of flavonoids. **Clin Biochem** 2000;33:238, #40.

207. Scorilas A, Kyriakopoulou L, *Diamandis EP*. Cloning of a human gene, encoding a member of the SER/ARG-rich family of proteins that interact with RNA POL-II. **Clin Biochem** 2000;33:239, #42.

208. Soleas G, Grass L, Josephy D and *Diamandis EP*. Resveratrol, a red wine constituent, anticarcinogenic properties. **Clin Biochem** 2000;33:240, #44.

209. Yousef GM and *Diamandis EP*. The new human kallikrein gene family on chromosome 19q13.3-q13.4 and associations to various tumours. **Clin Biochem** 2000;33:242, #51.

210. Black MH, *Diamandis EP*. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. **Dept of Defense Breast Cancer Res Prog** 2000; p 49, #J-5.

211. Scorilas A, Kyriakopoulou LG, Yousef GM, *Diamandis EP*. Molecular characterization of a human homolog of the rat A1 gene. **Proc Endo Society** 2000; p 112, #437.

212. Chang A, Yousef GM, Magklara A, *Diamandis EP*. Hormonal regulation of a novel kallikrein-like gene, KLK-L4, in breast cancer. **Proc Endo Society** 2000; p 117, #461.

213. Yousef GM, Magklara A, *Diamandis EP*. KLK-L5 is a new, hormonally regulated member of the kallikrein gene family. **Proc Endo Society** 2000; p 188, #765.

214. Rosenberg Zand RS, *Diamandis EP*, Stanczyk FZ. Hermaphrodiol may contribute significantly to the estrogenic/androgenic hormonal milieu of breast and prostate cancer cells. **Proc Endo Society** 2000; p 190, #773.

215. *Diamandis EP*, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, Yu H. Changes in serum insulin-like growth factor binging protein-2 (IGFBP-2) and prostate cancer recurrence. **Proc Endo Society** 2000; p 493, #2036.

216. Magklara A, Cheung CC, Asa SL, *Diamandis EP*. Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. **Proc Endo Society** 2000; p 591, #2442.

217. Yousef GM, *Diamandis EP*. Characterization of the human kallikrein gene locus and discovery of six new genes. **Clin Chem** 2000;46:p A170, #659.

218. *Diamandis EP*, Magklara A, Scorilas A, Catalona WJ. Prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2): Two hormonally regulated kallikreins with application in breast and prostate cancer. **Intl Congress of Endocrinol (ICE) Proc**. 2000; # P819.

219. *Diamandis EP*. Kallikreins as cancer biomarkers. **Clin Biochem Revs** 2000;21:107.

220. Jenkins DJ, Kendall CW, Jackson CJ, Garsetti M, Rosenberg-Zand RS, Agarwal S, Rao AV, *Diamandis EP*, Parker R, Faulkner D, Vuksam V, Vidgen E. Effect of soy protein foods on LDL oxidation and ex vivo sex hormone receptor acticvity. **FASEB J** 2000;14:A495.

2001

221. Brauer PM, McKeown-Eyssen G, Jazmaji V, Logan AG, Andrews DF, Jenkins DJ, Marcon N, Sabil F, Cohen I, Stern H, Baron D, Greenberg G, *Diamandis EP,* Kakis G, Singer W, Steiner G. Familial aggregation of diabetes, hypertension and cardiovascular conditions in colorectal hyperplastic polyps. **Amer J Epidemiol** 2001;153:S117.

222. Brauer PM, McKeown-Eyssen G, Jazmaji V, Logan AG, Andrews DF, Jenkins DJ, Marcon N, Sabil F, Cohen I, Stern H, Baron D, Greenberg G, *Diamandis EP,* Kakis G, Singer W, Steiner G. Familial aggregation of prostate cancer in colorectal neoplasia. **Amer J Epidemiol** 2001;153:S117.

223. Yoursef GM, *Diamandis EP,* Cloning of seven novel human kallikrein genes: new poteintial cancer biomarkers. **Clin Chem** 2001;47:A130.

224. Yousef GM, Kyriakopoulou L, Scorilas A, Ponzone R, Giai M, Sismondi P, *Diamandis EP,* Rendel L, Ddiamandis M. A novel potential prognostric marker for breast carcinoma. **Clin Chem** 2001;47:A130.

225. Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, *Diamandis EP*. A novel prognostic marker in ovarian cancer. **Clin Chem** 2001;47:A132.

226. Yousef GM, Scorilas A, Kyriakopoulou LG, Rendel L, Diamandis M, Ponzone R, *Diamandis EP*. Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. **Can Breast Cancer Res Inst (CBCRI)** May 2001;195.

227. Nam R, Narod SA, Trachtenberg J, Magklara A, *Diamandis EP*. Use of human kallikrein-2 (hK2) levels in patient selection for prostate biopsy. **J Urol** 2001;165:204, #845.

228. Sauter ER, Chervoneva I, Diamandis A, Khosravi J, Litwin S, *Diamandis EP*. NAF biomarkers predict premenopausal and serum biomarkers predict postmenopausal breast cancer risk. **Proc AACR** 2001;42:11, #59.

229. Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, *Diamandis EP*. Tumour specific activity of kallikrein 6 protein is a prognostic marker of ovarian carcinoma. **Proc AACR** 2001;42:46-47, #243.

230. Luo L-Y, Bunting P, *Diamandis EP*. The KLK10 gene (also known as the normal epithelial cell-specific 1 gene; NES1): A new serum biomarker for ovarian cancer. **Proc AACR** 2001;42:47, #244.

231. Luo L-Y, Soosaipillai, *Diamandis EP*. Identification of immunoreactive antigens in ovarian and breast carcinoma. **Proc AACR** 2001;42:156-157, #838.

232. Bharaj B, Scorilas A, Giai M, *Diamandis EP*. Dinucleotide repeat length polymorphism on the $3^{/}$ untranslated region of the SRD5A2 gene in breast cancer. **Proc AACR** 2001;42:495-496, #2668.

233. Luo L-Y, *Diamandis EP*. Protein array analysis with laser-excited solid-phase time-resolved fluorometry. **Proc AACR** 2001;42:564, #3030.

234. Scorilas A, Katsaros D, Kwamie A, Fracchioli S, *Diamandis EP*. The SR-A1 gene, encoding a new member of the human Ser/Arg-Rich family of pre-mRNA splicing factors, is overexpressed in aggressive ovarian tumours and is an independent unfavourable prognostic indicator in ovarian cancer. **Proc AACR** 2001;42:579, #3106.

235. Luo L-Y, Katsaros D, Scorilas A, Fracchioli S, Massobrio M, *Diamandis EP*. Human kallikrein 1- (hK10, normal epithelial cell-specific 1, NES1) is a new prognostic biomarker for ovarian carcinoma. **Proc AACR** 2001;42:579, #3107.

236. Luo L-Y, Soosaipillai A, Jung K, *Diamandis EP*. Molecular cloning of a novel gene which appears to be down-regulated in testicular cancer. **Proc AACR** 2001;42:748, #4016.

237. Yousef GM, Scorilas A, Jung K, Ashworth L, *Diamandis EP*. Molecular cloning of a new human kallikrein gene, KLK15, which is up-regulated in prostate cancer. **Proc AACR** 2001;42:748, #4017.

238. Magklara A, Scorilas A, Katsaros D, Fracchioli S, Rigault de la Longrais I, Piccinno R, Yousef GM, *Diamandis EP*. The prognostic value of human KLK8 (neuropsin/ovasin) in ovarian cancer and evidence for alternative splicing. **Proc AACR** 2001;42:781, #4194.

239. Obiezu CV, Jung K, Katsaros D, *Diamandis EP*. Expression of a new splice variant of prostase/KLK4 is associated with tissues regulated by steroids. **Proc AACR** 2001;42:781-782, #4196.

240. Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, *Diamandis EP*. Down-regulation of a novel human kallikrein gene, KLK14, in endocrine related cancers. **Proc AACR** 2001;42:782, #4198.

241. *Diamandis EP*, Yousef G, Soosaipillai A, Bunting P. Zyme/protease M/neurosin (KLK5 gene): A new biomarker for ovarian cancer diagnosis and monitoring. **Proc AACR** 2001;42:782, #4200.

242. Rosenberg Zand RS, Jenkins DJA, *Diamandis EP*. Steroid hormone effects of natural products and nutraceuticals. **Proc AACR** 2001;42:870, #4667.

243. Katsaros D, Fracchioli S, Genta F, Yousef GM, *Diamandis EP, Diamandis EP*. Frist evidence of expression of the new human kallikrein gene family members (KLK4, KLK5, KLK6) in epithelial ovarian cancer: Genomic organization, molecular characterization and clinical implications. **Proc ASCO** 2001;20:#839.

244. *Diamandis EP*, Petraki C, Karavana VN, Skoufoggiannis PT, Little S, Howarth DJ, Yousef GM. Immunohistochemical localization of a new serine protease, human kallikrein 6, in the islets of Langerhan's and other endocrine organs. **Proc Endocr Soc Meeting** 2001;206, #P1-266.

245. Magklara A, Brown TJ, *Diamandis EP*. Characterization of androgen receptor and co-factor expression in human breast cancer cell lines. **Proc Endocr Soc Meeting** 2001;570, #P3-573.

246. Kollara A, Rosenberg Zand RS, *Diamandis EP*, Brown TJ. Characterization of androgen-dependent prostate specific antigen (PSA) secretion in androgen receptor-transfected human prostate cancer PC-3 cells. **Proc Endocr Soc Meeting** 2001;592, #P3-676.

2002

247. Chang A, Yousef GM, Kapadia C, Scorilas A, Ponzone R, *Diamandis EP*. Favorable prognostic value of KLK13 gene expression in breast cancer. **Proc AACR** 2002;43: 45, #230.

248. Yousef GM, Fracchioli S, Kyriakopoulou L, Zarghooni M, Scorilas A, Diamandis M, Puopolo M, Massobrio M, *Diamandis EP*, Katsaros D, Danese S. A new potential independent prognostic marker for ovarian cancer. **Proc AACR** 2002;43: 47, #236.

249. Borgoño CA, Katsaros D, Luo L-Y, Fracchioli S, Yamaguchi N, Soosaipilla A, Grass L, Rigault de la Longrais IA, Puopolo M, Yousef GM, Scorilas A, *Diamandis EP*. The prognostic value of human kallikrein 11 (hK11, trypsin-like serine protease, TLSP) in ovarian cancer cytosols. **Proc AACR** 2002;43: 47 #237.

250. *Diamandis EP*, Okui A, Mitsui S, Luo L-Y, Soosaipillai AR, Grass L, Nakamura T, Howarth DJC, Yamaguchi N. Human kallikrein 11: a potential new serum biomarker for prostate and ovarian cancer. **Proc AACR** 2002;43: 47 #238.

251. Zarghooni M, Bharaj B, Fracchioli S, Katsaros D, Rigault de la Longrais IA, *Diamandis EP*, Puopolo M. Identification of two novel single nucleotide polymorphisms (SNPs) within the human kallikrein 6 gene. **Proc AACR** 2002;43:53-54, #270.

252. Yousef GM, Magklara A, Borgoño C, Memari N, Abd Ellatif M, Grass L, *Diamandis EP*. Regulation of the human kallikrein gene 15 (KLK15) by steroids in breast cancer cell lines. **Proc AACR** 2002;43:117, #587.

253. Luo L-Y, Herrera I, Soosaipillai A, *Diamandis EP*. Identification of heat shock protein 90 as tumour antigen in ovarian cancer by serological screening. **Proc AACR** 2002;43:279, #1384.

254. Stephan C, Yousef G, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Welsh JB, Hampton GM, Leoning SA, Dietel M, *Diamandis EP*. Hepsin, potential new marker for prostate cancer. **Proc AACR** 2002;43:388, #1935.

255. Scorilas A, Kletsas D, Katsaros N, *Diamandis EP*. The new member of apoptosis-related proteins, BCL2L12, is down-regulated in aggressive breast tumours and in arrested human fibroblasts. **Proc AACR** 2002;43:529, #2622.

256. Sotiropoulou G, Tsetsenis T, Rogakos V, Symillides G, Pampalakis G, *Diamandis E*, Yiotakis A. Overexpression of active recombinant human kallikrein 13 and characterization of its proteolytic activity. **Proc AACR** 2002;43:538, #2671.

257. Petraki CD, Karavana VN, Gregorakis A, Papanastasiou P, Luo L-Y, *Diamandis EP*. The immunoexpression of human kallikrein 6 and 10 in benign and malignant prostatic tissues. **Proc AACR** 2002;43:563, #2793.

258. Yousef GM, Diamandis M, Stephan C, Jung K, *Diamandis EP*. Testicular acid phosphatase (ACPT): a new gene which is down-regulated in testicular cancer. **Proc AACR** 2002;43:630, #3127.

259. Scorilas A, Plebani M, Mazza S, Soosaipillai A, Katsaros N, Basso D, Pagano F, *Diamandis EP*. Human glandular kallikrein 2 (hK2) and insulin-like growth factor (IGF-1) as discriminating markers between prostate cancer and benign prostatic hyperplasia. **Proc AACR** 2002;43:730, #3620.

260. *Diamandis EP*, Scorilas A, Yousef GM, Stenman U-H, Henrik A, Soosaipillai A, Grass L, Katsaros D. Human Kallikrein 6: a novel serum biomarker for diagnosis, prognosis and monitoring of ovarian cancer. **Proc AACR** 2002;43:741-742, #3679.

261. Luo L-Y, Fracchioli S, Scorilas A, Grass L, Vergote I, van der Zee A, Stenman U-H, *Diamandis EP*, Katsaros D. Human kallikrein 10 is a new serum marker for ovarian cancer diagnosis and prognosis. **Proc AACR** 2002;43:743, #3686.

262. Kishi T, Grass L, Soosaipillai A, Shimizu-Okabe C, *Diamandis EP*. Human kallikrein 8 (neuropsin) is a potential tumour biomarker for ovarian cancer. **Proc AACR** 2002;43:743, #3688.

263. Yousef GM, Stephan C, Scorilas A, Chang A, Rendl L, Diamandis M, Jung K, *Diamandis EP*. Down-regulation of the human KLK5 gene in prostate cancer. **Proc AACR** 2002;43:763, #3786.

264. Yousef GM, Memari N, Scorilas A, Ponzone R, Biglia N, Giai M, Roagna R, Sismondi P, *Diamandis EP*. A new favorable prognostic marker for breast cancer. **Proc AACR** 2002;43:916, #4540.

265. Memari N, Nakamura T, Kishi T, Yousef GM, Hoffman BR, *Diamandis EP*. Cloning and protein expression of human kallikrein 12: A new poteintial biomarker for breast cancer. **Proc AACR** 2002;43:917, #4544.

266. Kyriakopoulou LG, Scorilas A, Yousef G, Ponzone R, Biglia N, Roagna R, Cacciari F, Sismondi P, *Diamandis EP*. Prognostic significance of human kallikrein 7 (KLK7) in breast cancer. **Proc AACR** 2002;43:917-918, #4548.

267. Yousef GM, Bharaj B, Hoffman B, Poulopoulos J, *Diamandis EP*. Identification of unique polymorphic minisatellites in the human kallikrein locus and their relation to malignancy. **Proc AACR** 2002;43:930-931, #4609.

268. Bharaj B, Luo L-Y, Jung K, Stephan C, Yu H, *Diamandis EP*. Prostate cancer risk associated with single nucleotide polymorphism (SNP) of the human kallikrein 10 gene. **Proc AACR** 2002;43:931, #4610.

269. Stephan C, Jung K, Soosaipillai A, Cammann H, Leoning SA, *Diamandis EP*. Clinical usefulness of human glandular kallikrein 2 within a neural network to improve prostate cancer detection. **Proc AACR** 2002;43:1067, #5286.

270. Stephan C, Yousef GM, Scorilas A, Nakamura T, Kishi T, Jung M, Jung K, Kristiansen G, Hauptmann S, *Diamandis EP*. Quantitative analysis of kallikrein 15 expression in prostate tissues. **Proc AACR** 2002;43:1067-1068, #5287.

271. Stephan C, Soosaipillai A, Jung K, Kristiansen G, Hauptmann S, *Diamandis EP*. The value of serum hK2 for distinguishing pathological stage and grade of prostate cancer. **Proc AACR** 2002;43:1068, #5288.

272. Obiezu CV, Soosaipillai A, Stephan C, Jung K, Howarth DHC, *Diamandis EP*. Immunofluorometric and immunohistochemical detection of a PSA-related protein, prostase (human kallikrein 4), in normal and cancerous prostatic tissues. **Proc AACR** 2002;43:1069, #5294.

273. Soleas G, Grass L, Josephy PD, *Diamandis EP*, Goldberg DM. The anticarcinogenic effects of red wine polyphenols in a mouse skin model. **Proc AACR** 2002;43:1145, #5675.

274. Bjartell A, Paju A, Stenman UH, Vaisanen V, Aumuller G, *Diamandis EP,* Becker C, Lilja H. Studies on phenotypic expression patterns of proteases and protease inhibitors in benign compared to malignant prostate tissues. **Prostate Cancer Prostate Dis** 2002;3:#S7.

275. Katsaros D, Fracchioli S, Yousef GM, Luo L-Y, Scorilas A, Puopolo M, Stenman U-H, van der Zee AGJ, Vergote I, *Diamandis EP*. Human kallikrein 6 (hK6) and 10 (hK10): New potential biomarkers for diagnosis and prognosis of epithelial ovarian cancer. **Proc ASCO** 2002;21:#817.

276. Luo LY, Katsaros D, Scorilas A, *Diamandis EP*. Serum human kallikrein 10: A novel marker for diagnosis and prognosis of ovarian cancer. **Proc Can Lab Med Congress** 2002;54, P2-05.

277. Yousef GM, Kyriakopoulou LG, Fracchioli S, Zarghooni M, Scorilas A, Diamandis M, Katsaros D, *Diamandis EP*. A new potential independent prognostic marker for ovarian cancer. **Proc Can Lab Med Congress** 2002;54, P2-06.

278. Kyriakopoulou LG, Scorilas A, Yousef GM, Ponzone R, Roagna R, Sismondi P, *Diamandis EP*. Human kallikrein 7 (KLK7) as a prognostic marker in breast cancer. **Proc Can Lab Med Congress** 2002;55, P2-07.

279. Diamandis EP. Genomic and proteomic technologies and their relevance to clinical diagnostics. **Proc Can Lab Med Congress** 2002;31, #W204.

280. Kollara A, Casper RF, *Diamandis EP*, Brown TJ. Differential expression of two androgen receptor associated protein 70 (ARA70) isoforms induced by androgen and resveratrol in androgen receptor transfected human prostate cancer PC-3 cells. **The Endocr Soc 2002**;368, P2-200.

281. Nakamura T, Mitsui S, Okui A, Miki T, Yamaguchi N, *Diamandis EP*. Human kallikrien 11: A new biomarker of prostate cancer. **J Urol** 2002;167:286, #1127.

282. Yousef GM, *Diamandis EP*. Prognostic value of kallikreins in endocrine-related malignancies. **Clin Chem** 2002; #A-77.

283. Yousef GM, Scorilas A, Borgono C, Fracchioli S, Richiardi G, Massobrio M, Katsaros D, *Diamandis EP*. Prognostic value of the human kallikrein gene 14 (KLK14) in ovarian cancer. **Clin Chem** 2002; #A-78.

284. Yousef GM, Scorilas A, Fracchioli S, Iskander L, Raouf AA, Massobrio M, Katsaros D, *Diamandis EP*. KLK15 is a new potential independent marker for unfavorable prognosis in ovarian cancer. **Clin Chem** 2002; #D-118.

285. *Diamandis EP*, Luo L-Y, Yousef GM, Bunting P, Soosaipillai A, Grass L. Two new ovarian cancer biomarkers. **J Clin Ligand Assay** 2002;25:118.

286. *Diamandis EP,* Magklara A, Yousef GM, Obiezu CV, Chang A, Sidiropoulos M. Towards identification of new prostatic biomarkers. **J Clin Ligand Assay** 2002;25:118

2003

287. Yousef GM, Borgoño CA, Robb D, Scorilas A, Ponzone R, *Diamandis EP*. Human kallikrein gene 14 (*KLK14*) expression: An indicator of poor prognosis in breast cancer patients. **ACOG, 7th Ann Winter Symp** 2003; #266.

288. Antoniou A, Papanastasiou P, Stefanides A, *Diamandis E*, Androulakakis PA. Assessment of serum PSA in childhood. Proc Eur Soc Pediatric Urology, XIVth Ann Meeting, **Br J Urol Intl** 2003;41-42, #E-60.

289. Nam R, Zhang W, Trachtenberg J, *Diamandis EP*, Jewett MA, Narod SA. A single nucleotide polymorphism of the human kallikrein -2 gene (KLK2) highly correlates with serum hK2 levels and in combination enhances prostate cancer detection. **J Urol** 2003;169:384, #1438.

290. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaipillai A, *Diamandis EP*. Analysis of serum human kallikrein 11 (hK11) for discriminating between prostate cancer and benign prostatic hyperplasia. **J Urol** 2003;169:385, #1439.

291. Barak V, Sherman Y, Doviner V, Edelman D, *Diamandis EP.* Kallikreins 6 and 10 as prognostic markers of ovarian cancer. **J Clin Ligand Assay** 2003;26:215, #16.

292. Yousef GM, Polymeris M, Yacoub GM, Fracchioli S, Scorilas A, Soosaipillai A, Popalis C, Katsaros D, *Diamandis EP*. In silico analysis of kallikrein gene expression in ovarian cancer. **Clin Chem** 2003;49:A96, #D-23.

293. Yousef GM, Borgoňo C, Polymeris A, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, Chan P, *Diamandis EP*. Human kallikrein 5 (hK5): A novel serum biomarker for ovarian and breast cancer. **Clin Chem** 2003;49:A96-A97, #D-24.

294. Yousef GM. Borgoňo CA, Scorilas A, Fracchioli S, Iskander L, Rigault de la Longrais IA, Puopolo M, *Diamandis EP*. Prognostic value of human kallikrein gene 14 (KLK14) in ovarian cancer. **Proc AACR** 2003;44:90, #477.

295. *Diamandis EP*, Scorilas A, Yousef G, Kishi T, Luo L-Y, Nakamura T, Rademaker AW, Liu D, Fishman DA. Multiparametric serum analysis of human kallikreins hK5, hK6, hK7, hK8, hK10 and hK11 in combination with CA125 for ovarian cancer diagnosis. **Proc AACR** 2003;44:90, #478.

296. Kapadia C, Chang A, Sotiropoulou G, Yousef G, Grass L, Soosaipillai A, *Diamandis EP*. Development of a sensitive and specific immunofluorometric assay to measure human kallikrein 13 which is overexpressed in ovarian cancer. **Proc AACR** 2003;44:90-91, #479.

297. Kishi T, Grass L, Soosaipillai A, Memari N, Little SP, *Diamandis EP*. Is human kallikrein 7 a new serum biomarker for ovarian cancer? **Proc AACR** 2003;44:91, #480.

298. Kishi T, Grass L, Soosaipillai A, Scorilas A, Memari N, Shimizu-Okabe C, Schmitt M, Harbeck N, Dorn J, Schmalfeldt B, *Diamandis EP*. Human kallikrein 8 as a serum biomarker for ovarian cancer. **Proc AACR** 2003;44:91, #481.

299. Pampalakis G, *Diamandis EP*, Sotiropoulou G. CpG island methylation as a basis for the aberrant expression of the protease M/human kallikrein 6 gene in breast tumour cells. **Proc AACR** 2003;44:222, #1116.

300. Sidiropoulos M, Pampalakis G, Sotiropoulou G, *Diamandis EP*. CpG island hypermethylation as a basis of differential NES-1/KLK10 gene expression in breast, ovarian and prostate cancers. **Proc AACR** 2003;44:223, #1121.

301. Scorials A, Chang P, Katsaros D, Yousef G, *Diamandis EP*. Cloning of a new gene, CEAL1, which encodes for a carcinoembryonic antigen-like protein: Overexpression in aggressive ovarian cancer. **Proc AACR** 2003;44:244, #1238.

302. Stephan C, Finne P, Stenman U-H, Cammann H, Jung K, *Diamandis EP*. Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. **Proc AACR** 2003;44:489-490, #2489.

303. Nakamura T, Scorilas A, Stephan C, Jung K, Soosaippillai AR, Miki T, *Diamandis EP*. The analysis of serum human kallikrein 11 (hK11) increases discrimination between prostate cancer and benign prostatic hyperplasia. **Proc AACR** 2003;44:490, #2490.

304. Kurlender L L, Yousef G, Chang A, *Diamandis EP*. Differential expression of kallikrein gene splice variants in cancer. **Proc AACR** 2003;44:626, #3156.

305. Magklara A, Mellati AA, Wasney G, Sotiropoulou G, *Diamandis EP*. Characterization of the enzymatic activity of human kallikrein 6 (hK6/zyme) and regulation by inhibitors. **Proc AACR** 2003;44:669-670, #R3365.

306. Kapadia C, Grass L, Wasney G, Obiezu C, Yousef G, *Diamandis EP*. Human kallikrein 13, a potential ovarian cancer marker, binds to alpha 1 antichymotrypsin, alpha 2 macroglobulin and alpha 2 antiplasmin. **Proc AACR** 2003;44:670, #3366.

307. Yousef GM, Borgoňo, Scorilas A, Ponzone R, Biglia N, Roagna R, Sismondi P, *Diamandis EP*. Human kallikrein gene 14 (*KLK14*) expression: An indicator of poor prognosis in breast cancer patients. **Proc AACR** 2003;44:670, #3367.

308. Fracchioli S. Borgono CA, Yousef GM, Rigault de la Longrais IA, Puopolo M, Massobrio M, *Diamandis EP,* Katsaros D. Human kallikrein 11 (hK11) and 15 (hK15) expression in ovarian cancer: New independent predictive and prognostic factors. **Proc ASCO** 2003;22, #3462.

309. Yousef GM, Kurlender LE, Borgoňo CA, Grass L, *Diamandis EP*. Regulation of human kallikrein gene 14 (KLK14) by steroids in breast and ovarian cancer cell lines. **Proc AACR** 2003;44:713, #3585.

310. Memari N, Grass L, Michael IP, Obiezu CV, *Diamandis EP*. Hormonal regulation of human tissue kallikrein 12 in prostate, breast and ovarian cancer cell lines. **Proc AACR** 2003;44:713-714, #3586.

311. Luo LY, Grass L, *Diamandis EP*. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. **Proc AACR** 2003;44:837, #4205.

312. Stephan C,Cammann H, Graefen M, Haese A, Djavan B, Remzi M, Semjonow A, Oberpenning F, Finne P, Stenman U-H, Jung K, *Diamandis EP*. Evaluation of a common program for predicting the outcome of prostate biopsy with 4 different PSA assays at PSA 2-10 ng/ml based on 4366 patients. **Proc AACR** 2003;44:880, #4438.

313. Michael I, *Diamandis E*. Expression profiling of the 15 human kallikrein genes. **Proc AACR** 2003;44:998, #5003.

314. Nakamura T, Stephan C, Scorilas A, Memari N, Yousef GM, Jung K, *Diamandis EP*. Quantitative analysis of KLK11 gene expression in prostatic tissues. **Proc AACR** 2003;44:999, #5006.

315. Nakamura T, Scorials A, Stephan C, Yousef GM, Kristiansen G, Jung K, *Diamandis EP*. Macrophage inhibitory cytokine 1 (MIC-1) gene is up-regulated in human prostatic cancer tissues. **Proc AACR** 2003;44:1001-1002, #5019.

316. Obiezu CV, Yousef GM, Jung K, Stephan C, Scorilas A, *Diamandis EP*. Kallikrein gene 5 is differentially expressed in healthy vs cancerous testicular tissues. **Proc AACR** 2003;44:1006-1007, #5046.

317. Petraki CD, Gregorakis AK, Vaslamatzis MM, Papanastassiou PA, Yousef GM, *Diamandis EP*. The immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Correlation with several prognostic factors. **Proc AACR** 2003;44:1077, #5412.

318. Petraki CD, Papanastassiou PA, Gregorakis AK, Karavana VN, Luo L, *Diamandis EP*. Down-regulation of human kallikreins 6, 10 and 13 in prostate cancer and correlation with established prognostic parameters. **Proc AACR** 2003;44:1077, #5413.

319. Borgoño CA, Soosaipillai A, Grass L, Fracchioli S, Yousef GM, Katsaros D, *Diamandis EP*. Development of an immunofluorometric assay for human kallikrein 14 (hK14): Preliminary clinical applications. **Proc AACR** 2003;44:11446-1147, #5745.

320. Borgoño CA, Yousef GM, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*. Human kallikrein 14 (hK14) expression in breast cancer tissues. **Proc AACR** 2003;44:1264, #6328.

321. Yousef GM, Grass L, Polymeris M-E, Soosaipillai A, Chan P-C, Scorials A, Borgoño CA, Harbeck N, Schmalfeldt B, Dorn J, Schmitt M, *Diamandis EP*. Human kallikrein 5 (hK5): A novel serum biomarker for breast and ovarian cancer. **Proc AACR** 2003;44:1266, #6337.

322. Diamandis EP. Practice guidelines for tumour markers. **Tumour Biol** 2003;24[Suppl]:23, #S-46.

2004

323. Economopoulou K, *Diamandis EP*. Kallikrein 6 as a biomarker for the detection of metastatic cancer cells in blood of ovarian cancer patients. **Proc AACR** 2004;45:241, #1058.

324. Scorilas A, Mathioudaki K, Leoutsakou T, Arnaouti M, *Diamandis EP*. Expression analysis of the SR-A1 gene, encoding for a novel member of the human Ser/Arg-rich family of proteins, in breast cancer. **Proc AACR** 2004;45:397-398, #1728.

325. Borgoño CA, Ghosh MC, Michael IP, Stoop A, Craik CS, Choe Y, Kapadia C, *Diamandis EP*. Enzymatic action, substrate specificity and regulation of human kallikrein 14 (hK14). **Proc AACR** 2004; 45:415, #1807.

326. Luo L-Y, Grass L, Soosaipillai A, *Diamandis EP*. Trypsin-like enzymatic activity of human kallikrein 10. **Proc AACR** 2004;45:416, #1810.

327. Petraki CD, Gregorakis AK, Papanastassiou A, *Diamandis EP*. The immunohistochemical expressionof human kallikreins 5, 6, 10 and 11 in normal urothelium and urinary bladder cancer. Correlation with histopathological variables. **Proc AACR** 2004;45:417, #1815.

328. Kapadia C, Ghosh MC, Stoop A, Craik CS, Choe Y, Borgoño C, *Diamandis EP*. Human kallikrein 13: Evaluation of its role in the degradation of extracellular matrix proteins and characterization of its substrate specificity. **Proc AACR** 2004;45:417-418, #1819.

329. Michael IP, Sotiropoulou G, Pampalakis G, Magklara A, Wasney GA, *Diamandis EP*. Human kallikrein 5 (hK5): Autoactivation, substrate specificity, regulation by inhibitors and cleavage of extracellular matrix and basement membrane components. **Proc AACR** 2004;45:529, #2294.

330. Yousef GM, White N, Kurlender L, Michael I, Desmond-Robb J, Memari N, Grass L, *Diamandis EP*. The KLK5-splice variant 2 is a new biomarker for ovarian cancer. **Proc AACR** 2004;45:764, #3300.

331. Petraki CD, Vaslamatzis MM, Petraki KD, *Diamandis EP*. Correlation between the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 and histopathological variables in colorectal cancer. **Proc AACR** 2004;45:766, #3306.

332. Pampalakis G, *Diamandis EP*. Cloning and characterization of novel isoforms of the human kallikrein 6 gene. **Proc AACR** 2004;45:798, #3454.

333. Kurlender L, Yousef GM, *Diamandis EP*. Differential expression of a novel KLK5 splice variant in ovarian and prostate cancer. **Proc AACR** 2004;45:838, #3632.

334. Michael IP, Kurlender L, Yousef GM, Memari N, Du DC, Katsaros D, *Diamandis EP*. Novel alternative splicing events within the human kallikrein locus. **Proc AACR** 2004;45:979, #4243.

335. Borgoňo CA, Kishi T, Scorilas A, Harbek N, Dorn J, Schmalfeldt B, Schmitt M, *Diamandis EP*. Human kallikrein 8 protein (hK8) in ovarian cancer cytosols: A new marker of favorable prognosis. **Proc AACR** 2004;45:1025, #4444.

336. Luo L-Y, Soosaipillai A, Grass L, *Diamandis EP*. Human kallikreins 6 and 10 are secreted as zymogen forms in ascites fluid from ovarian cancer patients. **Proc AACR** 2004;45:1025-1026, #4447.

337. Memari N, Hussack G, Cui S, Grass L, *Diamandis EP*. Production of polyclonal antibodies against human tissue kallikrein 9. **Proc AACR** 2004;45:1027, #4452.

338. Yousef G, Polymeris M-E, Yaboub GM, Fracchioli S, Scorilas A, Soosaipillai A, Popalis C, Desmond-Robb J, Katsaros D, *Diamandis EP*. In silico analysis of kallikrein gene expression in ovarian cancer. **Proc AACR** 2004;45:1029, #4461.

339. Obiezu CV, Michael IP, Wasney GA, *Diamandis EP*. Enzymatic activity of prostase/human kallikrein 4 (hK4): Determination of substrate preferences and degradation of extracellular matrix proteins. **Proc AACR** 2004;45:1032, #4474.

340. Stephan C, Chianlian X, Kishi T, Nakamura T, Brown DA, Breit SN, Cammann H, Jung K, *Diamandis EP*. Artificial neural network based on PSA, percent free PSA, and three new prostate cancer biomarkers. **Proc AACR** 2004;45:1033, #4478.

341. Memari N, Grass L, Hussack G, Soosaipillai A, *Diamandis EP*. Production of polyclonal and monoclonal antibodies against human tissue kallikrein 12. **Proc AACR** 2004;45:1212-1213, #5257.

342. Yousef G, Popalis C, Polymeris M-E, White N, Desmond-Robb J, Yacoub GM, Soosaipillai A, *Diamandis EP*. Kallikrein gene down-regulation in breast cancer. **Proc AACR** 2004;45:1213, #5258.

343. Katsaros D, Fracchioli S, Rigault de la Longrais IA, *Diamandis EP*. Human kallikreins (hKs) as novel serum biomarkers for diagnosis, prognosis and monitoring of epithelial ovarian carcinoma. **Int'l J Biol Markers** 2004;19:S29.

344. Yousef GM, Polymeris M, White N, Robb J-D, Yacoub GM, Raouf AA, *Diamandis EP*. Kallikreins are potential new breast cancer biomarkers. **Res & Practice** 2004;200:655, #70.

345. Yousef GM, Polymeris M, Hutchinson S, Robb J-D, Soosaipillai A, Serry E, *Diamandis EP*. The human kallikrein proteins 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors. **Res & Practice** 2004;200:655, #71.

346. Simon I, Kim NW, Sarno M, *Diamandis EP*, Valik D, Nekulova M, Simickova M, Frgala T, Wolfert RL. Characterization of three novel serum biomarkers for the early detection and prognosis of ovarian cancer. **MD Anderson Cancer Ctr 5th Intl Conf** 2004.

2005

347. Yousef GM, Katsaros D, *Diamandis EP*. The kallikrein proteins: New potential biomarkers for ovarian cancer. **Mod Pathol** 2005;18, 209A and **Lab Invest** 2005;85, 209A, #972.

348. White NM, Yousef GM, Michael IP, Robb JD, *Diamandis EP*. Differential expression of the human kallikrein 10 gene (*KLK10*), a candidate cancer biomarker. **Proc AACR** 2005;83, #36.

349. Yousef GM, White NMA, Borgono CA, Ellatif MA, Soosaipillai A, Robb, JD, *Diamandis EP*. Kallikreins are potential biomarkers for pancreatic and colon cancer. **Proc AACR** 2005;83, #37.

350. Elliott MB, Michael IP, Kuk C, Yousef G, *Diamandis EP*. Identification of single nucleotide polymorphisms in the human kallikrein locus: Potential association with cancer susceptibility. **Proc AACR** 2005;83, #39.

351. Yousef GM, Elliott MB, White NMA, Borgono CA, Robb JD, Michael IP, Economopoulou K, *Diamandis EP*. Differential expression of the human kallikrein gene 6 (*KLK6*) in various malignancies. **Proc AACR** 2005;83, #40.

352. Memari N, Grass L, Bansil A, Cho J-C, Shan SJC, Soosaipillai A, *Diamandis EP*. Production of the extracellular domain of Siglec-9 using an *E-coli* expression system and generation of anti-Siglec-9. **Proc AACR** 2005;108, #694.

353. Grutzmann R, *Diamandis EP*, Saeger H-D, Pilarsky C. Human kallikrein 10 mRNA up-regulation but not serum increase of the protein in patients with pancreatic cancer. **Proc AACR** 2005;133, #1245.

354. Petraki CD, Veloudis G, Komborozos VA, Scorilas A, Papanastasiou P, *Diamandis EP*. Immunohistochemical evaluation and prognostic significance of human kallikreins 6 and 10 in colorectal cancer. **Proc AACR** 2005;133, #1260.

355. Gunawardana G, Luo L-Y, *Diamandis EP*. Retrieval of autoantibodies from ovarian cancer cells present in ascites fluid. **Proc AACR** 2005;143, #1534.

356. Borgono CA, Soosaipillai A, GrassL, *Diamandis EP*. Development of a novel immunoassay for human kallikrein 14, a putative ovarian and breast cancer biomarker. **Proc AACR** 2005;143, #1547.

357. Michael IP, Yousef GM, Soosaipillai A, Grass L, *Diamandis EP*. A novel ELISA assay for human kallikrein 5, a candidate breast and ovarian cancer biomarker. **Proc AACR** 2005;143, #1548.

358. Shaw JL, Obiezu C, Memari N, Karakucuk I, *Diamandis EP*. Production of recombinant human kallikrein 15, a potential prostate and ovarian cancer biomarker. **Proc AACR** 2005;143, #1549.

359. Sidiropoulos M, Pampalakis G, Sotiropoulou G, *Diamandis EP*. Expression of human tissue kallikrein 5 in breast and prostate cancer cell lines after treatment with the demethylating agent 5-aza-2′-deoxycytidine. **Proc AACR** 2005;175, #1842.

360. Shan SJC, Michael IP, Soosaipillai A, Katsaros D, Rigault de la Longrais IA, Puopolo M, *Diamandis EP*. Over-expression of human kallikren 6 (hK6) protein and mRNA in ovarian carcinoma. **Proc AACR** 2005;176, #1860.

361. Leoutsakou T, Talieri M, Mathioudaki K, Stavropoulou P, Arnogianaki N, *Diamandis EP*, Scorilas A. Expression analysis and prognostic significance of SR-A1 gene, encoding for a new member of the human ser/arg-rich family of pre-mRNA splicing factors, in breast and ovarian cancer. **Proc AACR** 2005;177, #1899.

362. Memari N, Grass L, Michael IP, Fountas NP, *Diamandis EP*. Hormonal regulation of human tissue kallikrein 9 in human cancer cell lines. **Proc AACR** 2005;187, #2141.

363. Michael IP, Harris JL, Li J, Gavigan J-A, Borgono CA, Bowles B, *Diamandis EP*. Characterization of human kallikrein 5 (hK5) substrate specificity using combinatorial peptide libraries. **Proc AACR** 2005;229, #2956.

364. Michael IP, Komatsu N, Jayakumar A, Kang Y, Clayman GL, *Diamandis EP*. Regulation of the proteolytic activity of human kallikrein 5 (hK5) by tissue and plasma inhibition. **Proc AACR** 2005;229, #2970.

365. Dorn J, Harbeck N, Kates R, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*, Kiechle M, Schmalfeldt B, Schmitt M. Analysis of the differential expression of proteolytic factors uPA, PAI-I and seven tissue kallikreins (hK5, 6, 7, 8, 10, 11, 13) between primary ovarian carcinoma tissues and corresponding omentum metastases. **Proc AACR** 2005;229, #2972.

366. Borgono CA, Felber LM, Cloutier SM, Deperthes D, Li J, Gavigan J-A, Harris JL, Bowles B, *Diamandis EP.* Enzymatic profilinf of human kallikrein 14, a candidate cancer biomarkers, by phage display substrate and positional scanning peptide libraries. **Proc AACR** 2005;229, #2975.

367. Sardana G, Marshall J, Grass L, Soosaipillai A, *Diamandis EP*. Proteomic analysis of culture supernatants from prostate cancer cell lines. **Proc AACR** 2005;234, #3105.

368. Luo L-Y, Soosaipillai A, Du D, *Diamandis EP*. Purification and characterization of human kallikrein 11, a candidate prostate cancer biomarker, from seminal plasma. **Proc AACR** 2005;236, #3157.

369. van der Merwe D-E, *Diamandis EP*. Mass spectrometry as a cancer diagnostic tool: a meta-analysis of published data. **Proc AACR** 2005;307, #4361.

370. Michael IP, Pampalakis G, Mikolajczyk SD, Malm J, Sotiropoulou G, *Diamandis EP*. Involvement of human kallikreins in a proteolytic cascade pathway in the prostate. **Proc AACR** 2005;330, #4835.

371. Oikonomopoulou K, Simon I, Wolfert RL, Valik D, Nekulova M, Simickova M, Frgala T, *Diamandis EP*. Evaluation of human kallikreins 5, 6, 7, 8, 10 and 11 as prognostic markers in serum of ovarian cancer patients. **Proc AACR** 2005;332, #4877.

372. Oikonomopoulou K, Scorilas A, Grass L, Soosaipillai A, Rosen B, Murphy J, *Diamandis EP*. Kallikreins as markers of disseminated tumour cells in ovarian cancer. **Proc AACR** 2005;332, #4878.

373. Simon I, Kim NW, *Diamandis EP*, Valik D, Mekulova M, Simickova M, Frgala T, Sarno MJ, Wolfert RL. Evaluation of B7-H4 (DD-O110) as a prognostic marker in tissue and serum of ovarian cancer patients. **Proc AACR** 2005;332, #4882.

374. *Diamandis EP*, van der Merwe D-E, Simon I, Kobayashi H, Terao T. Multiparametric analysis of six tissue kallikreins and CA125 for ovarian cancer diagnosis. **Proc AACR** 2005;376, #5598.

375. Schmalfeldt B, Kates R, Dorn J, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*, Kiechle M, Schmitt M, Harbeck N. Impact of proteolytic factors on surgical success and survival in ovarian cancer. **Proc ASCO** 2005;471, #5068.

376. Schmalfeldt B, Kates R, Dorn J, Scorilas A, Grass L, Soosaipillai A, *Diamandis EP*, Kiechle M, Schmitt M, Harbeck N. Impact of proteolytic factors (uPA, PAI-I, tissue kallikreins) on surgical success and survival in ovarian cancer. **Thromb Haemostasis** 2005;93:A24.

377. Yousef GM, Katsaros D, *Diamandis EP*. The kallikrein proteins: New potential biomarkers for ovarian cancer. **Lab Invest** 2005;85:209A, #972.

378. Diamandis EP. Human tissue kallikreins as biomarkers for breast, ovarian and other malignancies. **Proc Era of Hope** 2005;100, #P13-9.

379. Komatsu N, Saijoh K, Sidoropoulou G, Tsai B, Levesque MA, Elliott MB, Takehara K, *Diamandis EP*. Quantification of human tissue kallikreins in the stratum corneum: dependence of age and gender. **J Invest Dermatol** 2005;124:A57.

380. Oikonomopoulou K, Hansen K, Saifeddine M, *Diamandis EP*. Cell signaling via proteinase-activated receptors (PARs): A new role for kallikreins. **Intl Proteolysis Soc** 2005;79, #P16.

381. Van Der Merwe D, *Diamandis EP*. Cancer biomarker discovery and validation by mass spectrometry [abstract] American Association for Clinical Chemistry. **Clin Chem** 2005;51:A61.

2006

382. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, *Diamandis EP*. Elevated Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Peeling Skin Syndrome-Type B Patients Suggests an Over-Desquamation of Corneocytes. **J Invest Dermatol** 2006;126, #348.

383. Fischer SE, *Diamandis EP*, Ezzat S, Asa SL. SELDI-TOF mass spectrometry analysis of normal, benign and malignant tyroid tissue. **Lab Invest** 2006;86:93A, #420.

384. Fischer SE, *Diamandis EP*, Ezzat S, Asa SL. SELDI-TOF mass spectrometry analysis of normal, benign and malignant tyroid tissue. **Modern Pathol** 2006;19:83A, #420.

385. Oikonomopoulou K, Hanssen K, Saiffedine M, *Diamandis EP*, Hollenberg MD. Kallikrein signaling in cancer via proteinase-activated receptors. **Natl Inst of Health Proteomicc Intl Group** 2006; #85.

386. Borgono CA, Michale IP, Komatsu N, Sotiropoulou G, Jayakumar A, Wu H-K, Clayman GL, Blaber M, Mikolajczyk SD, *Diamandis EP*. Multiple human tissue kallikreins are regulated by lympho-eipthelial Kazal-type inhibitor and digest desmoglein 1. **J Inves Dermatol** April 2006.

387. Simon I, *Diamandis EP*, Katsaros D, Kim NW, Wolfert RL. B7-H4 (DD-O110) protein is over-expressed in early-stage ovarian cancer tumor tissue. **Proc AACR** April 2006; #4505.

388. Shan SJC, Scorilas A, Soosaipillai A, Katsaros D, Rigault I, Puopolo M, *Diamandis EP*. Human tissue kallikrein 7 over-expression in ovarian carcinoma: a novel marker of unfavorable prognosis. **Proc AACR** April 2006; #4503.

389. Oikonomopoulou K, Shannon P, Petraki CD, *Diamandis EP.* Immunohisotchemical localization of kallikrein 6 in brain tumors. **Proc AACR** April 2006; #4488.

390. Emami N, Michael IP, *Diamandis EP*. Proteolytic cascades of human tissue kallikreins. **Proc AACR** April 2006; #4368.

391. Petraki C, Papanastasiou PA, Karavana VN, *Diamandis EP*. Immunohistochemical expression of human tissue kallikreins in neoplasms of various organs. **Proc AACR** April 2006; #4358.

392. Kulasingam V, *Diamandis EP.* Comparative qualitative proteomic analysis of conditioned media from breast cancer cell lines. **Proc AACR** April 2006; #3573.

393. Sardana G, Marshall J, *Diamandis EP.* Identification and characterization of novel candidate prostate cancer biomarkers through proteomic analysis of the secretome of three prostate cancer cell lines. **Proc AACR** April 2006; #3572.

394. Memari N, Grass L, Karakucuk EI, Shaw JL, *Diamandis EP.* Protein expression, antibody generation and development of a highly sensitive immunoassay for the detection of human tissue kallikrein 9. **Proc AACR** April 2006; #2889.

395. Shaw JL, Grass L, Soosaipillai A, Sotiropoulou G *Diamandis EP.* Development of an immunoassay for human kallikrein 15, a potential prostate and ovarian cancer biomarker. **Proc AACR** April 2006; #1985.

396. Memari N, *Diamandis EP,* Van Der Kwast T. Immunohistochemical localization and expression profiling of human kallikrein 12 in human prostate cancer tissues. **Proc AACR** April 2006; #1980.

397. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Andrade-Gordon P, Cottrell GS, Bunnett NW, *Diamandis EP*, Hollenberg MD. Kallikrein 14 signaling through proteinase-activated receptors. **Proc AACR** April 2006; #1686.

398. Paliouras M, *Diamandis EP.* Investigating the role of intracellular signaling pathways in regulating kallikrein expression. **Proc AACR** April 2006; #1655.

399. Shan SJC, Katsaros D, Paliouras M, Rigault I, Puopolo M, *Diamandis EP.* Up-regulation of human tissue kallikrein 6 in ovarian carcinoma. **Proc AACR** April 2006; #102.

400. White NMA, Yousef GM, *Diamandis EP*, Dorn J. The human kallikrein gene 6 (KLK6) in combination with CA125 is a more sensitive marker for ovarian cancer than CA125 alone. **Proc AACR** April 2006; #94.

401. Paliouras M, *Diamandis EP.* Coordinated hormone regulation of multiple kallikreins in breast cancer cell lines. **Proc AACR** April 2006; #91.

402. Borgono CA, Michael IP, Komatsu N, Sotiropoulou G, Jayakumar A, Wu H, Clayman GL, Blaber SI, Blaber M, Mikolajczyk SD, *Diamandis EP.* Multiple human tissue kallikreins are regulated by lympho-epithelial Kazal-type inhibitor and digest desmoglein 1. **J Invest Dermatol** 2006;126:60.

403. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Jayakumar A, Clayman GL, Shirasaki F, Takehara K, *Diamandis EP.* Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. **J Invest Dermatol** 2006;126:58.

404. Heshmat SM, Jarvi K, Mullen B, *Diamandis EP.* Seminal plasma lipocalin type PGDS: A potential marker for the diagnosis of obstructive azoospermia. **J Urol** 2006;175:523, #1623.

405. Kundig C, Cloutier SM, Aellen S, Felber LM, Chagas JR, Gygi CM, Jichlinski P, Leisinger HJ, *Diamandis EP,* Deperthes D. Human kallikrein 2 (hK2) inhibitors suppress tumor growth of prostate cancer xenografts in nude mice. **J Urol** 2006;175:263.

406. Fischer S, Kulasingam V, Paliouras M, *Diamandis EP,* Ezzat S, Asa S. Human thyroid cancer cell lines differentially express PSA, hK6, hK10 and hK11. **Modern Pathol** 2006;19:138, #639.

407. Darling M, Jackson L, Daley T, *Diamandis EP.* Human kallikrein expression in salivary gland tumors. **Modern Pathol** 2006;19:107, #489.

408. Heshmat SM, Jarvi K, *Diamandis EP*, Mullen B, Lo KC. Seminal plasma lipocalin type PGDS: A new marker for obstructive azoospermia. **Fertility & Sterility** 2006;86:S376.

409. Cho CKJ, *Diamandis EP.* Proteomic analysis of normal human amniotic fluid by two-dimensional liquid chromatography and mass spectrometry. **Mol Cell Proteomics** 2006;5:S371.

2007

410. Fischer SE, Kulasingam V, *Diamandis EP,* Ezzat S, Asa SL. Thyroid cancer biomarker discovery using two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS). **Lab Invest** 2007;87:101A.

411. Fischer SE, Kulasingam V, *Diamandis EP,* Ezzat S, Asa SL. Thyroid cancer biomarker discovery using two-dimensional liquid chromatography-tandem mass spectrometry (2D-LC-MS/MS). **Modern Pathol** 2007;20:101A.

412. Rabien A, Fritzsche FR, Jung M, *Diamandis EP,* Loening SA, Jung K, Kristiansen G, Stephan C. High expression levels of the human kallikrein-like peptidases KLK14 and KLK15 in prostatic adenocarcinoma are associated with elevated risk of prostate-specific antigen relapse. **Eur Urol** 2007;6:49.

413. Prassas I, Paliouras M, *Diamandis EP.* High-throughput screening for modulators of tissue-kallikrein expression. **Proc AACR** April 2007; #5554.

414. Paliouras M, *Diamandis EP.* Androgens act synergistically to enhance estrogen-induced up-regulation of human tissue kallikreins in breast cancer cells. **Proc AACR** April 2007; #4328.

415. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergote N, *Diamandis EP,* Hollenberg MD. Tumour-derived proteinases and signalling: kallikrein-mediated PAR activiation and inflammation. **Proc AACR** April 2007; #3091.

416. Paliouras M, *Diamandis EP.* Intracellular signaling pathways regulate expression of prostate specific antigen andother kallikreins in human breast cancer cells. **Proc AACR** April 2007; #2901.

417. Planque C, Soosaipillai A, Reckamp K, Chia D, Goodglick L, *Diamandis EP.* Human tissue kallikreins as serological biomarkers for lung cancer. **Proc AACR** April 2007; #2679.

418. Bayani J, Planque C, Paliouras M, Squire JA, *Diamandis EP.* Chromosomal rearrangements of the kallikrein locus in human cancer cell lines. **Proc AACR** April 2007; #1063.

419. Prassas I, Paliouras M, *Diamandis EP.* High-throughput screening for modulators of tissue-kallikrein expression. **Intl Proteolysis Soc** October 2007.

420. Emami N, *Diamandis EP*. Human tissue kallikrein 14 (KLK14): A new member of the seminal proteolytic cascade. **Intl Proteolysis Soc** October 2007.

421. Shaw JLV, Smith CR, *Diamandis EP*. A potential role for human tissue kallikreins in cervico-vaginal physiology. **Intl Proteolysis Soc** October 2007.

422. Oikonomopoulou K, Hansen KK, Chapman K, Vergnolle N, *Diamandis EP*, Hollenberg MD. Kallikreins and carcinogenesis: Put the blame of PARs. **Intl Proteolysis Soc** October 2007.

423. Planque C, Soosaipillai A, Zheng Y, Reckamp K, Chia D, Goodglick L, *Diamandis EP*. A combination of multiparametric members of the tissue kallikrein family improves the diagnosis of non-samll cell lung cancer. **Intl Proteolysis Soc** October 2007.

424. Paliouras M, *Diamandis EP*. P13K/AKT activity negatively regulates prostate specific antigen expression in prostate cancer cells – a model for androgen-indepencence. **Intl Proteolysis Soc** October 2007.

425. Kuzmanov U, *Diamandis EP*. Glycosylation pattern of ovariancancer derived kallikrein 6 and its potential use as a biomarker. **Intl Proteolysis Soc** October 2007.

426. Emami N, *Diamandis EP*. Major role of human tissue kallikrein 14 (KLK14) in seminal clot liquefaction. **Intl Symp on Kallikreins** October 2007.

427. Shaw JLV, *Diamandis EP*. Hormonal regulation patterns of human tissue kallikreins in cancer cell lines. **Intl Symp on Kallikreins** October 2007.

428. Shaw JLV, *Diamandis EP*. A potential role for human tissuekallikreins in cervico-vaginal physiology. **Intl Symp on Kallikreins** October 2007.

429. Oikonomopoulou K, Hansen KK, Chapman K, Saifeddine M, Vergnolle N, *Diamandis EP*, Hollenberg MD. Kallikreins as inflammatory modulators in cancer. **Intl Symp on Kallikreins** October 2007.

430. Eissa A, *Diamandis EP*. The role of human tissue kallikreins in skin physiology and pathobiology. **Intl Symp on Kallikreins** October 2007.

431. Planque C, Soosaipillai A, Zheng Y, Reckamp K, Chia D, Goodglick L, *Diamandis EP*. A multiparametric diagnostic model in lung cancer using several human tissue kallikrein biomarkers. **Intl Symp on Kallikreins** October 2007.

432. Paliouras M, *Diamandis EP*. The influence of intracellular signaling pathways ongenerit regulation of kallikrein gene expression – the development of cancer progression models. **Intl Symp on Kallikreins** October 2007.

433. Kuzmanov U, *Diamandis EP*. Glycosylation pattern of ovarian cancer derived kallikrein 6. **Intl Symp on Kallikreins** October 2007.

434. Kulasingam V, Smith CR, Buckler A, Jeffrey DA, *Diamandis EP*. "Product Ion Monitoring" assay for prostate-specific antigen in serum using a linear Ion-Trap. **HUPO** 2007.

435. Sardana G, Jung K, Stephan C, *Diamandis EP*. A comparison of the conditioned medium from three prostate cancer cell lines: Validation of candidate biomarkers for prostate cancer. **HUPO** 2007.

436. Gunawardana CG, Smith CR, Batruch I, *Diamandis EP*. Analyzing cell-line secretomes using 2D-liquid chromatography and mass spectrometry to reveal novel biomarkers of ovarian carcinoma. **HUPO** 2007.

437. Cho C-KJ, Smith CR, Winsor EJ, *Diamandis EP*. Discovery of candidate markers for early detection of Down syndrome through semi-quantitative proteomic analysis of human amniotic fluid. **HUPO** 2007.

438. Diamandis EP. Novel biomarkers for prognosis and therapy response in ovarian cancer. **Eur J Cancer** 2007;5:13, #S20.

2008

439. Christensen EJ, Menard C, Evans K, *Diamandis EP*, Chambers AF, Anborgh P, Pintile M, Lenarduzzi M, Bristow RG. Novel biomarkers of radiotherapy response in prostate cancer: A pilot study to determine protein expression patterns in blood and urine during radiotherapy for localized prostate cancer. **Proc AACR** April 2008;49:#1003.

440. Alexopoulou DK, Zheng Z, Li L, Soosaipillai A, *Diamandis EP*, Talieri M. Expression analysis of multiple tissue kallikrein-related peptidases in colorectal cancer. **Proc AACR** April 2008;49:#1155.

441. Kulasingam V, *Diamandis EP*. Two adhesion molecules: New serological diagnostic breast cancer biomarkers. **Proc AACR** April 2008;49:#4437.

442. Klem R, Saunders R, Sanders R, Adams T, McDermed JE, Sarno M, *Diamandis E*. Total PSA (tPSA) level post-prostatectomy (RP) monitored with the NADIA* ultrasensitive PSA assay can predict the risk for biochemical recurrence (BCR). **Clin Chem** 2008;54 (Suppl 6);A136, #C-117.

443. Klem R, Saunders R, Sanders R, Adams T, McDermed JE, Sarno M, *Diamandis E*. Evaluation of post-prostatectory (RP) total PSA (tPSA) levels using the NADIA* (Nucleic Acid Detection ImmunoAssay) untrasenstivie tPSA assay. **Clin Chem** 2008;54 (Suppl 6);A137, #C-119.

444. Cho C-K, Smith C, Winsor E, *Diamandis EP*. Quantitative proteomic analysis of human amniotic fluid. **HUPO** 2008.

445. Kuk C, Soosaipillai A, Kulasingam V, Smith CR, Batruch I, *Diamandis EP*. Ovarian cancer ascites flud subproteome: Home of potential biomarkers for ovarian cancer. **HUPO** 2008.

446. Yazdanpanah M, Chen Y, *Diamandis Ep*m Hoffman B, Wong PY. Determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry. **20th IFCC WorldLab** 2008.

447. Linbo RA, Vandell AGV, Larson NS, Keegan MB, Blaber SI, Blaber M, Sneve DM, Lucchinetti CF, Rodriguez M, *Diamandis EP*, Scarisbrick IA. Association of kallikreins with neuron loss and progressive multiple sclerosis. **Amer Neurol Assoc Ann Meeting** 2008.

2009

448. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential N-glycosylation of kallikrein 6 in ovarian cancer ascites and cerebrospinal fluids. **AACR** 2009; #4738.

449. Bayani J, Katsaros D, Graham C, Rosen B, Murphy J, Bernadini M, Shaw P, Squire J, Diamandis EP. Mechanisms of regulation of the kallikrein (KLK) gene family in ovarian carcinoma. **AACR** 2009; #571.

450. Gunawardana G, Kuk C, Smith CR, Batruch I, Diamandis EP. Mining for ovarian cancer biomarkers in conditioned media of ovarian cancer cell lines using 2D-liquid chromatography and mass spectrometry. **AACR** 2009; #3555.

451. Kuk C, Gunawardana CG, Soosaipillai A, Kobayashi H, Zheng Y, Lin L, Diamandis EP. Nidogen-2. **AACR** 2009; #3554.

452. Prassas I, Diamandis EP. Novel applications of cardiac glucosides in cancer therapies: insights into their molecular mechanism of action. **AACR** 2009; #4621.

453. Makawita S, Smith CR, Batruch I, Diamandis EP. Pancreatic cancer biomarker discovery: Elucidationof candidate biomarkers through mass spectrometry based proteomic analysis of cell line conditioned media. **AACR** 2009; #4484.

454. Schnabl KL, Yazdanpanah M, Wong P-Y, *Diamandis EP*, Cole D, Vieth R. Isotope-dilution, liquid chromatography-tandem mass spectrometry assay for analysis of 24, 24$(OH)_2$vitamin D_3 and25(OH) metabolites of Vitamins D_2 and D_3 in human serum. Clin Chem 2009;55:A232, #E-67.